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Abstract 
 
Background and aim: The rupture of atherosclerotic plaque is the key underlying 
cause of cardiovascular episodes including heart attack and stroke. A key 
contributor to plaque instability is the macrophage. We found that while M1 
macrophages are associated with plaque instability, M2 macrophages are not; rather 
they produce matrix molecules such as collagen that provide structural integrity to 
the cap. Modulating the balance of macrophage phenotypes in the plaques may 
hence be a treatment option. However, since some matrices, particularly the 
proteoglycans, can retain lipoproteins in the arterial wall, this study examined what 
proteoglycans M1 and M2 macrophages produce, and how is their degree of lipid 
binding.   
 
Method: Human monocyte-like THP-1 cells or the monocytes isolated from 
healthy donors were differentiated into M1 and M2 macrophages (and foam cells). 
The structure and low-density lipoprotein (LDL) binding ability of the 
proteoglycans were assessed.  
 
Results: M1 and M2 macrophages secreted a range of proteoglycans such as 
biglycan, perlecan and versican, with M2 macrophages producing more perlecan 
and versican. The glycosaminoglycan (GAG) chains decorating the core protein of 
these proteoglycans included chondroitin sulphate and heparan sulphate. The 
chondroitin sulphate produced by M1 macrophages were more sulphated than M2. 
Heparan sulphate from both cells included non-sulphated and sulphated 
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disaccharides, with the latter being more abundant in the M1. The M1 
proteoglycans bound more LDL than those of M2 and this was mediated by heparan 
sulphate. In contrast, LDL binding sites were found on the M2 proteoglycan core 
proteins, such as perlecan, with increased LDL binding evident upon cleavage of 
GAGs. M2 macrophages were co-localised with perlecan and lipid accumulation in 
plaques, suggesting that they may help in LDL retention via perlecan. When M1 
and M2 macrophages transformed into foam cells, they produced less proteoglycans. 
However, the proteoglycans did not differ in the degree of LDL binding between 
the phenotypes. 
 
Conclusion: Both M1 and M2 macrophages produced proteoglycans that could 
bind LDL, but in different ways: the M1 macrophage-derived proteoglycans bound 
LDL via heparan sulphate, whereas those produced by M2 macrophages used core 
proteins to bind LDL. Therefore, M1 and M2 macrophages are likely to contribute 
to LDL retention during the development of atherosclerosis. 
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1.1 Cardiovascular diseases 
 
The world population continues to burgeon at an unprecedented rate. 
Simultaneously, the growing population is also facing an alarming increase in poor 
lifestyle choices including tobacco use [1], physical inactivity [2] and an 
imbalanced diet [3], leading to non-communicable diseases (NCDs). Such diseases 
are the cardinal global causes of death, causing more deaths than all other causes 
combined, over 36 million people each year [4]. Of these deaths, cardiovascular 
diseases (CVDs) accounted for more than 17 million (31% of all global deaths) in 
2015, thus making CVDs the number one cause of death globally [5]. More than 3 
million of the deaths from CVDs occurred before the age of 60 and could have 
substantially been prevented [5]. Heart attacks and strokes are the main causes of 
death from CVDs, accounting for 7.4 million and 6.7 million deaths, respectively 
[5]. The most common underlying pathological process for CVDs is atherosclerosis 
[5]. 
 
1.1.1 Atherosclerosis 
 
Atherosclerosis or ‘hardening of the arteries’ is a chronic, complex inflammatory 
disease occurring in the wall of middle-sized and large arteries, particularly where 
the blood vessels divide [6]. It is the dominant underlying cause of cardiovascular 
episodes including heart attack, stroke, and peripheral artery disease. It is 
noteworthy, that an increase in atherosclerotic lesion size alone is rarely fatal; but 
it is thrombosis arising from lesion rupture that precipitates life-threatening clinical 
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events [7]. If the blood clot develops in a coronary artery, it can cause a heart attack; 
if it develops in the brain, it can cause a stroke.  
 
1.1.2 Risk factors of atherosclerosis  
 
Atherosclerosis is a multifactorial disease. Traditionally, the risk factors can be 
classified into modifiable or non-modifiable. The non-modifiable risk factors 
include age, gender and family history; whereas the modifiable risk factors, which 
are predominantly preventable, include dyslipidaemia, hypertension, poor diet, 
smoking, diabetes mellitus, obesity and sedentary lifestyle [5]. In addition, several 
novel risk factors for atherosclerosis has also been identified, including 
inflammation and haemostasis [8,9]. A better appreciation of the atherogenic effects 
of both traditional and novel risk factors has provided better predictive power than 
a single risk factor [10]. Hence, it is crucial to understand that the sum of these risk 
factors play a greater effect than individual factor in atherogenesis.  
 
1.1.3 Development of atherosclerosis in the arterial wall 
 
The tunicae intima, media and adventitia are the three layers that make up the 
arterial wall. The tunica intima is composed of a single layer of endothelial cells, 
resting on a basal lamina which is co-synthesised by them and smooth muscle cells, 
contributing to the extracellular matrix (ECM) proteins in the subendothelial space. 
The internal elastic lamina separates the intima from the media, which is comprised 
of numerous layers of smooth muscle cells, bordered by a basal lamina and 
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intercalated between elastic laminae. An external elastic lamina separates the media 
from the adventitia, which is made up of fibroblasts, mast cells, microvessels, 
lymphatic vessels and nerves, housed within an extended ECM [11].  
 
In atherosclerosis, the arterial endothelial and smooth muscle cells work in concert 
with emigrated blood cells, particularly monocytes, T-lymphocytes, dendritic cells 
and mast cells, accompanied by their secretory products such as chemokines and 
cytokines to initiate formation of the plaque [6]. The development of atherosclerotic 
plaques in the intima of the arteries changes the normal architecture of the vessel 
wall. Figure 1.1 illustrates the development of atherosclerosis.  
 
Initiation stage: lipid retention and the monocyte/macrophage recruitment to 
the arterial wall 
 
As outlined in the Response-to-Retention theory, atherosclerosis is initiated when 
LDL particles are retained in the subendothelial region of the vascular wall by their 
interactions with the arterial proteoglycans [12]. This theory is supported by several 
human studies demonstrating that the first abnormality in an atherosclerosis-
susceptible artery is the development of pathologic intimal thickening with early 
accumulation of lipids [13]. In addition, the proteoglycans isolated from the 
atherosclerosis-susceptible White Carneau pigeons have been found to be more 
sulphated and the molecules exhibited a higher LDL binding affinity than those 
from the atherosclerosis-resistant Show Racer pigeons [14], indicating that a change 
in the proteoglycan structure in an atherosclerosis-prone arterial wall is essential 
Introduction 
5 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The development of atherosclerosis. (1) Atherosclerosis is initiated by LDL retention by proteoglycans in the intima, 
followed by monocyte recruitment to the endothelial cells, migration of the bound monocytes into the intima. (2) Lesion 
progresses with the maturation of monocytes into macrophages, and their uptake of LDL. Concurrently, the migration 
of smooth muscle cells (SMCs) from the media to the intima and the increased synthesis of ECM proteins like collagens 
and proteoglycans occur. The accumulation of SMCs causes intimal thickening. (3) Macrophages and smooth muscle 
cells can die in advancing lesions, together with the extra- and intracellular LDL, accumulate to form a lipid core. 
Rupture of the plaque and thrombosis, the ultimate complication of atherosclerosis, can result in deadly coronary events 
(Original artwork by CY Ng 2015).  
 
Introduction 
6 
 
for LDL accumulation. This phenomenon occurs prior to influx of inflammatory 
cells [15], thus highlighting the absolute need for (1) subendothelial proteoglycan 
accumulation/structural changes and (2) LDL retention to initiate atherosclerosis. 
Upon stimulation by sustained high plasma levels of LDL, the permeability of the 
arterial endothelial layer increases [16]. This then promotes the entry and retention 
of LDL in the subendothelial space. Circulating atherogenic LDL particles enter the 
subendothelial space and are retained by ionic interactions between the positively 
charged residues (lysine and arginine) on apolipoproteins B and E with negatively 
charged sulphate groups on the GAG chains of the proteoglycans [17]. The trapped 
LDL then undergoes oxidative modifications to form oxidised LDL (oxLDL), that 
can induce the expression of cell adhesion molecules on the endothelial cells [18]. 
In addition, oxLDL can also switch the endothelial cells to a secretory phenotype, 
causing them to release chemoattractant and stimulant [19]. Consequently, these 
events enable the endothelial cells to tether the circulating monocytes on their 
surfaces, and direct the migration of the bound monocytes into the subendothelial 
space. Once resident in the arterial wall, the monocytes differentiate into 
macrophages. These macrophages clean up the trapped LDL to prevent further 
inflammation [6]. 
 
Progression stage: migration of arterial smooth muscle cells into intima and 
the subsequent intimal thickening  
 
During this stage, the immune response driven by the macrophages is joined by a 
proliferative response mediated by the arterial smooth muscle cells and endothelial 
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cells. Macrophages secrete cytokines and growth factors to recruit arterial smooth 
muscle cells from media to the intima [20]; and matrix metalloproteinases (MMPs) 
to degrade the internal elastic lamina to facilitate the migration of the recruited cells 
[21]. Then, endothelial cells secrete lipoprotein lipase, causing the arterial smooth 
muscle cells to switch phenotype from a quiescent contractile state to an active 
synthetic state [22]. This makes the cells start synthesising ECM such as collagens 
and proteoglycans to help in the further progression toward a stable plaque [23]. 
Due to their repairing activities, the intimal accumulation of smooth muscle cells is 
considered beneficial during this stage [24]. However, when the atherosclerotic 
stimuli persist, the cells can become voluminous and dominating, such that lumen 
is lost and blood flow is reduced [25]. This is known as intimal thickening.  
 
Late stage: cell death and plaque rupture 
 
When the in-principle protective activities of macrophages, endothelial cells and 
arterial smooth muscle cells are overwhelmed by LDL and other atherogenic stimuli, 
the cells can die, leaving the lipid behind as an unstable lipid-rich necrotic core, 
which is covered by a fibrous cap [26]. Cell death occurring in the core is 
detrimental to the stability of a plaque as it can contribute to the thrombogenicity 
of the plaque via circulating pro-coagulant materials [27]. In addition, 
macrophages/foam cells also secrete MMPs [28,29]. MMPs can thin the fibrous cap, 
making the plaque susceptible to rupture [30]. Macrophages also generate 
mediators that provoke the death of arterial smooth muscle cells, which are the 
paramount source of collagens, thus further destabilising the plaque [31]. At the 
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same time, the blood vessel itself become less pliable. Eventually, the lesion surface 
becomes disrupted, exposing the pro-coagulant materials in the necrotic core to the 
coagulation proteins in the circulation, triggering formation of a blood clot [32,33]. 
This event is known as thrombosis. Thrombosis is the ultimate deadly complication 
of atherosclerosis, responsible for most acute coronary syndromes [34].  
 
1.2 Macrophage phenotypes  
 
Macrophages, which differentiate from monocytes that are recruited from the 
circulation, are prodigious phagocytic cells that play a crucial part in the immune 
responses to pathogens [35]. They also contribute to the resolution of inflammation 
by eliminating cellular debris and cells that have undergone apoptosis [36]. 
Therefore, macrophages can exhibit pro- and anti-inflammatory functions 
depending on the cytokines from the local microenvironment [37].  
 
Polarisation is the process of changing the physiology of macrophage. It is crucial 
for macrophages to carry out their diverse yet specialised functions. Macrophages 
are generally classified into two main extremes: classically activated or type I 
macrophages (M1), which are pro-inflammatory; and alternatively activated or type 
II macrophages (M2) which exhibit anti-inflammatory properties [38]. This M1/M2 
paradigm was constructed on the observation that lipopolysaccharide (LPS) and 
interferon-ɣ (IFN-ɣ) trigger divergent effects on macrophages isolated from 
different strains of mice: while macrophages isolated from so-called Th1 strains 
(C57BL/6) secreted nitric oxide, those isolated from Th2 strains (Balb/c) had 
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arginine metabolism stimulated [39]. Over time, this macrophage dichotomy has 
led to multiple cytokines and surface markers being identified as predominantly M1 
or M2 based on culturing of the cells into two extremes, thus making it possible to 
infer two seemingly distinct macrophage subsets. However, this two-decade-old 
naming system is an in vitro construction that relies on stimulating macrophages in 
culture condition with a well-defined set of factors, meaning that it becomes 
problematic to properly represent an in vivo scenario. For example, in vitro culture 
of human monocytes with macrophage colony-stimulating factor (M-CSF) or 
granulocyte macrophages colony-stimulating factor (GM-CSF), followed by 
activation with diverse stimuli revealed considerable deviation from the M1/M2 
definition [40]. Thus, a macrophage can encounter different stimuli in vivo that lead 
to a phenotype outside the M1/M2 axis. 
 
Therefore, there have been several arguments on whether the M1/M2 paradigm 
should be abandoned altogether. Murray et al. [41] proposed naming macrophages 
according to the stimuli that they encounter. For example, macrophages activated 
with LPS would be called M(LPS), and those stimulated with interleukin (IL)-4 
would be called M(IL-4). However, this proposed naming system decidedly does 
not consider the cell origins, tissue microenvironment, and time, which are all 
important in vivo. More recently, Nahrendorf and Swirski [42] have also proposed 
to name macrophages according to their functions and natural habitats. Still, this 
does not completely define the diverse macrophage population and thus, none of 
these alternative nomenclatures have been widely adopted.  
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While efforts to define polarisation is advancing, the current M1/M2 nomenclature 
has the obvious advantage of reflecting the Th1/Th2 dichotomy, which has already 
extended to other cell populations, such as T-cell (Tc1), Tc2; natural killer (NK1), 
NK2. Reviewing the latest published atherosclerosis literature, the terms ‘M1’ and 
‘M2’ are still commonly used to describe macrophages in atherosclerotic lesions. 
As the macrophages in this thesis were cultured under specific M1 and M2 inducing 
conditions, then this thesis uses the M1/M2 nomenclature. The sections below 
briefly discuss these two phenotypes of macrophage, their distribution in the 
plaques, and their known contribution to the development of atherosclerosis.     
 
1.2.1 Pro-inflammatory M1 macrophages  
 
The term ‘M1’ has been used to designate the macrophages that are produced in 
response to type 1 T-lymphocyte (Th1) derived cytokines, which include interferon-
γ (IFN-γ), microbial moieties such as lipopolysaccharide (LPS) and other cytokines 
like tumour-necrosis factor-alpha (TNFα) and granulocyte macrophage colony-
stimulating factor (GM-CSF) [41]. They can also be transiently generated in 
response to innate stimuli following stress or viral infections [43]. M1 activation 
results in a macrophage population that possesses an enhanced microbicidal 
capacity through the production of nitric oxide and pro-inflammatory cytokines 
such as interferon-gamma (IFN-ɣ), IL-8, IL-12 and tumour necrotic factor-alpha 
(TNF-α), thus promoting strong pro-inflammatory Th1 immune responses [44]. 
Furthermore, M1 macrophages also produce reactive nitrogen and oxygen species, 
which result into heightened inflammatory responses [45].  
Introduction 
11 
 
In addition, the M1 population is thought to contribute to macrophage-mediated 
tissue injury [46]. They are oriented to elicit tissue apoptotic reactions [47]. Further, 
macrophage M1 activation also up-regulates several matrix metalloproteinases 
(MMPs) including MMP-1, -3, -7, -10, -12, -14 and -25, which are then involved 
in reorganisation of tissue matrices [48,49]. As such, while M1 macrophages are 
vital components of host defence, their activation can lead to tissue damage.  
 
1.2.2 Anti-inflammatory M2 macrophages 
 
The term ‘M2’ is generally used to describe all macrophages that are activated in 
the absence of Th1 cytokines [41]. Type 2 T-lymphocyte (Th2) type cytokines, such 
as interleukins (IL) 4, 5, and 13, induce M2 activation in the macrophages [50]. M2 
macrophages are characterised by little to no secretion of pro-inflammatory 
cytokines, but an elevated secretion of anti-inflammatory cytokines, promotion of 
tissue remodelling and repair, and increased capacity to fight parasitic infections 
[51]. Indeed, the inhibition of intracellular pathways that govern the generation of 
anti-inflammatory cytokines, such as the eicosanoid pathway [52], promotes 
macrophage M2 polarisation but attenuates M1 polarisation. Thus, M2 
macrophages are commonly termed in the current literature as anti-inflammatory, 
resolving, wound healing or regulatory macrophages and they are considered as the 
opposites of M1 macrophages. Furthermore, they also express a repertoire of 
surface markers leading to tolerance and a high phagocytotic capacity [53]. 
Through their high capacity to phagocytose tissue debris and apoptotic bodies, M2 
macrophages thus counteract the tissue damage caused by M1 macrophages [54]. 
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Unexpectedly, like M1 macrophages, a recent study has found that M2 
macrophages can also produce reactive oxygen species during the process of 
phagocytosis [55]. The mechanism of the generation and role of the reactive oxygen 
species produced by M2 macrophages is not clear, but this shows that, despite being 
opposite, the M2 macrophages appear to have overlapping functions with M1 
macrophages.    
 
1.2.3 Distribution of M1 and M2 macrophages within plaques 
 
Due to the distinct function of M1 and M2 macrophages in the immune response, 
the question arises whether these cells are specifically localised in the 
atherosclerotic plaques. Figure 1.2 depicts the distribution of M1 and M2 
macrophages in an atherosclerotic plaque. Stöger et al. [56] reported that M1 
macrophages dominate the shoulder regions of the human plaques, which is a 
critical region susceptible to rupture. In contrast, M2 macrophages are predominant 
in the adventitia. Both subsets are equally distributed in the fibrous cap region. 
Foam cells however display an ambiguous repertoire that incorporates both M1 and 
M2 markers. In addition, M2 macrophages are prominent in the more stable cell-
rich areas of plaque, away from the lipid core where M1 macrophages dominate 
[57]. This distinctive localisation of macrophage phenotypes within the plaques 
suggests three possibilities: first, that different monocytes give raise to these 
phenotypes; second, that sequential spatiotemporal recruitment of M1 and M2 
macrophages occurs within the plaque; third and most importantly, that 
macrophages polarise in response to the local microenvironment.  
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Figure 1.2 Distribution of M1 and M2 macrophage within an atherosclerotic 
lesion. M1 macrophages are predominant in the shoulder region and 
lipid core, which are a critical region susceptible to rupture. In 
contrast, M2 macrophages are abundant in the cell-rich media and 
adventitia. No differences between subsets in the fibrous cap 
(Adapted from [56,57]). 
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1.2.4 Possible roles of M1 macrophages in atherosclerosis 
 
M1 macrophages are generally considered pro-atherogenic because they contribute 
to an increased and sustained inflammatory response within the plaques via the 
secretion of pro-inflammatory cytokines [58,59]. These cytokines can provoke 
endothelial dysfunction by suppressing endothelial nitric oxide synthase [45], the 
functions of which are lowered oxidative stress, inhibited expression of pro-
atherogenic mediators and attenuated leukocyte-endothelial interactions [60]. 
Furthermore, M1 macrophages also generate reactive oxygen species, which have 
important consequences for LDL oxidation [61]. A comparison of human carotid 
with femoral atherosclerotic plaques revealed that M1 macrophages were abundant 
in carotid, whereas M2 macrophages were predominant in femoral, indicating that 
M1 accumulation is a characteristic of symptomatic lesions [62]. Indeed, several 
MMPs, which are upregulated in vitro, are also co-localised with M1 macrophages 
in atherosclerotic plaques [63]. We have also reported an inverse correlation 
between M1 macrophages and plaque cap thickness [64]. Thus, M1 macrophages 
may destabilise plaques.  
 
1.2.5 Possible roles of M2 macrophages in atherosclerosis 
 
M2 macrophages are generally considered atheroprotective due to their ability to 
dampen inflammatory response [65,66]. Additionally, M2 macrophages show a 
better capacity in eliminating LDL than M1 macrophages [67], which likely leads 
to reduced inflammation. However, the process of eliminating LDL can lead to 
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death of the M2 macrophages [68], thus contributing to the growth of the necrotic 
core. Like M1 macrophages, M2 macrophages can also secrete a variety of MMPs 
[59]. Though this suggests that M2 macrophages can destabilise the plaques, the 
effects of their MMPs on plaque stability have never been demonstrated in vivo. 
We have found that while M1 macrophages are associated with plaque instability, 
M2 macrophages are not. Rather, they have been found to be co-localised with 
collagen in the plaques [64]. As such, M2 macrophages can help in the plaque 
stability and therefore, it is thought that skewing the macrophages to M2 may be 
beneficial [69].    
 
1.3 Proteoglycans  
 
The ECM constitutes more than half of the arterial wall mass [70]. It is a mixture 
of collagen and elastic fibres embedded in a viscoelastic gel consisting of 
proteoglycans, hyaluronan, fibronectin, etc, collectively known as stroma or matrix. 
Integrity of the arterial wall depends on strength and elasticity of the matrix, with 
collagens and elastin as the main structural protein, cross-linked by proteoglycans 
(Figure 1.3).  
 
Proteoglycans are a group of non-fibrillar molecules of the ECM of different kinds 
of tissue that are characterised by the presence of a varying number of 
glycosaminoglycan (GAG) chains of variable length and type, that are covalently 
attached to a core protein. There are two main groups of GAG present in the arterial 
wall: chondroitin sulphate and heparan sulphate. They are chain-like negatively  
Introduction 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Extracellular matrix of the arterial wall. (A) The extracellular matrix 
is a mixture of collagen and elastic fibres embedded in a viscoelastic 
gel consisting of proteoglycans, hyaluronan and fibronectin. (B) A 
micrograph showing a matrix of proteoglycans. (C) A schematic 
representation of the basic structure of proteoglycans with many 
glycosaminoglycans attached to each core protein. (D) The chemical 
structure of different glycosaminoglycan side chains. (Images 
modified from [71])  
 
A 
B    C    D 
Smooth muscle cell 
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charged polysaccharides, composed of repeating disaccharide units which can be 
variously substituted by sulphate groups. The disaccharide units unique to each of 
these GAG chains and the positions on the disaccharides that can be sulphated are 
illustrated in Figure 1.4.   
 
1.3.1 Proteoglycans commonly found in arterial wall 
 
The arterial wall is a complex organ, particularly with respect to proteoglycans. To 
date, at least two major families are known: chondroitin/dermatan sulphate 
proteoglycans and heparan sulphate proteoglycans. Arterial smooth muscle cells 
are the prime source for these proteoglycans. In vitro, they have been shown to 
produce chondroitin/dermatan sulphate containing decorin, biglycan and versican, 
and the heparan sulphate perlecan [72,73]. However in vivo, biglycan, versican and 
perlecan constitute the bulk of the proteoglycans found in the arterial wall [74], 
therefore, this thesis focuses on these three proteoglycans.  
 
The distributions of these proteoglycans are organised with distinct predominance 
in the three layers of the arterial wall (Table 1.1). From the table, biglycan and 
versican are found to dominate the adventitia, whereas the intima is predominantly 
occupied by biglycan, perlecan and versican. Additionally, these proteoglycans 
also have varied biological properties, and some of these properties are implicated 
in the development of atherosclerosis. For example, chondroitin sulphate 
proteoglycans (notably biglycan) are capable of forming complexes with LDL,  
  
Introduction 
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Chemical structure of the repeating disaccharide units of chondroitin 
sulphate and heparan sulphate. The positions on the units (C-2, C-4 
or C-6) which can be substituted by sulphate groups are marked in 
red circles. (Image modified from [75]) 
 
Chondroitin sulphate 
Heparan sulphate 
D-glucuronic acid 
or 
L-iduronic acid 
 
N-acetyl-D-glucosamine 
or 
N-sulpho-D-glucosamine  
 
D-glucuronic acid
   
N-acetyl-D-galactosamine 
C-2 
C-2 C-2 
C-6 
C-6 
C-4 
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Table 1.1 Topographically distinct distributions of proteoglycans present in healthy arterial wall. Their distributions were detected 
by immunohistochemical staining on the blood vessel.  
 
 
Study Sample Subject Intima Media Adventitia 
 
Riessen et al. [76] Internal mammary artery Human  Biglycan +++ 
 
Biglycan + 
 
Biglycan +++ 
 
 
Evanko et al. [77] Thoracic aorta 
Abdominal aorta 
Non-human primate 
Macaca nemestrina 
Versican + 
Biglycan + 
Perlecan +++ 
Versican + 
Biglycan +  
Perlecan + 
Versican -  
Biglycan - 
Perlecan - 
 
O’Brien et al [78] Coronary artery Human Versican +++ 
Biglycan + 
Versican + 
Biglycan + 
Versican + 
Biglycan +++ 
 
Yamakawa et al. [79] Aorta New Zealand White rabbit Biglycan - 
 
Biglycan - 
 
Biglycan - 
 
 
Merrilees et al. [80] Coronary artery Human Versican +++ 
Biglycan +++ 
 
Versican + 
Biglycan + 
 
Versican +++ 
Biglycan +++ 
 
 
 Saphenous artery  Versican +++ 
Biglycan +++ 
 
Versican + 
Biglycan +  
 
Versican +++ 
Biglycan +++ 
 
 
 Radial artery  Versican + 
Biglycan + 
 
Versican + 
Biglycan + 
Versican +++ 
Biglycan +++ 
 
 
Huang et al. [81] Carotid artery Female LDLR-/- mice  Biglycan - 
Perlecan +++ 
Biglycan + 
Perlecan +++ 
Biglycan +++ 
Perlecan - 
 
Symbols are: -, undetectable staining; +, detectable/light staining; +++, strong staining
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leading to lipid accumulation in the arterial wall, which is a hallmark of 
atherosclerosis [78,81]. On the contrary, heparan sulphate perlecan is anti-
thrombogenic, and facilitates binding of the lipid-clearing enzyme to the arterial 
matrix [82]. Thus, these families seem to play an opposite role in atherosclerosis 
and the distinct co-localisations with lipid deposition in atherosclerotic lesions may 
give a hint at their different roles in LDL interactions (Table 1.2). However, 
proteoglycans can display heterogeneity even in the same family [83]. The 
following sections therefore further discuss the role of these proteoglycans in 
atherosclerosis. 
 
1.3.1.1 Biglycan  
 
Biglycan has a core protein of ~40 kDa with two chondroitin/dermatan sulphate 
GAG chains, thus its eponym meaning two (bi) GAG chains (glycan). It can be 
divided into four domains: the amino-terminal domain I which contains a signal 
peptide and pro-peptide; the domain II which contains cysteine residues where the 
GAG chains are attached; the leucine-rich domain III which functions to bind and 
interact with other proteins; and the domain IV which contains a relatively large 
loop with two cysteine residues (Figure 1.5) [84].   
 
Studies have shown that biglycan is the proteoglycan most consistently co-localised 
with apoB within atherosclerotic lesions in both mouse and human, thereby 
suggesting a leading role of biglycan in lipoprotein retention during atherosclerosis 
development [78,81]. The overexpression of biglycan by smooth muscle cells has 
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Table 1.2 Distribution of proteoglycans in atherosclerotic plaques as detected with immunohistochemistry. 
 
Proteoglycan Distribution in atherosclerotic plaques Sample Subject Sex / Age Study 
Biglycan • Fibrotic plaque infiltrated with 
macrophages 
• Co-localised with collagen types I and III 
 
Internal 
mammary artery 
Human NS / NS Riessen et al. [76] 
• Intimal thickening,  
• Fibrous cap   
• Myxoid area 
• Lipid-rich core  
 
Coronary artery Human M & F / 31 – 
66 years old 
Gutierrez et al. [85] 
• SMCs in fibrous cap Thoracic aorta 
Abdominal aorta 
 
Non-human primate 
Macaca nemestrina 
M / 3 – 5 years 
old 
Evanko et al. [77] 
• Areas of necrosis and dense macrophage 
infiltration 
• Co-localised with apoB in ECM 
 
Coronary artery Human NS / NS O’Brien et al. [78] 
• Stable plaques 
• Absent in eroded plaques 
Culprit plaque Human M & F / 30 – 
55 years old 
 
Kolodgie et al. [86] 
• Regions surrounding foam cells 
• Lipid cores 
Aortic sinus apoE-/- mice 
LDLR-/- mice 
M & F / 10 – 
73 weeks old 
 
Kunjathoor et al. 
[87] 
• Intimal thickening  
• Co-localised with apoB 
Right coronary 
artery 
Human M & F / 7 – 49 
years old 
 
Nakashima et al. 
[15] 
• Media 
• Co-localised with apoB  
Carotid artery LDLR-/- mice F / 10 – 12 
weeks old 
 
Huang et al. [81] 
• Intimal thickening 
• Necrotic core 
Coronary plaque Human M / 47.6 ± 11.1 
years 
Otsuka et al. [13] 
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Versican • Cellular areas surrounding the lipid core 
 
Carotid artery Human N / N  Halpert et al. [28] 
• Intima, co-localised with apo(a) and apoE 
 
Coronary artery Human N / N Lin et al. [88] 
• Intimal thickening 
• Fibrous cap 
• Zone of loose, myxoid connective tissue 
• Border of the lipid-rich core  
 
Coronary artery Human M & F / 31 – 
66 years old 
Gutierrez et al. [85] 
• Fibrous cap 
• Plaque margins 
• Absent in the plaque core 
Thoracic aorta 
Abdominal aorta 
 
Non-human primate 
Macaca nemestrina 
M / 3 – 5 years 
old 
Evanko et al. [77] 
• Area of necrosis and dense macrophage 
infiltration 
• Co-localised with apoB in ECM 
 
Coronary artery Human NS / NS O’Brien et al. [78] 
• Both stable and eroded plaques Culprit plaque Human M & F / 30 – 
55 years old 
 
Kolodgie et al. [86] 
• Mostly absent or detected at low levels in 
the lesion of all stages 
Aortic sinus apoE-/- mice 
LDLR-/- mice 
M & F / 10 – 
73 weeks old 
 
Kunjathoor et al. 
[87] 
• Fibrous cap 
• In close proximity to the necrotic core 
 
Carotid artery Human M & F / 52 – 
88 years old 
Tran et al. [89] 
• Virtually absent Aortic root apoE-/- mice 
 
N / 15 – 33 
weeks old  
Tran-Lundmark et 
al. [90] 
 
• Lipid pools in intimal thickening 
• Absent in necrotic core of late 
fibroatheromas 
 
Coronary plaque Human M / 47.6 ± 11.1 
years 
Otsuka et al. [13] 
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Perlecan • Superficial cap 
• Endothelial basement membrane and inner 
media directly beneath the lesion 
 
Thoracic aorta 
Abdominal aorta 
Non-human primate 
Macaca nemestrina 
M / 3 – 5 years 
old 
Evanko et al. [77] 
• Intima  Aortic sinus apoE-/- mice 
LDLR-/- mice 
 
M & F / 10 – 
73 weeks old 
Kunjathoor et al. 
[87] 
• Lipid core 
• Fibrous cap 
Aorta apoE-/- mice 
 
M / 12 – 24 
weeks old 
Vikramadithyan et 
al. [91] 
 
• Intima 
• Media 
• Intraplaque microvessels 
• Absent in the fibrous cap and shoulder 
region 
 
Carotid artery Human M & F / 52 – 
88 years old 
Tran et al. [89] 
• Co-localised with apoB Carotid artery LDLR-/- mice F / 10 – 12 
weeks old 
 
Huang et al. [81]  
 • Intima 
• Media 
• Cholesterol clefts in the lipid core 
Aortic root apoE-/- mice 
 
N / 15 – 33 
weeks old  
Tran-Lundmark et 
al. [90] 
Abbreviations are: apo(a), apolipoprotein (a); apoB, apolipoprotein B; apoE, apolipoprotein E; apoE-/-, apolipoprotein E-deficient; ECM, extracellular matrix; F, 
female; IP, immunoperoxidase staining; LDLR-/-, low density lipoprotein receptor-deficient; M, male; N, not mentioned; SMC, smooth muscle cell.  
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Figure 1.5 Schematic representation of the structural features of biglycan. 
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been found to lead to increased lipid retention and atherosclerosis in mice [92]. 
Indeed, in vitro studies performed using a gel mobility shift assay have already 
shown high-affinity interactions between purified biglycan and LDL [78]. However, 
some recent studies indicate that biglycan deﬁciency does not seem to protect 
against atherosclerosis in mice [93-95]; rather, both increased vascular biglycan and 
deﬁciency of vascular biglycan actually can lead to increased atherosclerosis. One 
possible confounding factor about these observations is that biglycan might also 
have interactions with other atherogenic players at the same time, including the 
Toll-like receptors in the pro-inflammatory signalling pathway [96], thus 
potentially leading to the sequestration of that receptor. Therefore, biglycan may be 
a double-edged sword in atherosclerosis. 
 
 
1.3.1.2 Versican  
 
Versican is a large chondroitin sulphate proteoglycan (~80 to ~370 kDa). It was 
named ‘versican’ in recognition of its highly versatile function in the interaction 
with other ECM proteins including hyaluronan [97]. Versican core protein (known 
as isoform V0) can be divided into three domains (Figure 1.6). The amino-terminal 
globular domain (G1), and the carboxy-terminal globular domain (G3) that contains 
a C-type lectin module. The central domain contains two subdomains, designated 
GAGα and GAGβ, which can be alternatively spliced to generate additional 
isoforms: V1, V2 and V3. All isoforms contain chondroitin sulphate GAG chains, 
except V3 [98]. V0 and V1 are the most ubiquitous isoforms in the arterial wall, 
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Figure 1.6 Schematic structures of different isoforms of versican.  
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whereas the V2 isoform is chiefly expressed in the neuronal tissues [99]. V3 is 
found produced by arterial smooth muscle cells [100]. 
 
Versican is prominent at the edges of the necrotic core in advanced lesions and in 
close proximity to deposited lipoproteins in animal models [77,86]. Although it also 
accumulates in human atherosclerotic lesions [89], versican appears to neither co-
localise with apolipoproteins B, E and A-I nor be present in the lipid-rich centre of 
the necrotic core [78], thus questioning about the importance of versican in lipid 
retention in human. The use of non-human models of atherosclerosis [77,86] may 
lead to these different observations because species differences exist regarding the 
proportions of proteoglycans in the vasculature. For example, the murine 
vasculature is rich in heparan sulphate proteoglycans, whereas the human 
vasculature is abundant with chondroitin sulphate proteoglycans [101]. This does 
not necessarily suggest that versican is involved in lipid retention in humans, but 
rather, it depends on where and how much versican is present during the lipid entry 
phase. Still, the role of versican in lipid retention in human atherosclerosis is 
unknown. 
 
1.3.1.3 Perlecan  
 
Perlecan is a large heparan sulphate proteoglycan (~460 kDa). The name ‘perlecan’ 
derives from its rotary shadowing appearance suggesting a string of pearls [84]. It 
has three heparan sulphate GAG chains. The core protein has five domains with 
disparate structural features. The amino-terminal domain I contains attachment sites 
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for the three GAG chains. Domain II contains cysteine-rich repeat units, known as 
LA modules that are highly homologous to the LDL receptor. Domain III harbours 
three distinct globular domains (termed as LamB modules) connected by EGF-like 
regions (LE modules). Domain IV is the largest and the most repetitive section due 
to the presence of 21 immunoglobulin-like repeats. Domain V has three distinct 
globular regions (known as LamG modules) connected by EGF-like repeats (EG 
modules) (Figure 1.7) [84].  
 
Since domain II of the perlecan core protein is structurally homologous to the LDL 
receptor [102], it therefore may be involved in lipid retention. Indeed, animal 
studies have demonstrated the binding of LDL to the perlecan core protein [90,91], 
and human recombinant perlecan domain II has also been found to interact with 
LDL, with the interaction depending on its glycans [103]. As such, perlecan may 
play a role in LDL retention during the development of atherosclerosis. However, 
just like versican, there are cross-species differences regarding the distribution of 
perlecan in atherosclerosis: while perlecan is increased in the animal lesions, it is 
not in human; rather, it is reduced [89]. Although it accumulates and often co-
localises with lipid deposits in the atherosclerotic lesions of mice [90,91], there is 
no direct evidence so far showing that perlecan is associated with lipid retention in 
human atherosclerosis. Additionally, findings regarding the role of the heparan 
sulphate chains of perlecan in atherosclerosis have also been conflicting thus far. 
While it seems to promote atherosclerosis in mice through increased retention of 
lipoproteins [90], research that spans more than two decades has clearly shown that 
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Figure 1.7 Schematic representation of the structural features of perlecan.  
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the heparan sulphate on perlecan is atheroprotective due to not only its inhibition 
of LDL binding to core protein (domain II) [104] but also other anti-atherogenic 
properties such as inhibition of the endothelial adhesion of monocytes [105,106] 
and the control of proliferation of arterial smooth muscle cells [107,108]. 
Atherogenic factors such as oxLDL have also been shown to inversely regulate 
perlecan expression, although the mechanism is not clear [109]. Combined all these 
studies makes it difficult to determine a role for perlecan in human atherosclerosis 
due to its negative correlation with human atherosclerosis and differences in 
expression between mice and humans.  
 
1.4 Macrophages in the production of proteoglycans 
 
Like the more well-established source – the arterial smooth muscle cells and 
endothelial cells – macrophages have also been shown to produce proteoglycans 
[110]. Theoretically as such, macrophages then might be able to promote LDL 
retention in the arterial wall. However, to date, much of the understanding of the 
structure of the proteoglycans in the arterial wall and their interaction with LDL has 
been derived from arterial smooth muscle cells and endothelial cells [111-115]. 
Less is known about the proteoglycans produced by monocytes/macrophages, let 
alone those secreted by the different phenotypes of these cells. Early studies have 
used mouse models [110;116], until human macrophages were also found to 
produce proteoglycans that bound LDL [117]. Since then, the interest in human 
macrophage-derived proteoglycans and their binding of LDL has been burgeoning. 
Macrophages can change their proteoglycan structure for an increased LDL binding 
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under certain circumstances associated with atherosclerosis, such as hypoxia [118] 
and a decrease in the extracellular pH [119]. Although the phenotype of these 
macrophages was not known, these studies suggested that macrophage production 
of proteoglycans and the consequential changes in the LDL binding can be 
influenced by the microenvironment of an atherosclerotic lesion. Given that 
macrophages are heterogenous in human atherosclerosis [56], the proteoglycans 
produced by M1 and M2 macrophages may vary, and hence, they may have 
differing roles in LDL retention.  
 
1.5 Aims of the study 
 
While skewing macrophages from a pro-inflammatory M1 to an anti-inflammatory 
M2 phenotype has recently been shown to be a possible way of stabilising 
atherosclerotic plaques [120], a complete understanding of the pro- and anti-
atherogenic functions of the macrophage phenotypes is lacking. In particular, how 
the different macrophages may contribute to atherosclerosis development through 
the lipid-proteoglycan interaction is unknown. Nor it is understood how the uptake 
of lipid itself impacts proteoglycan production. Therefore, the fundamental aim of 
this thesis was to determine what proteoglycans are produced by M1 and M2 
macrophages (and their foam cell forms) and assess the LDL binding of these 
proteoglycans. The specific aims are outlined below:  
 
1. To identify and examine the production as well as the structure of the 
proteoglycans and GAG chains produced by M1 and M2 macrophages.   
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2. To determine and compare the LDL binding of the proteoglycans produced 
by M1 and M2 macrophages.   
3. To examine the co-localisation of macrophages and proteoglycans in human 
atherosclerotic lesions.  
4. To investigate the proteoglycans and GAG chains produced by M1 and M2 
foam cells and their LDL binding.  
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2.1 Generation of polarised macrophages and their foam 
cell forms 
 
2.1.1 Sterile techniques 
 
All cell culture experiments were performed in a biohazard hood under sterile 
conditions in a Physical Containment Level 2 (PC2) laboratory. All necessary 
materials including pipette tips, Eppendorf tubes, containers, etc. were thermally 
sterilised in the autoclave at 121°C for 30 min. Sterile stock solutions (e.g. culture 
medium, cytokines etc.) were prepared in lipopolysaccharide (LPS)-free containers.  
 
2.1.2 Preparation of cell culture medium  
 
A bottle of powdered Roswell Park Memorial Institute (RPMI) 1640 medium (Cat. 
No.: R8755Sigma Aldrich, St. Louis, MO, USA), and 2 g of sodium bicarbonate 
were dissolved completely in 1 L of deionised water. The pH of the solution was 
adjusted to 7.0. The medium was sterilised by filtering it through a 0.2 µm 
membrane filter and stored at 4°C for a month or frozen until required. For cell 
culture, 10% volume/volume (v/v) of foetal bovine serum (FBS) (Cat. No.: 12003, 
JRH Biosciences) and 1% v/v of penicillin/streptomycin (P/S) (Cat. No.: P4458, 
Sigma Aldrich, St. Louis, MO, USA) (final concentration: penicillin, 50 U/mL; 
streptomycin, 50 µg/mL) were added to 200 mL of medium, and used within two 
weeks. 
 
Materials and methods 
36 
 
2.1.3 Preparation of macrophage-polarising cytokines 
 
Lyophilised cytokines were reconstituted with respective solvents under sterile 
conditions (Table 2.1). The powder was dissolved by swirling the vial gently. 
Reconstituted stocks were stored in a manual defrost freezer at -20°C until required. 
The stock solutions were further diluted to the desired working concentration with 
additional reconstituting agents.  
 
Table 2.1 Reconstitution of cytokines 
Cytokines Company 
(Cat. No.) 
Stock 
concentration 
Solvents 
 
 
Macrophage 
colony stimulating 
factor (M-CSF) 
R&D Systems 
(216-MC-
025) 
50 µg/mL Sterile phosphate 
buffered saline (PBS) 
with 0.2% bovine 
serum albumin 
 
LPS Sigma 
Aldrich 
(L3012) 
 
1 mg/mL RPMI-1640 without 
FBS and P/S 
 
Interferon-gamma 
(IFN-ɣ) 
R&D Systems 
(285-IF-100) 
 
0.1 mg/mL Sterile, deionised water 
Interleukin-4 (IL-4) Sigma 
Aldrich 
(I4269) 
 
0.1 mg/mL Sterile, deionised water 
 
2.1.4 Maintenance of human monocyte-like THP-1 cells 
 
In this study, THP-1 cells were generously provided by Dr Sophie Lev, Centre for 
Infectious Diseases and Microbiology, Westmead Institute for Medical Research, 
Westmead, NSW, Australia.    
Materials and methods 
37 
 
The cells were cultured according to the protocol from the American Type Culture 
Collection (ATCC) for propagation in RPMI-1640 medium supplemented with 10% 
FBS and 1% P/S in T-75 flasks (10 mL) under sterile standard culture conditions 
(5% CO2, 37°C), and the medium was changed every two to three days. Once 
confluency (approximately 8.0 × 105 cells/mL) was achieved, cell suspension was 
collected and centrifuged at 300 × g for 3 min. The supernatant was discarded and 
then the cells were resuspended in fresh medium. The cells were then counted and 
seeded into new flasks at density of 1.0 × 105 cells/mL. The cell density was 
maintained to not exceed 1.0 × 106 cells/mL. For all experiments, each batch of the 
cells were used only for a period of approximately three months’ time.  
 
2.1.5 Differentiation of THP-1 cells into M0 macrophages 
 
Cells (3.3 × 106 cells per 10 mL) were differentiated into naïve M0 macrophages 
by treatment with 5 ng/mL of phorbol-12-myristate 13-acetate (PMA) (Cat. No.: 
P8139, Sigma Aldrich, St. Louis, MO, USA) for 72 h in RPMI-1640 medium 
supplemented with 10% FBS. After differentiation, non-attached cells were 
removed by aspiration, and adherent cells were washed with fresh RPMI-1640 
medium without PMA three times. Then, the PMA-differentiated macrophages 
were allowed to rest for 24 h in RPMI-1640 medium with 10% FBS before further 
interventions [121].   
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2.1.6 Polarisation of M0 macrophages into M1/M2 phenotypes 
 
M0 macrophages were polarised into M1 or M2 phenotypes by stimulation with 
appropriate cytokines (Table 2.2) in RPMI-1640 medium supplemented with 10% 
FBS and 1% P/S, for 48 h. After stimulation, cell morphology was observed under 
a light microscope. The conditioned medium was collected and stored at -20°C until 
further assessments. Cells were harvested for macrophage phenotype analysis using 
flow cytometry or were subject to further interventions (e.g. the generation of foam 
cells).     
 
Table 2.2 Cytokines for polarising M0 macrophages 
Macrophage 
subset 
Polarising 
stimuli 
Company (Cat. No.) Final 
concentration 
(ng/mL) 
M1 LPS Sigma Aldrich (L6529) 100 
 IFN-ɣ R&D Systems (285-IF-
100) 
 
20 
 
M2 IL-4 Sigma Aldrich (I4269) 20 
 
   
 
2.1.7 Flow cytometric analysis of macrophage phenotypes 
 
After polarisation, the macrophages were recovered by scraping of the culture plate. 
The cells were centrifuged at 300 × g for 5 min followed by resuspension in sterile 
PBS with 2% FBS. Cells (50 µL, 1.0 × 105 cells) were aliquoted into each FACS 
tube. Non-specific binding was blocked by 1% w/v bovine serum albumin (BSA) 
in PBS for 10 min at room temperature. Fluorochrome-labelled monoclonal primary 
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antibodies against CD86 (1.25 µL; clone 2331, BD Biosciences, Franklin Lakes, 
NJ, USA), CD206 (5 µL; clone 19.2, BD Biosciences), CD163 (5 µL; clone 24F, 
BD Biosciences) or CD11b (5 µL; clone ICRF44, BD Biosciences) were added to 
the cells and incubated for 15 min at room temperature in the dark. Excess 
antibodies were removed by washing with 3 mL of PBS with 2% FBS (300 × g, 5 
min, room temperature). The supernatant was discarded, and the cells were fixed 
with 4% formaldehyde (diluted from 37% formaldehyde; Sigma Aldrich, St. Louis, 
MO, USA, Cat. No.: F1635). Cell surface marker expression was analysed on a 
flow cytometer (Becton Dickinson) and using FCS Express Version 4 software (De 
Novo Software, Glendale, CA, USA).     
 
2.1.8 Generation of foam cells from polarised macrophages  
 
After polarisation for 48 h, macrophages were washed with fresh RPMI-1640 twice. 
Then, the cells were transformed into foam cells by incubation with 50 µg/mL of 
human oxidised low-density lipoprotein (oxLDL) (Cat. No.: J65591, Alfa Aesar, 
Haverhill, MA, USA) in FBS-free RPMI-1640 containing the respective cytokines 
for 24 h [122]. Afterwards, the conditioned medium was collected and stored at -
20°C until further analysis.  
 
2.1.9 Oil Red O staining to confirm foam cell formation 
 
Foam cells were washed once with PBS and fixed in 4% paraformaldehyde-PBS 
for 10 min. After rinsing with 60% isopropanol, the cells were stained with 0.3% 
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Oil Red O in deionised water for 10 min, washed with 60% isopropanol again, and 
then counterstained with haematoxylin for 3 min. After copious washing with water 
(i.e. water rinsed off clear), the cells were observed under a light microscope.   
 
2.2 Purification of macrophage proteoglycans 
 
Anion exchange chromatography was performed to purify proteoglycans from the 
macrophage-conditioned medium. This technique works based on the reversible 
adsorption of negatively charged proteoglycans from macrophage-conditioned 
medium to the immobilised positively charged diethylaminoethyl (DEAE) groups 
on cellulose matrix of the column.  
 
The column was equilibrated with three column volumes of running buffer (250 
mM NaCl, 20 mM Tris-base, 10 mM EDTA, pH 7.5) at 4°C. The pooled 
conditioned medium was filtered and added with 0.02% of sodium azide. It was 
loaded onto the column at 4°C with a 1.0 mL/min flow rate. After that, the column 
was connected to fast protein liquid chromatography (FPLC, AKTA purifier, GE 
Biosciences) analyser. The column was washed with running buffer to remove 
unbound materials. A baseline UV absorbance was then established using running 
buffer. The buffer was changed to eluting buffer (1 M NaCl, 20 mM Tris-base, 10 
mM EDTA, pH 7.5). By increasing the ionic strength of buffer, the competition 
between the bound proteins and buffer ions became greater and so reduced the 
interaction between DEAE and proteins, causing the proteins to elute. The 1 M 
NaCl eluting peak (which contained proteoglycans) was collected. The column was 
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washed with three column volumes of regenerating buffer (2 M NaCl, 20 mM Tris-
base, 10 mM EDTA, pH 7.5) and it was then stored at 4°C.  
 
The 1 M NaCl eluting peak was concentrated by dialysing it in a large amount of 
sucrose for overnight at 4°C followed by a buffer exchange using dialysis against 
DPBS for 6 h at 4°C. Finally, the concentration of the proteoglycan-enriched 
fraction was determined by Coomassie protein assay and kept at -20°C until further 
analysis.  
        
2.3 Characterisation of macrophage proteoglycans  
 
2.3.1 Coomassie protein assay for total protein quantification  
 
The protein concentration of the proteoglycan-enriched materials was quantified by 
Coomassie protein assay. Protein standards with concentration ranging from 0 to 1 
mg/mL were prepared from bovine serum albumin (BSA). Then, 10 µL of each of 
the standards and samples were loaded in triplicate in a medium-binding 96-well 
plate. Coomassie reagent (200 µL; Pierce Thermo Scientific, Waltham, MA, USA, 
Cat. No.: 23200) was added into each well. The plate was incubated for 5 min at 
room temperature. Absorbance was then measured at wavelength of 595 nm using 
a plate reader (Infinite® 200 PRO, TECAN, Switzerland). A linear standard curve 
was prepared from the absorbance readings for protein standards and the 
concentrations of the samples were determined from the curve.  
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2.3.2 1,9-Dimethylmethylene Blue (DMMB) assay for GAG 
quantification 
  
DMMB reagent was prepared by dissolving 16 mg DMMB dye, 3.04 g glycine and 
2.37 g NaCl in 1 L of deionised water at pH 3.0 overnight. The reagent was filtered 
through a 0.2 µm membrane and divided into 50 mL aliquots. Each aliquot was 
wrapped in aluminium foil for storage at room temperature. Chondroitin sulphate 
standard solutions were prepared from lyophilised chondroitin sulphate sodium salt 
(Cat. No.: C9819, Sigma Aldrich, St. Louis, MO, USA) at stock concentrations of 
20, 40 and 60 µg/mL in deionised water, each was then diluted to various 
concentrations ranging from 0 to 20 µg/mL, 8 to 40 µg/mL, and 12 to 60 µg/mL, 
respectively. The standards and samples (50 µL; tested with different dilutions) 
were added in a medium-binding 96-well plate in triplicate. Then, 200 µL of the 
DMMB reagent was added to each well and absorbance was obtained immediately 
at wavelength of 535 nm using a plate reader. 
 
2.3.3 Mass spectrometry for proteoglycan peptides identification  
 
DEAE-enriched samples (10 µg) were reduced (10 mm DTT for 10 min at 95 °C), 
alkylated (25 mm iodoacetamide for 20 min at 25 °C), and digested with trypsin 
(sequencing grade; Promega, Sydney, Australia) at a final concentration of 20 
μg/mL in 50 mM NH4HCO3 at 30°C for 16 h. Samples were analysed by liquid 
chromatography coupled to tandem mass spectrometry (LC-MS2) using an LTQ 
mass spectrometer (Thermo Fisher Scientific). The results were analysed with 
XcaliburTM software (Bioworks version 3.1, Thermo Fisher Scientific) and the 
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Mascot database (Matrix Science, London, UK; version 2.5.1) with a National 
Centre for Biotechnology Information (NCBI) protein (Homo sapiens) database. 
Mascot was searched with a fragment ion mass tolerance of 0.40 Da and a parent 
ion tolerance of 4.0 PPM. Oxidation of methionine, carbamidomethyl of cysteine 
and propionamide of cysteine were specified in Mascot as variable modifications.  
 
2.3.4 Enzyme-linked Immunosorbent Assay (ELISA)  
 
ELISA was employed to detect the presence of different proteoglycans in the 
samples. A high-binding 96-well ELISA plate was coated with 50 µL of sample 
(0.5 µg of protein per well) in triplicate and incubated overnight at 4°C with gentle 
agitation. Where endoglycosidase digestion was required, the samples were treated 
with 0.01 U/mL heparanase III (to eliminate heparan sulphate), 0.05 U/mL 
chondroitinase ABC (to eliminate chondroitin/dermatan sulphate), or 0.05 U/mL 
chondroitinase B (to eliminate dermatan sulphate) for 16 h at 37°C prior to the 
coating. The wells were then washed twice with DPBS and blocked with 0.1% 
casein for 1 h at room temperature. After washing twice with PBST (0.05% w/v 
Tween 20 in DPBS), the proteins were reacted with 50 µL of primary antibodies, 
which were diluted in 0.1% casein (see Table 2.3), for 2 h at room temperature with 
gentle agitation. The wells were washed twice with PBST and appropriate 
biotinylated secondary antibodies were added into wells and incubated for 1 h at 
room temperature. Subsequently, the wells were incubated with 50 µL of 
streptavidin-horseradish peroxidase (1:500 in 0.1% casein) for 30 min, then washed 
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with PBST four times. ABTS colorimetric substrate (100 µL/well) was then added, 
the plate incubated overnight, and the absorbance of each well measured at 405 nm. 
 
Table 2.3 Monoclonal/polyclonal antibodies and their dilutions for ELISA 
Antigen Clone Species Isotype Source Conc. 
(µg/mL) 
 
Heparan 
sulphate  
Heparan N-sulphated 
glucosamines 
10E4  Mouse IgM Seikagaku  2 
 Heparan 
unsubstituted 
glucosamines 
JM403 Mouse IgM Seikagaku 2 
 
Chondroitin 
sulphate  
Chondroitin 4- and 
6-sulphate residues 
CS56 Mouse IgM Sigma 
Aldrich 
2 
 Sulphated and 
unsulphated 
oligosaccharides 
close to linkage 
region 
7D4 Mouse IgG * 2 
 Unsulphated stubs 1B5 Mouse IgG * 2# 
 4-sulphated stubs 2B6 Mouse IgG * 2# 
 6-sulphated stubs 3B3 Mouse IgG * 2# 
 
Biglycan 2E6-D1 Mouse IgG Abnova 2 
4E1-1G7 Mouse IgG Abnova 2 
 
Perlecan Domain I A71 Mouse IgG Abcam 2 
 Domain I A76 Mouse IgG Abcam  2 
 Unmapped epitope 5D7-2E4 Mouse IgG Abcam 2 
 Domain III 7B5 Mouse IgG † 2 
 Domain V E-6 Mouse IgG Santa Cruz 2 
 Domain I - V Polyclonal Rabbit IgG ‡ 1:1000 
 
Versican  5D5 Mouse IgG § 2 
 
*hybridoma conditioned media were generously given by Prof Bruce Caterson, Cardiff University, 
Wales, UK 
 
#samples need to be digested with chondroitinase ABC prior to reaction with antibodies  
 
†7B5 hydridomas were kindly donated by Prof Renato Iozzo, Thomas Jefferson University, 
Philadelphia, PA, USA, and were cultured and purified in the laboratory, Graduate School of 
Biomedical Engineering, UNSW, Sydney  
 
‡CCN-1 was developed in-house from the serum of the rabbit immunised with immunopurified 
endothelial cell-derived perlecan  
 
§5D5 was a generous gift from Agenta Biotechnologies, Birmingham, AL, USA 
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2.3.5 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE)  
 
When necessary, DEAE-enriched samples (5 µg protein per well) were digested 
with endoglycosidases prior to electrophoresis with heparinase III (0.01 U/mL), 
chondroitinase ABC (0.05 U/mL) or chondroitinase B (0.05 U/mL) in PBS 
overnight at 37°C. Loading dye (424 mM Tris HCl, 564 mM Tris base, 8% lithium 
dodecyl sulphate [LDS], 40% glycerol, 1% v/v Brilliant Blue R250 and 1% v/v 
phenol red in deionised water) was added to the samples at a dilution of 1:4. The 
maximum total loading volume per well was 10 µL. Depending on the protein of 
interest, some samples were reduced with 10 mM DTT for 10 min at 95°C.  
 
Proteins with expected molecular weights between 10 and 250 kDa were 
electrophoresed on 4 – 12% Bis-Tris NuPAGE® SDS-PAGE gels (Invitrogen, 
Sydney, Australia) in MES buffer (200 mM MES, 200 mM Tris HCl, 0.1% w/v 
SDS, 1 mM EDTA in deionised water) at 200 V for 40 min. Molecular weight 
markers (Cat. No.: 161-0373, Precision Plus, Bio-Rad, Gladesville, NSW, Australia) 
were run on each gel.  
 
Samples with expected molecular weights over 250 kDa were run on 3 – 8% Tris-
Acetate NuPAGE® SDS-PAGE gels in Tris-tricine buffer (50 mM tricine, 50 mM 
Tris-base, 0.1% w/v SDS in deionised water) at 160 V for 1 h. Molecular weight 
markers (Cat. No.: LC5699, HiMark standard, Invitrogen, Sydney, Australia,) were 
electrophoresed on each gel.  
Materials and methods 
46 
 
2.3.5.1 Coomassie staining of protein gel  
 
If Western blotting was not performed after SDS-PAGE, the gel was stained with 
Coomassie to visualise the protein bands. The gel was rinsed quickly with deionised 
water, followed by fixing in 40% v/v methanol and 10% v/v acetic acid in deionised 
water for 10 min. The gel was then stained with Simply Blue R250 (Cat. No.: 
LC6060, Invitrogen, Sydney, Australia) for 1 h at room temperature and destained 
with a copious amount of water.  
 
2.3.5.2 Gel drying  
 
The stained gels were dried by soaking in a drying solution of 30% methanol and 
5% glycerol for 10 min with gentle shaking. Each gel was then sandwiched between 
two sheets of cellophane which had been immersed in drying solution. The 
sandwich was aligned firmly on a gel drying frame and left to dry for 1 – 2 days. 
Excess cellophane was trimmed off and the dried gel was pressed between pages of 
a notebook for 2 days.     
 
2.3.6 Western blotting  
 
After SDS-PAGE, proteins were transferred onto a 0.45 µm polyvinylidene 
difluoride (PVDF) membrane (Immobilon P, Millipore, Billerica, MA, USA) with 
transfer buffer (5 mM bicine, 5mM Bis-Tris, 0.2 mM EDTA, 0.005% w/v SDS, 10% 
methanol, pH 7.2) in a semi-dry blotter (Invitrogen) at 300 mA, 20 V for 40 min 
(for 4 – 12% Bis-Tris gels) or 300 mA 25V for 1 h (for 3 – 8% Tris-Acetate gels).  
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After blotting, the membrane was washed with Tris-buffered saline (TBS) twice for 
5 min. The blot was then blocked with 1% w/v BSA/TBST for 2 h at room 
temperature and incubated with primary antibodies (see Table 2.4) overnight at 4°C 
with gentle agitation. The blot was rinsed twice with TBST for 15 min each, 
incubated with HRP-conjugated secondary antibodies for 1 h at room temperature 
followed by four 15 min washes with TBST. Then, chemiluminescence reagent was 
put onto the membrane for 2 min. Finally, the membrane was placed between two 
transparent overhead projector sheets and developed onto x-ray film. 
 
Table 2.4 Primary antibodies and their dilutions for Western blotting 
Antigen Clone Species Isotype Source Conc. 
(µg/mL) 
 
Biglycan Polyclonal Rabbit IgG LifeSpan 0.5 
 
Perlecan Domain I A71 Mouse IgG In-house 5 
 Unmapped epitope  5D7-2E4 Mouse IgG Sigma 2 
 Domain V E-6 Mouse IgG Santa Cruz 2 
 
Versican  Polyclonal Rabbit IgG LifeSpan 0.1 
 
 
2.3.7 Fluorophore-assisted carbohydrate electrophoresis (FACE) 
 
FACE is a procedure to determine the disaccharide composition of GAG chains. It 
employs endoglycosidases to cleave GAGs into disaccharides, characteristic of the 
enzyme specificity. Each cleavage exposes a new reducing terminus that is fluoro-
tagged by reductive amination with 2-aminoacridone (AMAC) in the presence of 
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sodium cyanoborohydride. The tagged products are then electrophoresed, identified 
by their characteristic migration, and quantitated by their molar fluorescence.   
 
2.3.7.1 Preparation of disaccharide standards  
 
A stock solution of 2 mg/mL disaccharide standard (Iduron, Alderley Edge, 
Cheshire, UK) was prepared by dissolving 0.5 mg of the disaccharide with 250 µL 
of Baxter water (Baxter, Old Toongabbie, NSW, Australia). From that, 150 µL 
stock was further diluted with 150 µL of Baxter water to get 1 mg/mL. Then, 0.5 
nM of the disaccharide from the 1 mg/mL solution was frozen at -80°C for 30 min 
followed by freeze-drying for 3 h. The powder was fluoro-tagged with 5 µL of 0.1 
M AMAC and 5 µL of 1 M sodium cyanoborohydride at 37°C for 16 h. The final 
volume of the standard was topped up to 500 µL with 50% glycerol. Electrophoresis 
was performed to determine the position of the standards. Standards were stored at 
-80°C for further use.  
   
2.3.7.2 Derivatisation of proteoglycan disaccharides  
 
Set amounts of proteoglycans (containing 5 µg of GAGs as determined by DMMB 
assay) were digested with 0.1 mg/mL pronase at 60°C for 16 h to free 5 µg of GAGs. 
Then, the released GAG chains were cut into disaccharides with 0.05 U/mL of 
chondroitinase ABC at 37°C for 9 h, followed by selective removal of the sulphate 
groups on carbon-4 (C-4) or carbon-6 (C-6) with 0.05 U/mL of chondro-4-
sulphatase or chondro-6-sulphatase, respectively, for 16 h. Disaccharides were 
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frozen at -80°C and then freeze-dried to become dry powder. This disaccharide 
powder was then fluoro-tagged with 5 µL of 1 M AMAC and 5 µL of 1 M sodium 
cyanoborohydride and mixed thoroughly until dissolved. Labelling was continued 
for 16 h at 37°C.   
  
2.3.7.3 Electrophoretic separation of fluoro-tagged disaccharides  
 
Gel-casting apparatus was assembled as follows: 1.0 mm thick glass plates (10 cm 
× 10 cm) were sandwiched together with 0.5 mm thick glass spacers and set up 
firmly on the gel box and checked for leakage by adding in water. Resolving gel 
solution was prepared by mixing gel stock solution (38% w/v acrylamide and 2% 
w/v N,N’-methylenebisacrylamide), 1.5 M Tris-Cl (pH 8.9), 10% ammonium 
persulphate (freshly prepared) and deionised water. Polymerisation of the gel was 
initiated by addition of TEMED and the gel solution was poured into the casting 
apparatus to a height of 0.5 cm below the bottom of the comb. The level of gel 
solution was flattened by immediately overlaying it with 1 cm of water. 
Polymerisation occurred within 15 min.  
 
Then, stacking gel solution was prepared by mixing the stacking gel stock solution 
(10% w/v acrylamide and 2.5% w/v N,N’-methylenebisacrylamide), 1.0 M Tris-Cl 
(pH 6.8), 10% ammonium persulphate and deionised water. Polymerisation was 
initiated by adding TEMED. The overlaying water was poured out and the 
remaining space in the glass sandwich was filled with stacking gel solution. A comb 
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with eight 8 mm wide teeth was inserted into the stacking gel to form sample wells. 
Polymerisation occurred within 15 min.  
 
Electrophoresis apparatus was set up in an ice box with ice completely covering its 
sides. The gel sandwich was inserted into the apparatus and secured firmly. Icy cold 
electrode buffer (1.92 M glycine and 0.25 M Tris base, pH 8.3, 4°C) was poured 
into the apparatus. The gel was pre-electrophoresed for 30 min at 30 mA, 300 V. 
Then, standards and samples (maximum volume 15 µL) were loaded into the wells. 
Electrophoresis was run at 50 mA, 350 V for 2 h 30 min. The gel (with both glass 
plates still attached) was visualised in the gel imager immediately as a delay of more 
than 20 min may result in some diffusion of the fluorescent bands. 
 
2.4 Gene expression of proteoglycans in macrophages 
 
2.4.1 RNA stabilisation  
 
RNA in cells was stabilised and protected from degradation with RNAlater® 
Stabilisation Solution (Cat. No.: AM7020, Life Technologies, Carlsbad, CA, USA) 
prior to its extraction. Cells were centrifuged at 300 × g for 5 min and supernatant 
was removed, followed by two PBS washes. Then, the cells were incubated with 5 
– 10 volumes of Stabilisation Solution overnight at 4°C to allow thorough 
penetration of the cells. Samples were stored at -80°C until further extraction.  
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2.4.2 RNA extraction  
 
Before extracting RNA, the RNAlater® Stabilisation Solution was removed from 
the samples. To achieve this, the samples were thawed at room temperature and 
diluted with an equal volume of icy cold PBS immediately before centrifugation at 
2100 × g for 5 min at 4°C. Supernatants were discarded and the cells were ready 
for RNA extraction.  
 
The cells were lysed with TRI Reagent® (Cat. No.: T9424, Sigma-Aldrich, St. 
Louis, MO, USA) at 1 mL per 106 – 107 cells, by gentle repeated pipetting. To 
ensure complete dissociation of nucleoprotein complexes, samples were allowed to 
stand for 5 min at room temperature. Then, 0.2 ml of chloroform per mL of TRI 
Reagent used was added to the cells, and the tubes subsequently shaken vigorously 
for 15 s before being let to stand for 3 min at room temperature. The resulting 
mixture was centrifuged at 13,700 × g for 15 min at 4°C into three phases: a red 
organic phase (containing protein), an interphase (containing DNA), and a 
colourless upper aqueous phase (containing RNA).  
 
The upper phase was transferred into a new Eppendorf tube. 0.5 mL of 2-propanol 
per mL of TRI Reagent used was added and mixed by inversion, followed by 
incubation at room temperature for 10 min. The mixture was centrifuged at 2100 × 
g for 15 min at 4°C to pellet RNA. The supernatant was removed carefully and the 
RNA pellet washed with 1 mL of 75% ethanol per mL of the TRI Reagent used, 
then centrifuged at 5,300 × g for 5 min at 4°C. The supernatant was removed and 
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the RNA pellet air dried for 1 h on ice. Finally, the pellet was dissolved in 10 – 50 
µL 0.1% v/v diethylpyrocarbonate (DEPC) water. The quantity and purity of RNA 
was measured with NanoVueTM using the ‘RNA Programme’ (GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). RNA was stored at -20°C for further 
procedures. 
 
2.4.3 Complementary DNA (cDNA) synthesis  
 
ProtoScript® First Strand cDNA Synthesis Kit (Cat. No.: E6300L, New England 
BioLabs, Ipswich, MA, USA) was used to synthesise cDNA from the extracted 
RNA. Samples and all kit components were thawed and put on ice. Then, 1 µg of 
RNA was transcribed into cDNA using 2 µL oligo-dT primer and the total volume 
was made up to 8 µL with nuclease-free water. Subsequently, 10 µL of M-MuLV 
Enzyme Mix (which contains M-MuLV Reverse Transcriptase and Murine RNase 
Inhibitor), 2 µL of M-MuLV Reaction Mix (which contains dNTPs) and 2 µL of 
Random Primer Mix (which contains a mix of hexamer and oligo primers) were 
added to the mixture. The reaction was started with an incubation step at 25°C for 
5 min, then the temperature was increased to 42°C for 1 h, followed by an enzyme 
inactivation step at 80°C for 5 min. The quality and quantity of the cDNA products 
were accessed with NanoVueTM using the ‘RNA Programme’ before being stored 
at -20°C until further analysis. 
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2.4.4 Polymerase chain reaction (PCR)  
 
A total mass of 100 ng of the cDNA product was mixed with 100 pmol forward and 
reverse primers (see Table 2.5) and 12.5 µL PCR Master Mix (Cat. No.: M75010, 
Promega, Madison, WI, USA), and the final volume adjusted to 25 µL. Human 
GAPDH was used as an endogenous control. Samples were subjected to 35 
reactions using the Bio-Rad C1000TM Thermal Cycler (Bio-Rad PTY Ltd., 
Gladesville, NSW, Australia). The programme was as follows: 94°C for 5 min (for 
hot-start), 94°C for 30 s, 60°C for 45 s, 60°C for 2 min for 35 cycles, 72°C for 7 
min and then held at 4°C.  
 
Table 2.5 PCR primers  
Gene Accession 
number 
 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Biglycan NM_001711.5 GAGCTCCGCAAGGATGACTT AGCTTGGAGTAGCGAAGCAG 
Versican V0 NM_004385.4 CCAGTTCCTGACTCTCAGTTCT GATCATGCACTGGATCTGTTTCT 
Versican V1 NM_001164097.1 GAGGAACGGCTTTGACCAGT CACAGATGGGGTGGTTGTCA 
Versican V2 NM_001164098.1 CCAACAAGACCACCCACTGT CACACTGGTCTCCGCTGTAT 
Versican V3 NM_001126336.2 GTGTTCCACCTCACTGTCCC AAGTTCACACTGGTCTCCGC   
HSPG2 
DV* 
NM-005529 GGTGCCAGAGCGGGTG CAGGGCAAGTTCCAGGGC 
  *HSPG2 is the gene name for perlecan; DV, perlecan domain V 
 
2.4.5 Quantitative real-time polymerase chain reaction (qPCR) 
 
A total mass of 500 ng of the cDNA product was mixed with 0.5 µL forward and 
reverse primers (10 µM each, see Table 2.5) and 5 µL Power SYBR Green PCR 
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Master Mix (Cat. No.: 4367659, Applied Biosystems, Mulgrave, VIC, Australia), 
and the final volume adjusted to 10 µL with RNAase-free water. Human GAPDH 
was used as an endogenous control and to normalise the results for each of the 
primer sets. Samples were subjected to 40 reactions using the ABI StepOnePlusTM 
Real-Time PCR system.   
 
2.4.6 Agarose gel electrophoresis 
 
The PCR products were visualised on a 1.0% agarose gel. A tablet (0.5 g) of agarose 
(Cat. No.: BIO-41028, Bioline, Sydney, NSW, Australia) was softened in 
Tris/Borate/EDTA (TBE) buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 
8.3) for 5 min prior to an one-minute heating in a microwave to dissolve it 
completely. The gel solution was let to cool to ~60°C before 0.01% v/v of nucleic 
acid stain GelRed (Cat. No.: 41003, Jomar Diagnostic, Scoresby, VIC, Australia) 
was added to it. Subsequently, the gel solution was poured into a gel tray with a 12-
well comb inserted, and left to solidify for 20 min. The comb was removed from 
the gel, which was then submerged completely with TBE buffer. Then, pre-stained 
(6× gel loading dye, Cat. No.: B70215, New England BioLabs, Ipswich, MA, USA) 
samples and a standard DNA ladder were loaded into the wells of the gel. 
Electrophoresis was run at 60 V for 1 h. The gel was visualised with a 312/302 nm 
UV transilluminator in a Bio-Rad GelDocTM EZ Imager system. 
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2.5 Investigation of the interaction between macrophage 
proteoglycans and human low-density lipoprotein  
 
2.5.1 Handling of LDL 
 
As compositional changes to human LDL particles may affect their binding to 
proteoglycans (Oörni et al. 1997; Flood et al. 2004), it is thus very important to 
handle LDL properly as per the manufacturer’s instruction. Upon arrival, the human 
LDL (Cat. No.: 02698, STEMCELL Technologies, Tullamarine, VIC, Australia) 
was aliquoted into small volumes (50 µL). The aliquots were then tightly sealed, 
protected from light and stored at 2 – 8ºC (freezing may cause structural or 
composition changes) and used within three months, in which the product would be 
stable. Violent shaking of the solution or vortexing was avoided as this will cause 
the mixture to foam. 
 
2.5.2 Quartz crystal microbalance with dissipation monitoring 
(QCM-D) 
 
QCM-D quartz crystal sensors were first cleaned in a UV ozone system for 10 min. 
Then the sensors were incubated in a solution of ammonium hydroxide: hydrogen 
peroxide: water (1:1:3 v/v) at 75°C for 10 min, rinsed in water and dried in nitrogen 
gas. They were cleaned in a UV ozone system for additional 10 min before being 
coated with matrix proteins.  
 
Interactions taking place on the sensor surfaces were monitored in real-time using 
an E4 instrument (Q-Sense, Göteborg, Sweden) and all experiments were 
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performed at 37°C. Measurements were obtained for the fundamental frequency (5 
MHz) and the 3th – 13th overtones. A continuous flow of 0.1 mL/min was applied 
throughout the experiments. To obtain a baseline for measurements, 10 mM PBS 
(pH 7.4, filtered and degassed) was run through the QCM-D system for 10 min or 
until it was stable. After a baseline was established, the sensor surfaces were coated 
with 2000 ng of macrophage proteoglycans in PBS, followed by PBS to wash away 
unbound molecules from the sensors. To avoid non-specific interactions, the 
surfaces were blocked with 2 mg/mL of BSA for 20 min, followed by PBS wash. 
Then, 5000 ng of human LDL (Cat. No.: 02698, STEMCELL Technologies, 
Tullamarine, VIC, Australia) in PBS was loaded to interact with the proteoglycans. 
The binding of analyte to the surface was monitored by QSoft software (Q-Sense, 
Göteborg, Sweden) with changes in frequency (Δf) and dissipation (ΔD) being 
recorded simultaneously. Non-specific interactions were monitored by adding LDL 
without proteoglycans. 
 
2.5.3 Turbidity assay 
 
The experiment was performed as per described by Mourão et al. [123] with some 
modifications. Increasing amounts of proteoglycans and 5 µg of human LDL were 
brought to 100 µL final volume with 0.05 M calcium chloride (CaCl2, pH 6.0) in 
distilled water, in a 96-well plate. The solution was mixed and incubated at 37°C 
overnight. The formation of insoluble complexes (turbidity) was measured at 620 
nm after 3s of shaking. Data were corrected for background (proteoglycans + 
CaCl2).  
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2.6 Immunohistochemistry of proteoglycans in human 
atherosclerotic lesions  
 
Slides of human atherosclerotic lesions (carotid tissues) were generously processed 
by Virginia James (Advanced Specialist Histology, Westmead Institute for Medical 
Research, Westmead).  
 
2.6.1 Deparaffinisation of the tissue specimens and heat-induced 
antigen retrieval  
 
The antibodies used for staining are listed (Table 2.6). After staining, the sections 
were deparaffinised in xylenes using three changes for 15 min each, and rehydrated 
gradually in graded alcohols: in 100% ethanol thrice for 10 min each, then 95% 
ethanol twice for 10 min each. The sections were washed in running tap water for 
one minute and antigen-retrieved in Borg Decloaker solution (pH 9.0) (Cat. No.: 
BD1000, Biocare Medical, Concord, CA, USA) at 95°C for an optimal time (Table 
2.7). The sections were then cooled in running tap water for 10 min before staining.  
 
2.6.2 Single immunohistochemical staining 
 
All steps were carried out by an automated intelliPATH FLX stainer (Biocare 
Medical, Concord, CA, USA). Briefly, the sections were incubated with hydrogen 
peroxide (Cat. No.: S2001, Dako, Santa Clara, CA, USA) for 10 min to block 
endogenous peroxidase, followed by Background Sniper (Cat. No.: BS966, Biocare 
Medical, Concord, CA, USA) for 10 min to reduce non-specific background 
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Table 2.6 Antibodies used in immunohistochemistry 
 
Antigen Host 
species 
Clone Isotype Source Cat. no. 
Perlecan Rabbit Polyclonal Poly IgG Produced in-
house* 
 
- 
Heparan 
sulphate 
 
Mouse 10E4 IgM Seikagaku 
 
370255-1 
CD86 Rabbit Polyclonal Poly IgG Bioss BS-1035R 
 
CD163 Mouse 10D6 IgG1 Leica NCL-L-
CD163 
 
 
*This anti-perlecan antibody, CCN-1 was developed in-house (UNSW) from the 
serum of the rabbit immunised with immunopurified endothelial cell-derived 
perlecan.  
 
 
Table 2.7 Optimised methods for the antibodies in immunohistochemistry 
 
Antigen Conc. 
(µg/mL) 
Retrieval 
(min) 
Antibody 
incubation 
(min) 
DAB 
incubation 
(min) 
Vina Green 
incubation 
(min) 
Perlecan 
 
1:500 20 30 5 N/A 
Heparan 
sulphate 
 
2.0 10 60 5 Not tested 
CD86 2.0 20 30 5 15 
 
CD163 
 
0.5 15 30 5 15 
 
Optimisation was performed on human positive controls including colon, placenta 
and stomach as per Section 2.6.2. Abbreviation: N/A, not applicable.  
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staining. The sections were then incubated with primary antibodies at room 
temperature (Tables 2.7). Isotype controls were performed for each antibody at the 
same concentration. The antibodies were detected with a MACH 2 HRP-Polymer 
detection system (Biocare Medical, Concord, CA, USA). Antibody binding was 
visualised with diaminobenzidine (DAB, which produce a brown colour) and 
counterstained with haematoxylin (which stains nuclei blue). All sections were left 
to air dry, and dehydrated in xylenes with three changes for 15 min each. The 
sections were cover-slipped using DPX mounting medium while they were still wet 
with xylene. All air bubbles were removed by gently scrolling forceps over the 
coverslip toward edges. The slides were left to dry in the fume hood overnight.   
 
2.6.3 Double immunohistochemical staining 
 
Staining was sequential, i.e. two single stains, one after the other (as per 2.6.2). 
Both stains used MACH 2 HRP-Polymer detection system directed at the relevant 
host species: rabbit for perlecan and mouse for CD163. For the first stain, DAB was 
used as the chromogen, and for the second Vina Green (Cat. No.: BRR807A, 
Biocare Medical, Concord, CA, USA) was used. The repeated blocking of 
endogenous peroxidase ensured that the second chromogen reacted to the second 
use of HRP only. Though the host species for the two single stains were different, 
a denaturing step (Cat. No.: DNS001, Biocare Medical, Concord, CA, USA) was 
still performed before the second staining (to denature the antibodies from the first 
staining reaction) to ensure that non-specific binding of the second stain secondary 
antibody to the antibodies from the first reaction could not occur.  
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2.6.4 Digital acquisition of the immunohistochemical staining 
 
Digital images of the immunohistochemical staining were acquired using the 
‘Bright Field’ programme built in the Nanozoomer Digital Pathology (NDP).view2 
scanning software of the machine (Hamamatsu Photonics K.K., Hamamatsu City, 
Japan). Calibration was performed using the calibration slide provided by the 
company prior to image acquisition. Samples slides were made sure to be dry, clean 
and the slide edges were smooth before loading into the scanning machine. Any 
lumps of excess mounting medium on the edges were smoothed using sand paper. 
Then the slides were cleaned with 100% ethanol. Digital images of the slides were 
acquired at a resolution of either 20× (460 nm per pixel) or 40× (230 nm per pixel) 
in 16-bit colour. Focusing was performed either manually or automatically, with 
white balance set at automatic. Images were saved as NDPi files and navigated on 
the Nanozoomer system or the Aperio ImageScope viewing software version 12 
(Leica Biosystems Pathology Imaging, Nussloch, Germany).    
 
2.7 Statistical analysis  
 
All experiments were performed with three replicates and at least two independent 
runs. Mean values (± standard deviation) were obtained for each macrophage 
subsets. For some analyses, such as qPCR, means were compared using Student t 
test. Paired t tests were applied for comparing means of paired values (e.g. for the 
experiments examining the amount of LDL bound pre- versus post-sodium 
challenges in the M1 macrophage-derived samples). A one-way analysis of 
Materials and methods 
61 
 
variance (ANOVA) followed by Tukey’s Honestly Significant Differences (HSD) 
post-hoc test was performed to compare statistical difference between different cell 
origins and conditions (e.g. for the experiments examining the LDL binding 
function of the proteoglycans with different endoglycosidase digestions). Results 
of p < 0.05 were considered significant for all analyses. Analyses were performed 
using GraphPad Prism version 7 (GraphPad Software, La Jolla, CA, USA). 
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3.1 Introduction  
 
To extensively characterise the proteoglycans that M1 and M2 macrophages secrete 
requires a large amount of samples, which accordingly requires a large number of 
macrophages. Although primary human monocytes/macrophages are clinically 
relevant, their use is limited by the number of cells able to be isolated, 
contamination with other blood components and a limited survival period in culture. 
Using a monocytic cell line has the advantage that the source of cells is not limited. 
THP-1 and U937 cells are the most widely used cell lines to investigate the function 
of monocytes/macrophages. The basic difference between THP-1 and U937 cells is 
the origin and maturation stage. U937 cells, which was established from the 
histiocytic lymphoma of a 37-year-old male [124], are of tissue origin, thus at a 
more mature stage; whereas THP-1 cells originate from a one-year-old blood 
leukaemic boy, hence the cells are at a less mature stage [125]. However, perhaps 
due to their already mature stage, the U937 cells demonstrate more discrepancies 
in M1/M2 differentiation than THP-1 cells [126]. U937 cells show a propensity to 
differentiate towards the M2 phenotype, which may create a bias [127]. THP-1 cells 
resemble primary monocytes/macrophages in both morphological and functional 
properties, including differentiation markers [128]. Therefore, THP-1 cells were 
used in this study.  
 
In this chapter, how well the THP-1 cells represent a M1/M2 macrophage 
polarisation model was assessed by comparing the expression of cell surface CD 
markers and their cell morphology to primary monocyte-derived macrophages. 
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Typically, M1 polarisation can be characterised by an up-regulation of CD86. 
Conversely, M2 macrophages express CD206, CD163 and CD11b on their cell 
surface [129,130]. However, to generate primary M1/M2 macrophages, the method 
for isolating monocytes from human blood was first optimised.   
 
3.2 Materials and methods  
 
Prior to using human blood specimens, this study was reviewed and approved by 
the local ethics committee Western Sydney Local Health District (WSLHD) as well 
as Human Research Ethics Committee (HREC) at UNSW. Human monocytes were 
isolated from the whole blood provided by the Australian Red Cross Blood Service, 
Alexandria, NSW.  
 
3.2.1 Separation of human peripheral blood mononuclear cells 
from whole blood 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from human whole 
blood by density gradient centrifugation using 50 mL SepMateTM tubes 
(STEMCELL Technologies, Tullamarine, VIC, Australia, Cat. No.: 15430). 
Density gradient medium LymphoprepTM (15 mL, STEMCELL Technologies, 
Tullamarine, VIC, Australia, Cat. No.: 07861) was added to the bottom of the 
SepMateTM tube through the central hole of its insert. Then, the sample which had 
been pre-diluted with an equal volume of PBS + 2% FBS (a total volume of 30 mL) 
was added by pipetting it down the side of the tube. The sample was then 
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centrifuged at 1200 × g for 20 min at room temperature, with the brake off. The top 
layer, which now was enriched with PBMCs, was swiftly (by inverting the 
SepMateTM tube for no longer than 2 sec) poured out into a new 50 mL tube. The 
enriched PBMCs were washed twice with PBS + 2% FBS by centrifuging at 300 × 
g for 8 min at room temperature, with the brake off.     
 
3.2.2 Isolation of monocytes from human peripheral blood 
mononuclear cells 
 
There were three methods available in the laboratory to isolate primary human 
monocytes from PBMCs. Although the basic principle of these methods is similar, 
as the CD14+ monocytes are first immunomagnetically labelled with microbeads 
and then the cells are separated from unlabelled cells by the magnetic field of a 
separator, there are still several steps which differ between these methods. To make 
sure that the cells isolated are pure and representative as possible of the macrophage 
phenotypes, a preliminary experiment was performed to determine which method 
can best isolate monocytes. The three methods are outlined below. 
  
Method 1: Magnetic Activated Cell Sorter (MACS) 
CD14+ monocytes were purified from the PBMCs using the MACS system as per 
the manufacturer’s instruction. An equal volume of DPBS was added to the PBMCs 
and centrifuged (300 × g, 5 min, room temperature, brake off). The supernatant was 
discarded and the pellet was re-suspended with MACS wash buffer (0.5% bovine 
serum albumin, 2mM EDTA in DPBS, pH 7.2) and transferred to a new 15 mL tube. 
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The cell suspension was topped up to a 10 mL with MACS wash buffer and a cell 
count was performed. The cell suspension was then centrifuged (300 × g, 5 min, 
room temperature, brake off), with the supernatant being discarded afterwards and 
the cells were combined with CD14 MicroBeads (Miltenyi Biotec GmbH, Gladbach, 
Germany, Cat. No.: 130-050-201) at a set ratio (20 µL of CD14 beads and 80 µL 
MACS wash buffer per 1 × 107 cells), 4°C for 15 min. The separation of CD14+ 
cells used the MACS system (Miltenyi Biotec GmbH, Gladbach, Germany, Cat. 
No.: 130-042-201). Prior to loading the cell suspension, the column was washed 
three times with 500 µL MACS wash buffer. The cell suspension was then loaded 
onto a pre-separation filter (Miltenyi Biotec GmbH, Gladbach, Germany, Cat. No.: 
130-041-407) and passed through the MACS MS separator column (Miltenyi 
Biotec GmbH, Gladbach, Germany, Cat. No.: 130-042-201). The column was 
washed five times with 500 µL MACS wash buffer to ensure all unlabelled cells 
were washed out of the column. The column was removed from the magnet, and 
the CD14+ cells were then eluted from the column into a separate tube by plunging 
in 1 mL of MACS buffer through the column, followed by five wash steps with 1 
mL of RPMI each. The collected cells (both labelled and unlabelled) were 
centrifuged (300 × g, 5 min, room temperature) and prepared for purity assessment 
using flow cytometry.  
 
Method 2: EasySep™ Human Buffy Coat CD14 Positive Selection Kit 
This method was similar to above, but did not isolate PBMCs from whole blood 
first. The experiment was performed as per the manufacturer’s instruction 
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(STEMCELL Technologies, Tullamarine, VIC, Australia, Cat. No.: 18088). An 
equal volume of DPBS was added to the whole blood which was then centrifuged 
(300 × g, 5 min, room temperature, brake off) to obtain a buffy coat. A maximum 
volume of 4.5 mL of the buffy coat was transferred into a new 15 mL tube. Note 
that a small portion of plasma and concentrated red blood cells was included to 
ensure maximum leucocyte yield. The red blood cells were lysed by adding 1X 
EasySep® RBC Lysis Buffer into the buffy coat at a ratio of 1:1. Meanwhile, the 
CD14+ cells were labelled with EasySep® Positive Selection Cocktail (Component 
no.: 18088C), which was added to the buffy coat at 50 µL/mL buffy coat/lysis 
buffer mixture (e.g. for 2 mL of buffy coat/lysis buffer mixture, 100 µL cocktail 
was added). The mixture was mixed well and incubated at room temperature for 15 
min. Then, EasySep® Whole Blood Magnetic Nanoparticles (Component no.: 
18180) were added to the mixture at 50 µL/mL buffy coat/lysis buffer mixture, 
followed by an incubation for 10 min at room temperature to allow nanoparticles to 
bind the cocktail antibodies. The total volume was topped up to 10 mL with RPMI 
and the tube (without cap) was placed into an EasySepTM Magnet (STEMCELL 
Technologies, Tullamarine, VIC, Australia, Cat. No.: 18001) and set aside for 10 
min. The unlabelled cells were separated from the CD14+ cells by pouring off the 
supernatant from the tube (which was still in the magnet) in one smooth continuous 
motion. The cell suspension was washed with 10 mL DBPS and the magnetic 
separating step was repeated twice. The tube was removed from the magnet and the 
CD14+ cells were now ready for purity assessment using flow cytometry.  
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Method 3: EasySep™ Human CD14 Positive Selection Kit  
Unlike Method 2, PBMCs were isolated from whole blood prior to using this kit as 
per manufacturer’s instructions (STEMCELL Technologies, Tullamarine, VIC, 
Australia, Cat. No.: 18058). A cell count was performed using a haemocytometer 
and the cells were resuspended in PBS containing 2% FBS and 1 mM EDTA to a 
concentration of 1.0 × 108 cells/mL (the final volume not greater than 8 mL) in a 
15 mL polystyrene round-bottom tube. If the number was less than 2.5 × 107 cells, 
the cell pellet was resuspended in 0.25 mL. Monocytes were then targeted with anti-
CD14 antibodies by incubating each 1 mL of the sample with 100 µL of EasySepTM 
CD14 Positive Selection Cocktail (Component no.: 18058C) for 15 min, followed 
by 50 µL EasySepTM Magnetic Nanoparticles (Component no.: 18150) for 10 min, 
at room temperature. The CD14+ cells were separated from unwanted CD14- cells 
by pouring out the supernatant after a 5 min incubation in EasySepTM Magnet 
(STEMCELL Technologies, Tullamarine, VIC, Australia, Cat. No.: 18001). The 
remaining cell suspension was washed with PBS (containing 2% FBS + 1 mM 
EDTA) and the magnetic separation repeated twice. The purity of the positively 
selected cells was assessed by flow cytometry.  
 
3.2.3 Monocyte purity assessment by flow cytometry 
 
Both the CD14+ and CD14- cells obtained from the magnetic separation were 
transferred into fluorescence-activated cell sorting (FACS) tubes (BD Falcon, 
Biosciences, Bedford, MA, USA, Cat. No.: 342054) at a cell density of 1.0 × 105 
cells per 50 µL. The cells were centrifuged (300 × g, 5 min, room temperature) and 
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the cell pellet resuspended in 50 µL PBS with 2% FBS. The cells were then 
incubated with antibodies (Table 3.1) for detection of surface markers in the dark 
at room temperature for 15 min. Excess antibodies were removed by washing with 
3 mL of PBS with 2% FBS (300 × g, 5 min, room temperature). The supernatant 
was discarded and the cells were fixed with 4% formaldehyde. Samples were 
analysed immediately or stored in the dark at 4°C and analysed within two days.   
 
Table 3.1 Flow cytometry analysis of the purity of CD14+ cells 
Group V450-conjugated 
antibody 
Vol. 
(µL)2 
APC-conjugated 
antibody 
 
Vol. 
(µL)2 
Isotype/CD451 IgG2bĸ (BD 
Horizon, 560374) 
 
0.75 CD45 (BD 
Pharmingen, 
555485) 
 
2 
CD14/CD45 CD14 (BD 
Pharmingen, 
560349) 
0.75 CD45 (BD 
Pharmingen, 
555485) 
2 
1CD45 is a marker for leucocytes. 
2The reagents were pre-diluted for use at the recommended volume per test.  
 
 
3.2.4 Generation of M0 macrophages and M1/M2 polarisation  
 
Naïve M0 macrophages were generated from the isolated CD14+ monocytes as 
described by Martinez et al. [50]. The resuspended CD14+ monocytes were 
cultured at a density of 3.3 × 105 cells per mL of RPMI supplemented with 10% 
FBS, 1%penicillin/streptomycin (P/S) and 100 ng/mL of M-CSF (R&D Systems, 
Minneapolis, MN, Cat. No.: 216-MC-025) in culture flasks. The cells were grown 
for 72 h in a humidified 95% air/5% CO2 atmosphere at 37°C. The medium was 
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replaced with fresh medium containing 100 ng/mL M-CSF and the cells were 
incubated for a further 72 h. The cells were then washed thrice with DPBS and let 
rest for 24 h without the supplementation of M-CSF. The cells then underwent 
M1/M2 polarisation in the same way as the THP-1 cells in Section 2.1.6. The cell 
phenotypes were confirmed by evaluating the cell-surface expression of specific 
CD markers using flow cytometry as per Section 2.1.7. 
 
3.3 Results  
 
3.3.1 Comparison of the monocyte isolation methods 
 
Table 3.2 compares the monocyte isolation methods. Method 1 isolated the most 
monocytes among the methods from the same volume of blood. However, that came 
with a significant disadvantage as the isolated cells showed the lowest purity for 
CD14, whereas Methods 2 and 3 produced CD14+ cells with high purity (>95%).  
 
Method 2 was the fastest method, taking only 1 – 2 h to finish because it skipped 
through the PBMCs isolation steps. But the absence of the PBMCs isolation might 
lead to the lowest yield of cells among the methods, as the buffy coat may not all 
have been obtained. Moreover, this method needed more wash steps than those 
described by the manufacturer, because some remnants of the lysed red blood cells 
were still visible in the cell suspension even after three times of magnetic separation. 
This may be problematic when it comes to processing a larger volume of blood. 
Method 3 produced the highest purity in the CD14+ cells. It also isolated a decent 
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number of cells, sitting between Methods 1 and 2. Since it can isolate plenty of cells 
with high purity, making media collection faster, Method 3 was used to obtain 
primary cells for the comparison to THP-1 cells.  
 
  
THP-1 as an M1/M2 model 
 
72 
 
Table 3.2 Comparison between the monocyte isolation methods. 
 
 Method 1 
 
Method 2 Method 3 
Number of CD14+ cells 
isolated from 20 mL whole 
blood 
 
5.0 × 106 cells  8.0 × 105 cells  2.8 × 106 cells  
Purity of CD14+ cells 
isolated 
90.0% 96.6% 97.8% 
 
PBMCs isolation 
 
Needed Not needed Needed 
Number of PBMCs the 
system can handle per run 
 
Up to 108 cells Not applicable  Up to 108 cells 
Duration of the whole 
preparation 
2 – 3 hours 1 – 2 hours  2 – 3 hours 
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3.3.2 Phenotypic characterisation of macrophage polarisation 
 
Upon stimulation with LPS and IFN-ɣ, there was an obvious shift in CD86 
compared to the isotype in both primary and THP-1 macrophages. Although it was 
smaller than that of CD86, the primary macrophages also showed a shift in CD206 
from the isotype, which was not observed in the THP-1 cells. On the other hand, 
the IL-4 stimulation induced a shift in CD86 and CD206, with the primary cells 
showing greater shifts from the isotype than THP-1 cells. Although the shift in 
CD206 was smaller than the primary cells, the overall results showed that THP-1 
cells expressed CD206 only when there was an M2 stimulus; meanwhile, the shift 
in CD86 was smaller compared to those cells stimulated with the M1 cytokines. 
Another M2 marker CD163 did not show any shift for either THP-1 or the primary 
macrophages. For CD11b, both macrophages treated with M1 or M2 stimuli 
showed a shift greater than the isotype. However, the shifts were greater in the cells 
treated with IL-4 (Figure 3.1).  
 
The geometric means for fluorescence for each of the markers obtained from at least 
three separate trials were analysed (Table 3.3). Generally, the THP-1 and primary 
monocytes responded to M1/M2 polarisation with a similar trend, except with 
different amplitudes. Also, it should be noted that the deviations obtained from the 
primary macrophages tend to be quite large (note CD86 for primary M2). This 
indicated genetic variability between the donors. Overall, the response towards the 
polarising cytokines displayed by the THP-1 was more homogeneous compared to 
the human counterparts. 
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Figure 3.1 Representative histogram plots obtained from the analysis of PE-
conjugated CD marker antibodies (solid line) and their matching 
isotype controls, IgG1 (grey area) on the polarisation of primary and 
THP-1 derived macrophages.      
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Table 3.3 The level of expression of surface CD markers on the primary cell- 
and THP-1 derived macrophages following M1/M2 polarisation, as 
determined by flow cytometry. Data were presented as mean ± SD 
of mean fluorescence intensity (geometric mean) of at least three 
separate trials, normalised to the corresponding isotypes.     
 
CD markers Treated with LPS + IFN-γ 
(M1) 
 
Treated with IL-4  
(M2) 
Primary 
 
THP-1 Primary THP-1 
CD86 9.56 ± 8.92 8.82 ± 4.77 15.95 ± 22.70 5.27 ± 3.41 
CD206 1.63 ± 0.97 0.95 ± 0.04 4.45 ± 2.09 1.09 ± 0.05 
CD163 0.61 ± 0.13 0.97 ± 0.07 0.76 ± 0.16 1.02 ± 0.05 
CD11b 3.30 ± 1.78 15.64 ± 7.79 27.15 ± 20.68 36.63 ± 16.92 
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3.3.3 Morphologic characterisation of macrophage polarisation 
 
The THP-1 macrophages were shown to adopt a similar morphology as the primary 
macrophages upon stimulation with the cytokines. Treatment with LPS and IFN-γ 
resulted in macrophages adopting a spindle morphology, whereas IL-4 induced a 
spheroid morphology (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Representative microphotographs showing the cell morphology of 
the primary human and THP-1 monocytes treated with pro-M1 
LPS/IFN-γ or pro-M2 IL-4 as observed under a light microscope. 
Scale: 100 µm.    
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3.4 Discussion 
 
As the THP-1 cell line was found to generate M1/M2 phenotypes that shared CD 
marker expression patterns and morphology comparable to the primary cells, it was 
deemed to represent a suitable model for studying macrophage polarisation, in 
agreement with previous studies [126,127]. In addition, the THP-1 cell line had an 
advantage over the primary monocytes for their more homogeneous response to the 
polarising stimuli.  
 
The CD marker expressions for M1/M2 phenotypes are very dependent on the 
culture conditions [131]. For example, PMA is a potent inductor of CD86, and this 
could lead to the expression of CD86 in both M1 and M2 in the THP-1 cells [132]. 
In fact, CD86 is known to be expressed by macrophages induced with IL-4, though 
the expression is higher in those stimulated with LPS [133,134]. So, this is actually 
expected in the M2 macrophages. CD163 was not expressed by macrophages. It 
was not surprising as CD163 has not been routinely shown to be upregulated by IL-
4 or IL-10 [135]. The M2 polarisation is usually characterised by the upregulation 
of CD206 and CD11b [133], which was seen here. The cell morphology also 
confirmed the polarisation as LPS/IFN-γ act on the cytoskeleton of the macrophage 
to stimulate them to stretch [136,137].  
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3.5 Summary 
 
EasySep™ Human CD14 Positive Selection Kit was the best method to isolate 
monocytes from human blood. THP-1 cells are a suitable model for studying M1 
and M2 macrophage polarisation. The availability of the cells allows this study of 
M1 and M2 proteoglycan production to be taken to a greater depth.  
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4.1 Introduction  
 
Given that M1 and M2 macrophages are present in atherosclerotic plaques [56], the 
experiments in this chapter aimed to characterise and compare the proteoglycans 
and GAGs produced by M1 and M2 macrophages. Having shown a suitable model 
for M1/M2 polarisation in Chapter 3, the data in this chapter were based on THP-1 
(indicated as ‘M1’ or ‘M2’). Samples obtained from the primary cells were also 
included. Due to their limited sample size however, only some of the experiments 
were performed on the primary cells. Their data are indicated as ‘Primary’ or ‘P’ 
whenever applicable.  
 
4.2 Material and methods 
 
Proteoglycans were enriched from their conditioned media by anion exchange 
chromatography as described in Section 2.2. Various techniques including mass 
spectrometry, ELISA, Western blotting and FACE were used to characterise the 
proteoglycans as per Section 2.3.  
 
4.3 Results 
 
 
4.3.1 M1 macrophages produce more biglycan; whereas M2 
macrophages produce more perlecan and versican  
 
As many previous studies have already suggested, perlecan, biglycan and versican 
are among the most prominent proteoglycans present in both the healthy arteries 
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and atherosclerotic lesions [77-80]. Changes in their expression in the arterial wall 
may contribute to the progression of atherosclerosis [77,78,85-90]. These studies 
suggested a difference in the ability of these proteoglycans to retain lipoproteins in 
the arterial wall. Therefore, the level of expression of these proteoglycans was 
evaluated to determine the contribution of M1 and M2 macrophages to LDL 
binding.  
 
First, the proteoglycans secreted by M1 and M2 macrophages were purified by 
performing anion exchange chromatography. An example of a chromatography run 
on the THP-1 M2 macrophage-conditioned medium is shown in Figure 4.1. Non-
bound materials were washed off from the column (indicated by Peak 1 in the UV 
absorbance) in 250 mM NaCl buffer with a conductivity of ~30 mS/cm. Then, the 
retained proteoglycans were eluted from the column in 1 M NaCl buffer, with a 
conductivity of ~120 mS/cm. The elution of the proteoglycans was indicated by 
Peak 2. Chromatography was completed by regeneration of the column with 2 M 
NaCl buffer, with a conductivity of ~220 mS/cm. The concentration of the 
proteoglycans enriched was then evaluated with Coomassie protein assay (Table 
4.1). From 550 mL of THP-1 M1 conditioned medium, approximately 11 mL of 
peak material was collected and concentrated to 3.2 mL with the total protein 
estimated to be 8.4 mg. For THP-1 M2, approximately 7.5 mL of peak material was 
obtained from 280 mL conditioned medium, which was then concentrated to 2.8 
mL with an estimated total protein of 3.0 mg. On the other hand, from 90 mL of 
primary cell-conditioned medium (M1 and M2), approximately 9 mL of peak 
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materials were collected and concentrated to approximately 2.6 mL. The total 
protein was estimated to be around 1.2 mg. The protein yield from these samples 
were fairly similar, indicating a similar amount of proteins secreted by the cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Representative of a DEAE anion exchange chromatography 
performed to enrich for proteoglycans in the macrophage-
conditioned medium. Shown here is the THP-1 M2 macrophage-
conditioned medium with an initial volume of 280 mL.  
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Table 4.1 The proteoglycan-enriched fractions obtained from M1 or M2-
conditioned media by DEAE chromatography.  
 
 
  Volume of 
conditioned 
medium 
(mL) 
Volume 
of peak 
fraction 
(mL) 
Volume of 
peak fraction 
after 
concentration 
(mL) 
 
Total 
protein 
(mg) 
Yield 
(mg/L) 
M1 THP-1 
 
550 
 
11 3.2 8.4 15.3 
Primary 
 
90 9 2.7 1.3 
 
14.4 
M2 THP-1 
 
280 
 
7.5 2.8 3.0 10.7 
Primary 
 
90 9 2.6 1.0 11.1 
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Mass spectrometry was used to identify peptides derived from proteoglycans in the 
M1 and M2 fractions, instead of the commonly used radiolabelling technique. This 
is because mass spectrometry is more sensitive than radiolabelling and more 
importantly, it bypasses the obstacle of needing antibodies to identify the 
proteoglycans of interest, especially when not all proteoglycans have good 
antibodies available. Given that the proteoglycans that can be produced by M1/M2 
macrophages were largely unknown, the more sensitive mass spectrometry was 
therefore employed here. 
 
A range of heparan sulphate proteoglycans including agrin, perlecan, glypican, 
syndecan and testican were identified in the THP-1 M1 and M2 fractions. Based on 
the molecular mass search (MOWSE) scores, agrin was the most abundant heparan 
sulphate proteoglycan in these fractions, followed by perlecan. Whereas only 
perlecan was identified in the primary cell fractions. Taken together, these mass 
spectrometry data suggest that M1 and M2 macrophages (regardless of which origin) 
secrete an abundance of perlecan into the conditioned medium (Table 4.2).  
 
Chondroitin sulphate proteoglycans such as aggrecan, biglycan and chondroitin 
sulphate proteoglycan-4 (CSPG4) were identified in the M1 fractions, with 
aggrecan and CSPG4 being the most abundant chondroitin sulphate proteoglycans 
in the THP-1 and primary M1 fractions, respectively. Like the M1 fractions, 
aggrecan was among the chondroitin sulphate proteoglycans identified in the M2 
fractions of both origins. Its abundance in the THP-1 M2 fraction was close to that 
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of versican, as suggested by the MOWSE scores. CSPG4 was the most abundant 
chondroitin sulphate proteoglycan in the primary M2 fraction, followed by 
aggrecan and biglycan (Table 4.2).    
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Table 4.2 Proteoglycan core proteins identified in the chromatography-enriched M1 and M2 fractions as detected by peptide LC-
MS2 from an in-solution tryptic digestion. Peptides were categorised into either HSPGs or CSPGs in an alphabetical 
order and the values shown were the molecular mass search score (MOWSE).  
 
Peptide 
identified 
Accession 
number* 
Molecular 
mass (Da) 
M1 M2 
MOWSE 
score# 
Peptides 
matched† 
Sequence 
coverage (%)‡ 
MOWSE 
score# 
Peptides 
matched† 
Sequence 
coverage (%)‡ 
   T P T P T P T P T P T P 
HSPGs               
Agrin  O00468 212,745 561  20  20  777  20  19  
Glypican-4 O75487 62,358       147  2  2  
Perlecan P98160 468,525 331 467 7 12 6 9 295 578 8 16 8 13 
Syndecan-2 P34741 22,160 56  2  2  210  4  3  
Syndecan-4  P31431 21,594 61  1  1        
Testican-2  Q92563 46,749 60  1  1  73  3  2  
CSPGs               
Aggrecan  P16112 250,040 174 110 7 5 6 3 83 147 2 6 2 3 
Biglycan P21810 44,254 97 70 4 4 4 3  78  2  2 
CSPG4 Q6UVK1 250,342 65 162 3 3 3 5  235  7  7 
Versican P13611 74,201       89  3  3  
 
* Obtained from Swiss-Prot.  
# MOWSE as determined by Mascot query. This is the value (p) that is a measure of the probability that the match is a random event 
expressed as -10log(p). The higher the score means that the more confidence that the match is not due to a random event.  
† The number of peptide sequences that matched to theoretical sequence in the NCBI database.  
‡ The number of amino acids detected as a proportion of the total number of amino acids in the protein listed in Mascot.  
Abbreviations are: CSPGs, chondroitin sulphate proteoglycans; HSPGs, heparan sulphate proteoglycans; P, primary cell; T, THP-1. 
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Having seen that perlecan was detected in mass spectrometry, its presence in the 
M1 and M2 fractions was further investigated. ELISA was performed on the 
fractions with a range of antibody clones specific to the different domains of the 
perlecan core protein. Unlike M1, the M2 fraction consistently showed reactivity 
towards the antibody clones (except to those against domain I), suggesting an 
abundance of perlecan present in the fraction. Furthermore, these data also indicated 
the presence of at least two domains of perlecan (domains III and V) in the fractions 
(Figure 4.2A).  
 
To determine if these domains were present as fragments or as a part of a full-length 
core protein, Western blotting was performed on the fractions and probed with 
monoclonal antibody specific to domain I (A71), unknown epitope (5D7-2E4), and 
domain V (E-6) of perlecan. Although perlecan in the M1 fraction was only detected 
by the antibody clone E-6, both fractions produced bands only at ~460 kDa, thus 
suggesting that perlecan was expressed as full-length molecules in the fractions. 
The key limitation of this experiment was that although a same amount of samples 
(2 µg as determined from the Coomassie protein assay) and exposure time (5 min) 
were used, a concrete interpretation about the relative expression of perlecan could 
not be established directly from this result because it was performed on two 
different gels (Figure 4.2B).  
 
As a summary, full-length perlecan was secreted by M1 and M2 macrophages.    
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Figure 4.2 The presence of perlecan in the M1 and M2 proteoglycan-enriched 
fractions. Antibody clones specific to each of the domains were 
employed and their epitope was indicated below the antibody clone. 
(A) ELISA. Data were corrected for DPBS background and 
presented as mean ± standard deviation (n = 3).  (B) Western blotting. 
Molecular weight (MW) standards were electrophoresed on each gel 
and are indicated on the left.  
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M1 and M2 macrophages were suggested to secrete biglycan by mass spectrometry. 
ELISA was performed to ascertain the presence of biglycan in their fractions. Two 
monoclonal antibody clones against full-length recombinant biglycan core protein, 
4E1-1G7 and 2E6-D1, were used to detect the protein by performing ELISA. 
However, the data were below detection limit of ELISA (data not shown).  
 
Therefore, Western blotting and PCR, which are more sensitive than ELISA, were 
performed. The fractions were blotted and probed with 2E6-D1. There was a band 
at ~50 kDa indicating the core protein, and other high molecular weights (from ~75 
kDa to ~200 kDa), which may result from the interaction between biglycan and 
other matrix components such as collagens [138] (see Appendix 1) (Figure 4.3A). 
 
Like perlecan, the limitation of the experiment was that the relative expression of 
biglycan could not be established directly from this Western blotting because it was 
performed on two different gels. Relative gene expression levels were obtained 
however by PCR, using a pair of primers specific to biglycan domains I – II. 
Transcripts generated from mRNA isolated from M1 and M2 macrophages 
produced a major band at the expected size for the primers (Figure 4.3B). This 
indicated the expression of biglycan in both M1 and M2 macrophages.   
 
The relative gene expression for biglycan in M1 and M2 macrophages was further 
determined by performing quantitative real time PCR (qPCR) over 40 cycles 
compared to GAPDH expression. Albeit a lower average for M2 macrophages, the 
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result indicated a non-statistically different expression of biglycan in both 
macrophage phenotypes (Figure 4.3C).  
 
To summarise, M1 and M2 macrophages produced biglycan, with the protein 
structure and gene expression being similar between the macrophage phenotypes.  
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Figure 4.3 Biglycan protein and gene expression in M1 and M2 macrophages. 
(A) Western blotting performed on the fractions with an anti-
biglycan antibody clone, 2E6-D1. Molecular weight (MW) 
standards were electrophoresed on each gel and are indicated on the 
left. (B) Gene expression of biglycan was analysed by PCR and the 
base pair lengths are indicated on the left. (C) qPCR analysis of 
biglycan gene expression in M1 and M2. Data presented as a fold 
change compared to M0 and corrected for GAPDH expression (n = 
3). Not significant (NS) vs. M1 (t-test).        
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Mass spectrometry suggested a difference in the production of versican between 
M1 and M2 macrophages. The following experiments were performed to determine 
the level of versican in the fractions. The presence of versican was determined by 
ELISA with a monoclonal anti-versican G3 antibody clone, 5D5. The M2 fraction 
showed a higher absorbance than the M1 fraction, suggesting that M2 macrophages 
produce more versican than M1 macrophages (Figure 4.4A). 
 
To confirm this difference in production, Western blotting was performed on the 
fractions on a same gel and probed with a polyclonal anti-versican antibody, LS-
C312902. The intensity of the immunoreactive bands obtained from the M2 fraction 
appeared to be considerably stronger than those generated from the M1 fraction, 
suggesting that M2 macrophages produced a higher amount of versican than M1 
macrophages. The versican secreted by both macrophages was present as a major 
form at ~150 kDa. In addition, there were also other immunoreactive bands in the 
M2 fraction, including a ~80 kDa, ~100 kDa, ~200 kDa and ~250 kDa. As the blot 
was probed with an antibody against the full-length versican, each of these bands 
may indicate one of the known isoforms of versican: ~80 kDa (V3), ~150 kDa (V2) 
and ~250 kDa (V0 or V1) (Figure 4.4B).  
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Figure 4.4 The presence of versican in the M1 and M2 proteoglycan-enriched 
fractions. (A) ELISA was performed to detect versican in the M1 
and M2 proteoglycan-enriched fraction with an anti-G3 antibody 
5D5. Data were corrected for DPBS background and presented as 
mean ± standard deviation (n = 3). (B) Western blotting was 
performed on the same gel (shown separately here for a clearer 
presentation) and versican was detected with a polyclonal anti-
versican LS-C312902. Molecular weight (MW) standards were 
electrophoresed on each gel and are indicated on the left. The 
possible versican isoforms represented by the bands are indicated in 
the right.  
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The data from Western blotting (Figure 4.4B) suggested the presence of different 
isoforms of versican, particularly in the M2 fraction. PCR was used to investigate 
which isoforms were being expressed by the macrophages. Knowing which 
versican isoforms were produced is important for this study because chondroitin 
sulphate, which is hypothesised to bind LDL [139], is only present on V0, V1 and 
V2, not V3. Also, the numbers of GAG on each of the isoforms are different, which 
may have an impact on the isoform’s affinity of LDL [139]. Here, primers specific 
to the isoforms of versican, i.e. V0, V1, V2 and V3, were used. Transcripts obtained 
from M2 macrophages produced major bands at the expected size for each of the 
primers, whereas M1 transcripts only generated bands for V1 and V3 (Figure 4.5A).  
 
qPCR analysis also showed that there was up-regulation of the genes for versican 
isoforms (V1 to V3) in M2 macrophages. V1 gene expression was decreased in M1 
macrophages. Consistent with the protein levels, these results indicated that M2 
macrophages secreted more versican than M1 macrophages (Figure 4.5B). The 
expression of the gene for V0 was not quantified real-time due to the large size 
(over 800 bp) of the PCR product of the primers.  
 
To summarise, M2 macrophages produced more versican than M1 macrophages. 
All four known isoforms of versican were expressed by M2 macrophages.  
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Figure 4.5 Versican gene expression in M1 and M2 macrophages. (A) PCR 
performed using versican isoform specific primers. The base pair 
lengths are indicated on the left. (B) qPCR analysis of V1, V2 and 
V3 gene expressions in M1 and M2 macrophages. Data presented as 
a fold change compared to M0 and corrected for GAPDH expression 
(n = 3). **p < 0.01 vs. M1 (t-Test).   
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4.3.2 M1 macrophages secrete glycosaminoglycans that are more 
highly sulphated than those produced by M2 macrophages  
 
The previous section established that M1/M2 polarisation affected the production 
of perlecan, biglycan and versican by macrophages. Therefore, the experiments in 
this section were performed to examine the structure of the GAG chains of the 
proteoglycans secreted by M1 and M2 macrophages. This is important to know 
because the nature of the association between LDL and proteoglycans depends on 
the positively-charged regions in the surface of lipoproteins and the negatively-
charged GAG chains [17].  
 
First, a DMMB assay was performed to determine the GAG content in the fractions. 
Although it appeared to be higher in the M1 fractions, the GAG content was actually 
lower than the M2 fractions when it was normalised to the protein concentration. 
These data indicated that the proteoglycans secreted by M2 macrophages were more 
highly decorated with GAGs than those secreted by M1 macrophages (Figure 4.6). 
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Figure 4.6 The content of GAG, protein and the ratio of GAG to protein of the 
M1 and M2 proteoglycan-enriched fractions. The concentration of 
protein and GAG was determined by Coomassie assay and DMMB 
test, respectively (n = 1). 
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ELISA was performed to determine the presence of certain structural motifs in the 
GAGs produced by M1 and M2 macrophages. Antibody clones against certain 
motifs on chondroitin sulphate or heparan sulphate were used in this experiment 
(Figure 4.7).  
 
Chondroitin 4- and 6-sulphate residues (detected by antibody clone CS-56) were 
detected in both M1 and M2 fractions. However, both fractions were not reactive 
with antibody clone 7D4, which recognises the sulphated and non-sulphated 
oligosaccharide sequences close to the linkage region, which is the attachment site 
that links chondroitin sulphate to the proteoglycan core protein [140].   
 
On the other hand, the M2 fraction showed a reactivity with the heparan sulphate 
antibody clone 10E4, which recognises heparan N-sulphated glucosamines; 
whereas the M1 fraction showed a background reading. For antibody clone JM403, 
which reacts with heparan unsubstituted glucosamines, both M1 and M2 fractions 
showed readings that were below the detection limit of ELISA.  
 
To summarise, although the reactivity of these anti-GAG antibodies was not 
discriminant to define the level of total chondroitin sulphate and heparan sulphate 
in the samples, these data are informative of the subtle changes in the structural 
features of these GAGs during M1/M2 polarisation.    
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Figure 4.7 The level of expression of the GAG structures in the M1 and M2 
proteoglycan-enriched fractions as determined by ELISA. 
Antibodies specific to the GAG structures were used and the epitope 
was indicated below the antibody clone. Data were corrected for 
DPBS background and presented as mean ± standard deviation (n = 
3).  
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Having seen that the structure of chondroitin sulphate produced by M1 and M2 may 
be different, the sulphation degree and pattern of the GAGs was then examined. 
First, the proteoglycan-enriched fractions were digested with chondroitinase ABC 
to reveal the unsaturated terminal disaccharide structures after the linkage region of 
the chain, known as the ‘stubs’. An ELISA was performed on the fractions with 
antibody clones 1B5, 2B6 and 3B3 to detect the presence of unsulphated, 4- and 6-
sulphated stubs, respectively.  
 
Both M1 and M2 fractions were not reactive with the antibody clone 1B5, which 
means that the stubs were sulphated. Indeed, both M1 and M2 fractions showed a 
reactivity towards the antibody clone 2B6, indicating that the stubs were sulphated 
at the position C-4 of galactosamine. However, 6-sulphated stubs were only 
detected in the M1 fraction with the antibody clone 3B3, not the M2 fraction. This 
indicated that the chondroitin sulphate stubs in the M1 fraction were also sulphated 
at the position C-6 of galactosamine (Figure 4.8). 
 
As a summary, this experiment showed the difference in the pattern of sulphation 
in stubs of the chondroitin sulphate produced by M1 and M2 macrophages. It should 
however be noted that these data do not represent the chondroitin sulphate chain 
structure. This is because these antibodies are specific to epitopes in the stub or 
linkage region of chondroitin sulphate near the proteoglycan core protein.   
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Figure 4.8 The presence of chondroitinase ABC-generated stub neo-epitopes in 
the M1 and M2 proteoglycan-enriched fractions as determined by 
ELISA with a suite of anti-chondroitin sulphate stub antibody clones, 
1B5, 2B6 and 3B3. Data were corrected for DPBS background and 
presented as mean ± standard deviation (n = 3).  
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The next experiment was performed to provide more structural information on the 
composition of the chondroitin sulphate chain. The fractions were digested with 
chondroitinase ABC to cut the chain into disaccharides, and with either chondro-4-
sulphatase or chondro-6-sulphatase to remove the sulphate groups at positions C-4 
or C-6, respectively. The resulting disaccharides were analysed by FACE. 
 
Digestion of the M1 and M2 fractions with chondroitinase ABC confirmed the 
presence of chondroitin sulphate as indicated by the appearance of disaccharides 
migrating in a similar way to the disaccharide standards (Lane 1 for all groups). 
After the treatment with chondro-4-sulphatase or chondro-6-sulphatase, both M1 
and M2 fractions showed an increase in the intensity of the bands that ran to the 
same positions as the chondroitin 0-sulphate disaccharide standard (Lanes 2 and 3 
for all groups). These data indicated the presence of chondroitin 4-sulphate and 6-
sulphate disaccharides in the chondroitin sulphate produced by M1 and M2 
macrophages. Furthermore, the intensity of these unsulphated disaccharides after 
the chondro-4-sulphatase digestion of the M1 fractions appeared to be much denser 
than those obtained from the M2 fractions. This observation suggested that there 
were more chondroitin 4-sulphate disaccharides in the M1 chondroitin sulphate 
chains than those of M2 macrophages (Figure 4.9A).  
 
To determine the relative proportions of disaccharides in each of the fractions, the 
density of the bands was quantified. The fractions derived from THP-1 M1 
macrophages contained ~23% of unsulphated, ~68% of 4-sulphated, and ~9% of 6-
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sulphated chondroitin sulphate disaccharides. In contrast, the M2 fraction contained 
a larger proportion of unsulphated disaccharides than the M1 fraction, which was 
at ~33%; whereas the proportions for 4-sulphated and 6-sulphated chondroitin 
sulphate disaccharides were ~58% and ~9%, respectively, in the  fraction. The 
fraction derived from primary cells also showed a similar trend to the THP-1, with 
the M2 fraction containing a larger proportion of unsulphated disaccharides (~20%) 
than the M1 fraction (~11%). The primary M1 fraction contained ~48% of 4-
sulphated and ~41% of 6-sulphated chondroitin sulphate disaccharides; whereas the 
4- and 6-sulphated disaccharides were at a similar proportion of ~40% and ~39%, 
respectively, in the primary M2 fraction (Figure 4.9B).    
 
Due to the unavailability of commercial chondro-2-sulphatase that removes 
sulphates from the position C-2, the presence of chondroitin 2-sulphate was not 
directly identified and quantified in this study. However, in the future, a standard 
chondroitin 2-sulphate disaccharide may be used.   
 
In summary, these experiments indicated that the chondroitin sulphate secreted by 
M1 macrophages was more sulphated than that produced by M2 macrophages, 
predominantly at the position C-4 of galactosamine. 
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Figure 4.9 (A) Disaccharide compositional analysis by FACE of the chondroitin sulphate GAGs in the M1 and M2 fractions after 
digestion with chondroitinase ABC and/or chondro-4-sulphatase or chondro-6-sulphatase. Standard disaccharides were 
electrophoresed on each gel and indicated by numbers. (B) The density of the bands was quantified to determine the 
relative proportions of the chondroitin sulphate disaccharides in each of the fractions, and shown in the pie charts. The 
numbers in the charts are the percentage (%) of the disaccharides.  
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Like chondroitin sulphate, the data from ELISA also indicated that the structure of 
the heparan sulphate secreted by M1 and M2 macrophages may be different. The 
next experiment was performed to examine the disaccharide composition of 
heparan sulphate in the macrophage fractions. The fractions were digested with 
heparinase III and the disaccharides obtained were analysed by FACE. 
 
Digestion of the M1 and M2 fractions with heparinase III confirmed the presence 
of heparan sulphate because the bands migrated in a similar way as the disaccharide 
standards. A range of different disaccharide bands were generated from the 
digestion of each of the fraction with heparinase III. This indicated that the heparan 
sulphate chains contained different structural motifs. In the M1 fractions (both 
THP-1 and primary), the bands ran to a similar position as the standards for non-
sulphated uronic acid-N-sulpho-D-glucosamine (∆UA – GlcNAc), mono-sulphated 
uronic acid-N-sulpho-D-glucosamine (∆UA – GlcNS), mono-sulphated uronic 
acid-N-sulpho-D-glucosamine, 6S (∆UA – GlcNAc,6S) and di-sulphated uronic 
acid, 2S-N-acetyl-D-glucosamine, 6S (∆UA,2S – GlcNAc,6S). For the THP-1 M2 
fractions, the bands generated from the digestion also migrated in a similar way as 
those in the M1 fractions, whereas the primary M2 fraction only contained ∆UA – 
GlcNAc and ∆UA – GlcNS disaccharides. These observations indicated that the 
heparan sulphate secreted by M1 and M2 macrophages was composed of different 
disaccharides (Figure 4.10A).  
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To determine the relative proportions of disaccharides in each of the fractions, the 
density of these bands was quantified. About nine-tenths of the heparan sulphate 
disaccharides in the THP-1 M1 fraction were sulphated (~40% of mono-sulphated 
∆UA –GlcNS and ~50% of di-sulphated ∆UA,2S – GlcNAc,6S), but only ~79% of 
the heparan sulphate disaccharides in the THP-1 M2 fraction were sulphated (~40% 
of ∆UA – GlcNS, ~19% of ∆UA – GlcNAc,6S and ~20% of ∆UA,2S – GlcNAc,6S). 
The proportion of the unsulphated ∆UA – GlcNAc was ~10% and ~18% in the 
THP-1 M1 and M2 fractions, respectively. For the primary macrophages, the 
heparan sulphate produced by M1 and M2 macrophages contained unsulphated 
∆UA – GlcNAc at ~18% and ~23%, respectively. The sulphated disaccharides in 
the M1 fraction consisted of ~60% of ∆UA – GlcNS, ~7% of ∆UA – GlcNAc,6S 
and ~15% of ∆UA,2S – GlcNAc,6S; whereas only ∆UA – GlcNS was identified in 
the M2 fraction. Overall, the results showed that the M1 fractions had more 
sulphated disaccharides than M2 fractions. (Figure 4.10B).  
 
In summary, unlike chondroitin sulphate, the heparan sulphate that M1 and M2 
macrophages secreted exhibited differences in the type of disaccharides and the 
degree of sulphation.      
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Figure 4.10 (A) Disaccharide compositional analysis by FACE of the heparan sulphate GAGs in the M1 and M2 fractions after 
digestion with heparinase III. Standard disaccharides were electrophoresed on each gel and indicated by numbers. (B) 
The density of the bands was quantified to determine the relative proportions of the heparan sulphate disaccharides in 
each of the fractions, and shown in the pie charts. The numbers in the charts are the percentage (%) of each of the 
disaccharides. Abbreviations are: UA, uronic acid; GlcNAc, N-acetyl-D-glucosamine; GlcNS, N-sulpho-D-glucosamine. 
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4.3.3 M1 and M2 macrophages differentially glycosylate the 
biglycan and perlecan, but not the versican, that they 
produce  
 
While the previous section explored the structure of GAGs in the fractions, the 
experiments in this section aimed to examine the glycosylation (also known as 
gaglylation) of particular proteoglycans that the macrophages produced, namely 
perlecan, biglycan and versican. This is important to know because while these 
proteoglycans are associated with atherosclerosis (Table 1.2, Chapter 1), their roles 
in lipid retention may depend on their GAG chains [17,139].     
 
The type of GAGs decorating the perlecan core protein that M1 and M2 
macrophages produced was examined. Western blotting was performed on the 
fractions that were either undigested or digested with heparinase III (to remove 
heparan sulphate) and/or chondroitinase ABC (to remove chondroitin sulphate and 
dermatan sulphate) or chondroitinase B (to remove dermatan sulphate), and probed 
for domain I (A71), an unknown epitope on perlecan (5D7-2E4), and domain V (E-
6). Compared to the undigested bands, the intensity of the ~460 kDa core protein 
increased and migrated further down after treatment with heparinase III (Lane B on 
each of the M2 blots). This was particularly noticeable in the fractions probed with 
the antibody clones A71 and 5D7-2E4. This indicated that the perlecan M2 
macrophages produced was decorated with heparan sulphate (Figure 4.11).  
 
While no immunoreactive bands were observed from the antibody clones A71 and 
5D7-2E4, the intensity of the ~460 kDa band generated from probing the M1 
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fraction with the antibody clone E-6 appeared to be increased and migrated further 
than the undigested band after digestion with heparinase III (Lane B) or 
chondroitinase ABC (Lane C). This indicated heparan sulphate and chondroitin 
sulphate on the perlecan produced by M1 macrophages. Unexpectedly, the fraction 
treated with a mixture of heparinase III and chondroitinase ABC generated a band 
(Lane E) with a similar intensity and position as the untreated band (Figure 4.11). 
The limitation of this experiment was that this observation was not further 
examined.     
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Figure 4.11 The glycosylation of perlecan in the M1 and M2 proteoglycan-
enriched fractions as determined by Western blotting. Fractions 
were untreated (Lane A) or treated with either heparanase III (Lane 
B) or chondroitinase ABC (Lane C) or both (Lane E), or 
chondroitinase B (Lane D) and probed for perlecan domain I (A71), 
an unmapped epitope on perlecan (5D7-2E4), and domain V (E-6). 
Molecular weight (MW) standards were electrophoresed on each gel 
and were indicated on the left.  
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Next, the glycosylation of biglycan secreted by M1 and M2 macrophages was 
examined. The proteoglycan-enriched fractions were pre-digested with a range of 
endoglycosidases before Western blotting was performed with an anti-biglycan 
antibody clone, 2E6-D1. The endoglycosidases used in this experiment included 
heparinase III (to remove heparan sulphate), chondroitinase AC II (to remove 
chondroitin sulphate), chondroitinase B (to remove dermatan sulphate) and 
chondroitinase ABC (to remove both chondroitin sulphate and dermatan sulphate). 
These endoglycosidases were used because biglycan is known to have dermatan 
and/or chondroitin sulphate on its core protein [141].  
 
The results showed that the ~50 kDa (i.e. the core protein) and the ~75 kDa bands 
in the M1 fractions were sensitive to the digestion with all endoglycosidases (Lanes 
B – E). This indicated that the biglycan produced by M1 macrophages was 
glycosylated with chondroitin/dermatan sulphate and heparan sulphate. In contrast, 
the core protein and ~75 kDa bands in the M2 fraction were sensitive only to either 
chondroitinase B or ABC digestions (Lanes C and D), indicating that it was 
decorated with chondroitin/dermatan sulphate. The bands at ~100 kDa to ~200 kDa 
in both M1 and M2 fractions were not sensitive to any digestions, probably due to 
the interaction with other matrix components (Figure 4.12).  
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Figure 4.12 The glycosylation of biglycan in the M1 and M2 proteoglycan-
enriched fractions as determined by Western blotting with an anti-
biglycan antibody, 2E6-D1. Fractions were either untreated or 
treated with endoglycosidase as indicated by the letters. Molecular 
weight (MW) standards were electrophoresed on each gel and were 
indicated on the left. Note the changes in the band intensity after 
treatments.  
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The glycosylation of versican was also investigated. Western blotting was 
performed on the fractions (digested with chondroitinase ABC or heparinase III) 
and probed with a polyclonal anti-versican antibody, LS-C312902. The ~80 kDa 
(V3), ~150 kDa (V2) and ~250 kDa (V0 or V1) bands were only sensitive to the 
digestion with chondroitinase ABC (Lanes B), as indicated by the decreased band 
intensity, which was more noticeable in the M2 fraction than the M1 fraction. 
Overall, this indicated that the versican produced by both M1 and M2 macrophages 
was decorated with chondroitin sulphate (Figure 4.13).   
 
 
 
     
 
 
 
 
 
Figure 4.13 The GAGs decorating the versican in the M1 and M2 proteoglycan-
enriched fractions as determined by Western blotting with a 
polyclonal anti-versican antibody LS-C312902. Fractions were 
either untreated or treated with endoglycosidase as indicated by the 
letters. Molecular weight (MW) standards were electrophoresed on 
each gel and were indicated on the left.  
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4.4 Discussion  
 
In this chapter, the extracellular proteoglycan production of M1 and M2 
macrophages was characterised and compared. While there have been few similar 
studies on macrophage polarisation and proteoglycans, the data in this chapter 
further the current understanding by showing that polarisation not only influences 
macrophage production of proteoglycans, but it also affects the glycosylation of the 
proteoglycans in terms of the content and structure of the GAG chains.  
 
For the first time, this chapter reports that M2 macrophages produce more perlecan 
than M1 macrophages. The M2 polarising cytokine IL-4 has been also shown to 
induce the expression of perlecan-like protein in human fibroblasts [142], but the 
effect of M1 stimuli is not known. The present study also shows that the perlecan 
secreted by polarised macrophages is differentially glycosylated: while the perlecan 
produced by M2 macrophages was decorated with heparan sulphate only, that 
produced by M1 macrophages was decorated with both heparan and chondroitin 
sulphates. Perlecan can be decorated with multiple types of GAG depending on the 
cell type. For example, perlecan derived from arterial endothelial cells contains 
heparan sulphate only [143], whereas that isolated from epithelial cells is decorated 
with heparan, chondroitin and keratan sulphates [144]. The present study adds new 
findings to this understanding that the glycosylation of perlecan produced by the 
same cell type also depends on the local microenvironment.    
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On the other hand, biglycan was expressed by both M1 and M2 macrophages. While 
this study agrees that M0 macrophages express biglycan mRNA after activation by 
LPS [145], this is the first time to report the effect of IL-4 on biglycan production 
in macrophages or even any other cells. Additionally, like perlecan, the biglycan 
produced by M1 macrophages was decorated with heparan and chondroitin 
sulphates, whereas the biglycan produced by M2 macrophages is only decorated 
with chondroitin sulphate. While it is better known as a chondroitin sulphate 
proteoglycan [146,147], the presence of biglycan decorated with heparan sulphate 
is not impossible. While rare, other cells such as human embryonic kidney (HEK-
293) cells have been found to secrete biglycan with heparan sulphate [148]. 
Although the macrophage phenotype is not known, the biglycan with chondroitin 
sulphate has been found to stimulate the inflammatory signalling pathways in 
macrophages [149], whereas the function of the biglycan with heparan sulphate 
remains unknown.  
 
Like perlecan, M2 macrophages produced more versican than M1 macrophages. 
This finding contrasts with the previous study reporting that the macrophage 
expression of versican is increased only in response to the M1, but not the M2 
polarisation [150]. However, the use of murine macrophages in their study may 
account for the differences with the results in this study. Besides, the changes in the 
culture conditions may also cause the differences observed in this thesis. The 
macrophages reported in Chang et al. [150] were polarised to an M2 phenotype 
with a combination of IL-4 (10 ng/mL) and IL-13 (10 ng/mL); whereas M2 
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polarisation was achieved with 20 ng/mL IL-4 only in this study. It should be noted 
though that either IL-4 and IL-13 or a combination of both are commonly used to 
obtain M2 macrophages [131,151-154]. The present study provides novel data of 
the expression of versican by human macrophages: the M2 phenotype expresses all 
four known isoforms, whereas only V1 and V3 are expressed by the M1 phenotype. 
The isoforms however have the same glycosylation – chondroitin sulphate, in both 
M1 and M2 phenotypes.    
 
Besides the production of proteoglycans, macrophage polarisation also influences 
the content and structure of the GAG chains that the cells produce. Here, the 
extracellular proteoglycans produced by M2 macrophages were found to be more 
glycosylated than those of M1 macrophages. This is consistent with a previous 
study on the cell-surface proteoglycans [155]. Interestingly, their study found that 
M2 macrophages produce twice as much heparan sulphate as M1 macrophages, 
whereas the chondroitin sulphate level was fairly similar in both phenotypes. 
Coincidentally in this study, the M2 proteoglycans showed a higher reactivity 
towards the heparan sulphate antibody, while a similar reactivity as the M1 
macrophages towards the chondroitin sulphate antibody. Whether these results also 
indicating a similar finding as what Martinez et al. [155] found however cannot be 
established directly because the total level of these GAG chains was not examined 
here.  
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The GAG chains (both chondroitin and heparan sulphates) produced by M1 
macrophages were more highly sulphated than those of M2 macrophages. This is 
not consistent with the previous studies [155,156] – however, those were examining 
the cell-surface, not the extracellular GAG chains. Although they have reported that 
the increase in the expression of GAG-modifying enzymes, such as 
sulphotransferases, during the M2 polarisation with IL-4 can increase the 
sulphation degree of the GAG chains on the cell-surface proteoglycans, the role of 
these enzymes on the extracellular GAG chains has not been examined. It is not 
known if the cell-surface GAG chains can be shed and thus contributing to the 
extracellular GAG population. With the present and the past study [155] reporting 
a different disaccharide composition on the extracellular and cell-surface GAG 
chains, respectively, from the same macrophage phenotype, this direct contribution 
hence seems to be unlikely. Taken together, this study thus provides a novel finding 
that the GAG sulphation of the extracellular proteoglycans produced by 
macrophages is associated with the M1/M2 polarisation. Albeit with unknown 
macrophage phenotype, it has also been suggested that the extracellular GAG 
profile produced by macrophages depends on their source and activation [157].    
 
The significance of the different expression and structure of proteoglycans 
produced after polarisation and their association with the role of M1 and M2 
macrophages in LDL binding is not known. These data demonstrate the different 
ability of their proteoglycans to bind LDL. For example, with M2 macrophages 
producing an abundance of perlecan, the expression of which is inversely 
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proportional to the development of human atherosclerosis [89], it suggests that the 
M2 proteoglycans may not bind much LDL. However, like M1 macrophages, they 
also produce biglycan, a molecule established to promote atherogenesis [87,92,158]. 
However, it is difficult to predict the contribution to LDL binding solely based on 
what proteoglycans are produced, given that the association between LDL and 
proteoglycans has been well established on the positively-charged regions in LDL 
and the negatively-charged GAG chains [17]. The higher sulphated GAG chains 
that M1 macrophages produce theoretically have a higher LDL binding ability than 
those produced by M2 macrophages. Several studies have also reported the increase 
in the charge density of GAG chains during atherosclerosis to increase the retention 
of LDL [159,160]. Therefore, it is tempting to hypothesise that the proteoglycans 
produced by M1 macrophages are more LDL-retentive than those of M2 
macrophages. Apart from sulphation, the heparan sulphate produced by M1 and M2 
macrophages also contained different disaccharides that were substituted by 
sulphates at different positions. The function of the heparan sulphates in LDL 
binding is unknown. The data in this chapter thus provides exciting insights into the 
role of heparan sulphate in binding LDL when presented as part of the 
proteoglycans that M1 and M2 macrophages produce. The next chapter sought to 
determine the LDL binding of their proteoglycans and understand the relevance of 
proteoglycan structure in that aspect. 
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4.5 Summary 
 
Macrophage polarisation affects proteoglycan production, as evidenced by the 
distinct pattern in the level of expression as well as the structure of the 
proteoglycans that M1 and M2 macrophages produced. While both secreted 
biglycan, M2 macrophages produced more versican and perlecan than M1 
macrophages. The GAG chains produced by M1 macrophages had a larger 
proportion of sulphated disaccharides than those of M2 macrophages. M1 and M2 
macrophages also produced heparan sulphate that contained different disaccharides 
that were sulphated at different positions. Lastly, while they were decorated with 
heparan and chondroitin sulphates in M1 macrophages, the biglycan and perlecan 
produced by M2 macrophages were decorated only with chondroitin sulphate and 
heparan sulphate, respectively. The versican produced by both macrophages was 
decorated with chondroitin sulphate. 
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Chapter 5 
The binding of low-density lipoproteins to the 
extracellular proteoglycans secreted by THP-1 
derived M1 and M2 macrophages  
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5.1 Introduction 
 
As M1 and M2 macrophages produce proteoglycans, theoretically, both can 
contribute to LDL binding as proteoglycans are known to interact with LDL via the 
GAG chains [17], thus having a role in the initiation of atherosclerosis. However, 
having seen that the GAG chains produced by these phenotypes are structurally 
different, the LDL binding ability of their proteoglycans may be different. 
Therefore, the experiments in this chapter aimed to examine and compare the LDL 
binding of the proteoglycans produced by M1 and M2 macrophages. The 
experiments also further explored the component(s) of the proteoglycans that bound 
LDL. The results in this chapter were based mainly on THP-1 cells. When primary 
cells were used, this is indicated by the prefix ‘Human buffy coat’.  
 
The QCM-D technique was employed in this thesis rather than the more commonly 
used radiolabelling because it offered a more sensitive real-time measurement at 
the nanogram level, which then saved samples and LDL. As such, LDL used in 
these experiments was from a same batch. This is important as LDL composition 
changes may affect the proteoglycan binding. For example, the ability of LDL to 
bind to human aortic proteoglycans decreases after oxidation [161]. The net 
negative charge on the LDL particles increases after oxidation, which is 
accompanied with loss of free lysine residues. Since the binding of LDL to 
proteoglycans is mediated by the ionic interaction between the positive charge from 
lysine residues of LDL and the negatively charged sulphate groups from GAG 
chains of proteoglycans, oxidation thereby neutralises LDL and causes the decrease 
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of LDL binding. Additionally, the size of LDL particles also influences the binding 
to proteoglycans as the smaller LDL particles have been found to bind 
proteoglycans more tightly than the larger ones [162]. Therefore, this thesis took 
the precaution by using a single batch of LDL to minimise the variability in the 
LDL preparation. 
 
5.2 Materials and methods 
 
The binding of LDL to proteoglycans was assessed by performing QCM-D and 
turbidity assays as per Section 2.5. The involvement of the core protein of 
proteoglycans in LDL binding was examined by pre-blocking them with specific 
antibodies. The role of the GAG chains in this interaction was studied by pre-
digesting the samples with endoglycosidases.  
 
5.3 Results  
 
5.3.1 Immobilisation of a stable proteoglycan layer onto the quartz 
crystal sensor surface for low-density lipoprotein binding 
measurement  
 
The aim of this experiment was to establish whether a similar mass of the M1 and 
M2 proteoglycans was adsorbed onto the gold surface of the quartz crystal sensors, 
so that the LDL binding ability of these proteoglycans could then be compared. In 
addition, the biophysical behaviour of the layer formed by the proteoglycans was 
examined, so that an appropriate model (Sauerbrey or Voigt) could be applied in 
mass determination.    
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The QCM-D technique works based on the resonance frequency of a quartz crystal 
sensor induced by an alternating electric field. Deposition of mass on the gold 
surface decreases the sensor’s oscillation frequency (i.e. negative frequency shift). 
For a thin, rigid and uniformly distributed layer, the frequency shift (Δf) is 
proportional to mass change (Δm), and thus the mass adsorbed can be calculated 
using the Sauerbrey equation [163]. However, when a thick or non-rigid layer is 
bound to the surface, this will not be the case. This is because water or other liquid 
or solvent molecules can act as an additional mass by direct hydration or entrapment 
in the adsorbed layer [164]. As such, the layer behaves as a viscoelastic solid, and 
its dissipative nature can interfere with the sensor’s oscillatory motion propagating 
into and through the layer [165,166]. This causes ∆f to be no longer directly 
proportional to ∆m as per the Sauerbrey relation. In this case, fitting dissipation 
shift (ΔD), as in the Voigt model, allows a more accurate estimate of Δm of a 
viscoelastic layer.  
 
In this experiment, 2 µg of proteoglycans, either undigested or digested with a 
mixture of chondroitinase ABC and heparinase III to yield core proteins, in the 
same total volume was injected into the QCM-D chambers at 0.1 mL/min. The Δf 
and ΔD at the fundamental frequency (5MHz) and three successive odd overtones 
(15, 25 and 35MHz) were measured simultaneously in real time.   
 
For this result presentation, the third overtone, at 15 MHz, was chosen to report the 
data. This is because as the overtone number increases, the area of the quartz crystal 
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sensor measured decreases. However, the fundamental frequency can be affected 
by the edge effects of the sensor. The third overtone thus reflects the most 
presentation of the events on the sensor and at the same time, without the edge 
effects [167].   
 
As shown in the plot of the third overtone ∆f and ∆D as a function of time (the Df-
t plot), the binding of proteoglycans (either undigested or digested) onto the gold 
surface of the sensors from ~7 to ~13 min induced a negative ∆f and a positive ∆D. 
After the 13 min, the main part of the ∆f and ∆D were stable. This negative ∆f 
indicated a deposition of proteoglycans onto the gold surface of the sensors, 
whereas the positive ∆D suggested a viscoelastic property of the adsorbed layer. 
After the ~13 min, the sensors were rinsed with DBPS for ~5 min to remove any 
unbound proteoglycans from the surface. No noticeable ∆f and ∆D changes were 
observed in this step, suggesting that the proteoglycans had firmly bound onto the 
sensors (Figure 5.1).   
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Figure 5.1 Comparison of proteoglycan deposition onto the gold surface of 
quartz crystal sensors as monitored using QCM-D. Representative 
plots of the third overtone ∆f and ∆D as a function of corresponding 
time (the Df-t plot) showing the deposition of an equal mass (2 µg 
as determined by Coomassie protein assay) of the M1 and M2 
proteoglycans, with or without endoglycosidase digestion, on the 
gold surface of the sensors. 
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The third overtone ∆f and ∆D were not significantly different between the M1 and 
M2 proteoglycans, regardless of digestion. The overall ∆f was an average value of 
–30 ± 8 Hz, whereas ∆D was 2 ± 0.3 × 10-6 (Figures 5.2A & B).  
 
Since the adsorbed layers of the proteoglycans were viscoelastic as indicated by the 
∆D, the ∆m of proteoglycans thus would be underestimated by the Sauerbrey 
equation. Therefore, the Voigt model was used to calculate adsorbed mass. The 
software supplied from Q-Sense, Q-Tool (Goteborg, Sweden) interpreted the Δf and 
ΔD data from the measurements based on the Voigt model to estimate viscoelastic 
properties of the adsorbed proteoglycan layer, assuming homogenous thickness, 
density and non-slip conditions. In this model, the viscoelastic properties of the 
layer were represented by four parameters: density, viscosity, shear elasticity, and 
thickness. From them, the mass per unit area (ng/cm2) of the proteoglycan layer was 
obtained by multiplying the thickness (nm) by the density, which was assumed to 
be 1100 kg/m3 for the protein/lipid layer with trapped water and the fluid viscosity 
set at 0.001 kg/m3.  
 
The mass of proteoglycans adsorbed onto the gold surfaces did not differ between 
M1 and M2, indicating a similar mass of proteoglycans was deposited (Figure 5.2C). 
This result also showed that the removal of GAGs from the proteoglycans did not 
affect the mass bound. This is probably because the immobilisation of 
proteoglycans onto the gold surface was mediated by core proteins, not GAG chains, 
as proteins tend to adsorb to gold surfaces by hydrophobic interactions [168]; 
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whereby it has proven technically challenging to bind carbohydrates, e.g. GAG 
chains, onto gold surfaces, and it usually requires some pre-experimental 
modifications to the molecules such as coupling with alky thiol linker and reductive 
amination [169,170].  
   
To summarise, a similar mass of M1 and M2 proteoglycans was adsorbed onto the 
gold surface of the quartz crystals, thus their LDL binding could be compared in all 
subsequent experiments. The Voigt model was used to calculate the mass of LDL 
bound in this study.  
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Figure 5.2 The third overtone (A) ∆f and (B) ∆D measured for deposition of 
each of the proteoglycans on the gold surface of the sensors using 
QCM-D. (C) The mass of proteoglycans adsorbed was calculated 
the Voigt-based ∆f and ∆D model. Data were presented as mean ± 
SD (n = 8). Not significant between all groups (ANOVA with post-
hoc Tukey).  
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5.3.2 M1 macrophages secrete proteoglycans that bind more low-
density lipoproteins than those of M2 macrophages 
 
This experiment was performed to compare the level of LDL bound to the 
proteoglycans produced by M1 and M2 macrophages. The representative Df-t plots 
showed the typical QCM-D experiment performed as per Section 2.5. Under the 
same flow and temperature, these plots showed that LDL bound to both the M1 and 
M2 proteoglycan preparations, indicated by a decrease in the Δf and an increase in 
the ΔD (note the highlighted areas). However, the Δf and ΔD changes appeared to 
be greater for the M1 proteoglycans compared to those of M2. It suggested a larger 
amount of LDL bound to the M1 proteoglycans than the M2 proteoglycans (Figure 
5.3A).   
 
Indeed, the Voigt-based modelled data showed that both M1 and M2 proteoglycans 
bound LDL, with the M1 proteoglycans binding significantly more LDL than the 
M2 proteoglycans (p < 0.05). In addition, the proteoglycans derived from THP-1 
and human buffy coat showed a similar trend in LDL binding. This further 
supported the findings from Chapter 3 that THP-1 is a suitable model for M1/M2 
polarisation (Figure 5.3B).   
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Figure 5.3 LDL binding to the proteoglycans produced by M1 and M2 
macrophages as determined by QCM-D. (A) Representative Df-t 
plots showing the experiment performed. Note the different degree 
of the Δf and ΔD between M1 and M2 during the LDL binding in 
the highlighted area. The dotted line indicates the Δf whereas the 
solid line indicates the ΔD. (B) Voigt-modelled data showing the 
amount of LDL bound. Data were corrected for BSA background 
and presented as mean ± standard deviation (n = 4). *p < 0.05; **p 
< 0.01 vs. corresponding M1 (ANOVA with post-hoc Tukey).  
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A turbidity assay was performed to compare the affinity of LDL for the M1 and M2 
proteoglycans. The formation of insoluble complexes between proteoglycans and 
LDL was measured spectrophotometrically using a wavelength of 620 nm [123].  
 
While the development of insoluble complexes between the M1 proteoglycans and 
LDL appeared to be directly proportional to the amount of proteoglycans, this was 
not the case for M2; rather, after an increase in the turbidity from 2.5 to 10 µg of 
proteoglycans, a plateau in binding was reached despite further addition of 
proteoglycans. These results supported the QCM-D data that both M1 and M2 
proteoglycans can bind LDL. These results also suggested that the M1 
proteoglycans bound LDL more readily than the M2 proteoglycans, because the M2 
proteoglycans showed a plateau which indicated that the LDL-proteoglycan 
interaction was already saturated (Figure 5.4).  
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Figure 5.4 A turbidity assay performed to evaluate the formation of insoluble 
complexes between the M1 or M2 proteoglycans and LDL as 
measured in mixtures containing 5 µg of LDL and increasing 
amounts of proteoglycans in a final volume of 100 µL 0.05 M CaCl2. 
Data were corrected for background (proteoglycans + CaCl2) and 
presented as mean ± SD (n = 3). *p < 0.05 vs. corresponding mass 
of the M1 proteoglycans (ANOVA with post-hoc Tukey).  
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5.3.3 The M1 macrophage-derived proteoglycans bind low-density 
lipoprotein via glycosaminoglycans; those of M2 
macrophages use core proteins  
 
In Chapter 4, the GAG chains (both chondroitin and heparan sulphates) attached to 
the proteoglycans produced by M1 macrophages were more highly sulphated than 
those produced by M2 macrophages. Their GAG chains were thus hypothesised to 
bind LDL. This experiment aimed to determine if the LDL binding involved the 
GAG chains. Here, the proteoglycans were digested with a mixture of 
chondroitinase ABC and heparinase III to remove all GAG chains. The digested 
proteoglycans were then analysed for their LDL binding with QCM-D.  
 
The representative Df-t plots showed that LDL bound to the digested M1 
proteoglycan preparation with a smaller degree in both the decrease of Δf and the 
increase of ΔD compared to the undigested proteoglycan preparation (the 
highlighted areas). This indicated a smaller amount of LDL was bound to the 
digested proteoglycans (Figure 5.5A).  
 
In contrast, the Df-t plots showed that LDL bound to the digested M2 proteoglycan 
preparation with a greater decrease in the Δf and increase in the ΔD than the 
undigested M2 proteoglycan preparation (the highlighted areas). This suggested 
that more LDL was bound to the M2 proteoglycans after removal of the GAG chains 
(Figure 5.5B).   
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Figure 5.5 The involvement of GAG chains in LDL binding. Representative 
Df-t plots showing the binding of LDL to the (A) M1 or (B) M2 
proteoglycans, with or without digestion. The dotted line indicates 
the Δf whereas the solid line indicates the ΔD. Note the different 
degree of the Δf and ΔD between the undigested and digested 
samples during the LDL binding indicated in the highlighted area.  
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As shown in the Voigt-modelled data, both the THP-1 and human buffy coat-
derived macrophages showed a similar trend in LDL binding after removal of the 
GAG chains from their proteoglycans: the amount of LDL bound by the M1 
proteoglycans decreased significantly (p < 0.05) after the removal, suggesting that 
GAG chains are the key LDL binding factors in the M1 proteoglycans. In contrast, 
more LDL was bound by the M2 proteoglycans after GAGs were removed (p < 
0.05). This suggested that, unlike M1, the M2 proteoglycans used their core proteins 
in binding LDL. In addition, both digested M1 and M2 proteoglycans bound LDL, 
but the M2 bound more than the M1 (p < 0.05). This suggested that the proteoglycan 
core proteins produced by M2 macrophages had a higher LDL binding ability than 
those produced by M1 macrophages (Figure 5.6).  
 
To summarise, the M1 proteoglycans used predominantly their GAG chains rather 
than their core proteins to bind LDL; whereby the M2 proteoglycans used primarily 
their core proteins, not their GAG chains, to bind LDL. The results also suggested 
an inhibitory effect of the GAG chains produced by M2 macrophages on the LDL 
binding.   
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Figure 5.6 The involvement of GAG chains in LDL binding derived from the 
proteoglycans produced by M1 and M2 macrophages. The Voigt-
modelled data showing the amount of LDL bound by the 
proteoglycans with or without digestion. Data were corrected for 
BSA background and presented as mean ± standard deviation (n = 
4). *p < 0.05; **p < 0.01 (ANOVA with post-hoc Tukey). 
Abbreviations are: C’ase ABC, chondroitinase ABC; H’ase III, 
heparinase III. 
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5.3.4 The low-density lipoprotein binding ability of the M1 
proteoglycans does not depend on chondroitin sulphate  
 
The role of chondroitin sulphate, but not heparan sulphate, in LDL binding has been 
well-established [171-177]. Having seen that the M1 proteoglycans used 
predominantly their GAGs to bind LDL, this experiment aimed to determine if the 
LDL binding was mediated by chondroitin sulphate. Here, the proteoglycans were 
digested with chondroitinase ABC to remove chondroitin sulphate before their LDL 
binding assessed with QCM-D.  
 
As indicated by the highlighted section, the representative Df-t plots showed that 
LDL bound to the undigested and digested M1 proteoglycan preparations with a 
similar amplitude in the decrease of the Δf and increase in the ΔD (Figure 5.7A). 
Similarly, LDL also bound to the undigested and digested M2 proteoglycan 
preparations with a similar degree of decrease in the Δf and increase in the ΔD 
(Figure 5.7B). These data suggested a similar amount of LDL bound to the M1 and 
M2 proteoglycans even after the removal of chondroitin sulphate.  
 
The Voigt-modelled data showed no significant changes to the amount of LDL 
bound to all the proteoglycans after removal of the chondroitin sulphate, regardless 
of which macrophage phenotype and origin. Thus, it suggested that the chondroitin 
sulphate present in the M1 and M2 proteoglycans did not bind LDL (Figure 5.7C).  
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Figure 5.7 Chondroitin sulphate in LDL binding. Representative Df-t plots 
showing the LDL binding to the (A) M1 or (B) M2 proteoglycans, 
with or without digested with chondroitinase ABC (C’ase ABC). 
The dotted line indicates the Δf whereas the solid line indicates the 
ΔD. (C) Modelled data showing the amount of LDL bound by the 
proteoglycans after the removal of chondroitin sulphate. Data were 
corrected for BSA background and presented as mean ± standard 
deviation (n = 4). Not significant (NS) vs. corresponding undigested 
(ANOVA with post-hoc Tukey).   
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It was surprising to see that the LDL binding to the M1 proteoglycans was not 
mediated by chondroitin sulphate. However, here the role of chondroitin sulphate 
was examined in the presence of heparan sulphate as the samples were digested 
with chondroitinase ABC only. Heparan sulphate has been found to interfere with 
LDL binding [104], which may then affect the results.   
 
Furthermore, it has been suggested that the pattern of sulphation of the chondroitin 
sulphate can influence its LDL binding [178]. This experiment thus aimed to 
confirm the involvement of chondroitin sulphate in the LDL binding derived from 
the M1 proteoglycans without heparan sulphate. It also aimed to study the impact 
of sulphation pattern on the LDL binding of chondroitin sulphate.  
 
Here, the M1 proteoglycans were first deprived of their heparan sulphate with 
heparinase III, and then the chondroitin 4- and/or 6-sulphates on the remaining 
chondroitin sulphate were removed by chondro-4-sulphatase and/or chondro-6-
sulphatase.    
 
The representative Df-t plots showed that LDL bound to all the proteoglycan 
preparations with a similar amplitude in the Δf decrease and ΔD increase. This 
indicated a similar amount of LDL binding to the proteoglycans (highlighted in 
yellow; Figure 5.8A). The Voigt-modelled data showed that the removal of sulphate 
groups from the chondroitin sulphate, regardless of which positions, did not affect 
the amount of LDL bound (Figure 5.8B). Therefore, this experiment confirmed that 
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chondroitin sulphate did not participate in the LDL binding derived from the M1 
proteoglycans. It also suggested that the pattern of sulphation did not influence the 
LDL binding to chondroitin sulphate.  
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Figure 5.8 Sulphation pattern on the LDL binding of chondroitin sulphation 
produced by M1 macrophages. (A) Representative Df-t plots 
showing the binding of LDL and the proteoglycans with different 
digestions. The dotted line indicates the Δf whereas the solid line 
indicates the ΔD. (B) Data modelled showing the amount of LDL 
bound. Data were corrected for BSA background and presented as 
mean ± standard deviation (n = 4). Not significant (NS) vs. digested 
with H’ase III (ANOVA with post-hoc Tukey). Abbreviations are: 
C4S’ase, chondro-4-sulphatase; C6S’ase, chondro-6-sulphatase; 
H’ase III, heparinase III.  
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5.3.5 Heparan sulphate is involved in the LDL binding to the M1 
macrophage-derived proteoglycans 
 
Chondroitin sulphate in the M1 macrophage-derived proteoglycans was found not 
to bind LDL, even though the proteoglycans used their GAGs to bind LDL. 
Therefore, this experiment aimed to determine the involvement of heparan sulphate 
in the LDL binding. Here, the proteoglycans were first digested with heparinase III 
to remove heparan sulphate.  
 
The representative Df-t plots showed that LDL bound to the digested M1 
proteoglycan preparation with a smaller decrease of the Δf and increase of the ΔD 
compared to the undigested sample. This indicated less LDL bound to the M1 
proteoglycans after the removal of heparan sulphate (Figure 5.9A).  
 
In contrast, LDL bound to both M2 proteoglycan preparations with a similar degree 
in the Δf decrease and ΔD increase (the highlighted areas). This indicated that a 
similar amount of LDL bound to these proteoglycan preparations (Figure 5.9B).  
 
As observed in both the THP-1 and human buffy coat-derived macrophages, the 
Voigt-based modelled data showed a significant decrease in the amount of LDL 
bound to the M1 proteoglycans after removal of the heparan sulphate (p < 0.05), 
but not in the M2 proteoglycans. This suggested that heparan sulphate mediated the 
LDL binding to the M1 proteoglycans, not the M2 proteoglycans (Figure 5.9C).    
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Figure 5.9 Heparan sulphate in the LDL binding derived from the 
proteoglycans produced by macrophages. Representative Df-t plots 
showing the binding of LDL to the (A) M1 or (B) M2 proteoglycans, 
with or without digestion with heparinase III (H’ase III). The dotted 
line indicates the Δf whereas the solid line indicates the ΔD. (C) Data 
modelled showing the amount of LDL bound by the proteoglycans. 
Data were corrected for BSA background and presented as mean ± 
standard deviation (n = 4). *p < 0.05 (ANOVA with post-hoc Tukey).  
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This experiment aimed to determine if the LDL-heparan sulphate interaction in the 
M1 proteoglycans was mediated by the negative charges of the GAGs. Like the last 
experiment, the M1 proteoglycans were first digested with chondroitinase ABC. 
The LDL binding was then challenged with a stronger cation (1 M of sodium ions).   
 
The representative Df-t plot in Figure 5.10A showed that LDL bound to the 
proteoglycan preparation with a decrease in the Δf and an increase in the ΔD 
(highlighted in yellow) When 1 M of sodium ions (Na+) was injected into the QCM-
D system, a sharp decrease in the Δf and increase in the ΔD were seen. These abrupt 
changes were due to changes in the buffer properties that altered the sensor 
resonance causing an offset in the Δf and ΔD. When the flow of Na+ finished at ~45 
min, the sharp changes in the Δf and ΔD were over. The amplitudes of the Δf and 
ΔD were then noticeably smaller compared to those before the injection of Na+ 
(note the area highlighted in red). This suggested a proportion of the bound LDL 
was lost with the exposure to the Na+. 
 
The Voigt-modelled data showed a significant amount of LDL was eluted with the 
injection of Na+ (p < 0.01). This result suggested that the binding between LDL and 
heparan sulphate involved the negative charges on the GAG chains (Figure 5.10B). 
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Figure 5.10 The involvement of the negative charges on heparan sulphate in 
binding LDL in the M1 proteoglycans. (A) Representative Df-t plot 
showing the binding of LDL to the M1 proteoglycans digested with 
chondroitinase ABC. The dotted line indicates the Δf whereas the 
solid line indicates the ΔD. 1 M Sodium ions (Na+) was injected to 
challenge the LDL binding. Note the changes in the Δf and ΔD after 
the injection (the area highlighted in red). (B) Data modelled 
showing the amount of LDL bound. Data were corrected for BSA 
background as well as its loss to Na+ elution, and presented as mean 
± standard deviation (n = 4). *p < 0.05 vs. native; **p < 0.01 vs. 
C’ase digested (paired t-test). Abbreviation: C’ase ABC, 
chondroitinase ABC.  
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5.3.6 Perlecan core protein contributes to low-density lipoprotein 
binding to the M2 proteoglycans upon cleavage of 
glycosaminoglycans  
 
So far, the removal of neither chondroitin sulphate nor heparan sulphate affected 
the binding of LDL to the M2 proteoglycans. However, the binding was increased 
significantly when both GAG chains were removed (Figures 5.5 and 5.6). This 
suggested that the GAG chains were concealing the LDL binding sites on the M2 
proteoglycan core proteins. Therefore, this experiment aimed to determine the core 
protein(s) that bound LDL.  
 
The M1 proteoglycans were not included in this experiment because their core 
proteins bound less LDL than M2 (Figure 5.6). Here, the GAG chains were 
removed with a mixture of chondroitinase ABC and heparinase III to yield core 
proteins. Perlecan, biglycan or versican core proteins, which are associated with 
atherosclerosis (Table 1.2, Chapter 1), were inhibited with polyclonal antibodies 
CCN-1, LS-C341858 or LS-C312902, respectively.  
 
The representative Df-t plots showed that LDL bound to the core protein 
preparation inhibited for perlecan with a decrease in the Δf and an increase in the 
ΔD that were smaller compared to the core protein preparations uninhibited or 
inhibited for biglycan and versican. This suggested that less LDL bound to the 
perlecan-inhibited core protein preparation (Figure 5.11A).  
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The Voigt-modelled data showed that the inhibition of biglycan and versican core 
proteins in the M2 proteoglycans did not alter the amount of LDL bound compared 
to the uninhibited core protein. However, there was a ten-fold decrease in the 
amount of LDL bound when perlecan was blocked (p < 0.01). This suggested that 
the perlecan core protein, but not biglycan and versican, contributed to the LDL 
binding derived from the M2 proteoglycans upon cleavage of GAGs (Figure 5.11B).  
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Figure 5.11 Core proteins in the M2 proteoglycans in binding LDL as 
determined by QCM-D. (A) Representative Df-t plots showing the 
binding of LDL to the M2 proteoglycan core proteins with or 
without the inhibition for perlecan, versican or biglycan. The dotted 
line indicates the Δf whereas the solid line indicates the ΔD. (B) Data 
modelled showing the amount of LDL bound. Data were corrected 
for BSA background and presented as mean ± standard deviation (n 
= 4). **p < 0.01 vs. core protein; not significant (NS) vs. core protein 
(ANOVA with post-hoc Tukey).  
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5.3.7 Low-density lipoprotein binding ability of the perlecan 
produced by M2 macrophages is modulated by heparan 
sulphate  
 
Having seen that the perlecan produced by M2 macrophages bound LDL, this 
proteoglycan was immunopurified from the proteoglycan-enriched fraction to 
further study its binding mechanism. Perlecan was isolated from the M2 
proteoglycan-enriched fraction by running the fraction through an immunoaffinity 
column that contained immobilised beads conjugated with the anti-perlecan 
antibody clone, A74. The antibody was purified from hybridoma-conditioned 
media.  
 
1. Purification of the anti-perlecan antibody clone, A74  
 
Protein G Sepharose 4 Fast Flow column was used to isolate A74. The column was 
first washed with 20% ethanol for 10 min followed by 15 min of DPBS, at a flow 
rate of 1.0 mL/min. Filtered hybridoma-conditioned medium with added 0.02% of 
sodium azide was loaded onto the column at the same flow rate. Non-specific 
binding of proteins inside the column was washed away with running DPBS until 
the UV absorbance became stable. Antibody was then eluted with 0.1 M glycine 
(pH 3.0, filtered and degassed) and collected when a peak in UV absorbance 
appeared. The fraction was adjusted to pH 7.0 with 1 M Tri-HCl at pH 9.0 (usually 
~60 µL of Tris-HCl per 5 mL fraction). The fraction was concentrated by 
centrifuging (5000 × g, 4°C, 30 min) three times. The concentration and mass of 
the antibody obtained were determined with measurements from NanoVueTM (GE 
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Healthcare, Little Chalfont, Buckinghamshire, UK) using the ‘Protein IgG’ 
programme. Finally, the column was washed with DPBS for 15 min followed by 
20% ethanol for 20 min before it was stored at 4°C.   
 
2.  Conjugation of A74 to sepharose beads 
 
The A74 (~6.0 mg) was dialysed in coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, 
pH 8.3) overnight at 4°C. Lyophilised sepharose beads were washed with 1 mM 
HCl (1 g sepharose gives 3.5 mL) on a Buchner funnel connected to a sintered glass 
filter for 1h to make the beads swollen. The unit was then washed twice with 
coupling buffer. Dialysed antibody was added immediately to the swollen bead 
solution (5 – 10 mg protein per mL solution) in a stoppered vessel. The mixture was 
rotated end-over-end at 4°C for overnight. Then, it was washed three times with 
coupling buffer (1000 × g, 4°C, 3 min). The mixture was blocked to minimise non-
specific binding by rotating it in 15 mL 0.2 M glycine overnight at 4°C. The beads 
were then washed with three cycles of alternating pH buffers [low pH buffer (0.1 
M sodium acetate, 0.5 M NaCl, pH 4.0) followed by high pH buffer (0.1 M Tris-
HCl, 0.5 M NaCl, pH 8.0)] which were of five times the bead volume (1000 × g, 
4°C, 3 min). Before packing column, the beads were washed with DEAE eluting 
buffer (1 M NaCl, 20 mM Tris-base, 10 mM EDTA, pH 7.5) once (1000 × g, 4°C, 
3 min). The column was run through DEAE eluting buffer extensively. Lastly, the 
conjugation of A74 to the beads was tested on an FPLC analyser by running 6 M 
urea (in DPBS, pH 7.4) through the column for three times to check if any was 
eluted. The column was kept at 4°C.  
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3.  Isolation of perlecan from the M2 proteoglycan-enriched fraction 
 
The A74 column was equilibrated with eluting buffer (1 M NaCl, 20 mM Tris-base, 
10 mM EDTA, pH 7.5) at 0.5 mL/min at 4°C. Then, the M2 proteoglycan fraction 
(obtained as per Section 2.2, but without dialysing it) was re-circulated into the 
column at a flow rate of 1.0 mL/min at 4°C for overnight. On the next day, by 
connecting the column to the FPLC analyser, unbound proteins were washed away 
with 1 M NaCl buffer at 0.5 mL/min, with a conductivity of ~100 mS/cm. After 
that, perlecan was eluted by running 6 M urea (in DPBS, pH 7.4) through the 
column with the same flow rate, with a conductivity of ~10 mS/cm. The eluted 
perlecan was collected as indicated by a peak in the UV absorbance. The column 
was regenerated in 1 M NaCl, with a conductivity of ~100 mS/cm (Figure 5.12).  
 
The perlecan-rich peaks were concentrated by centrifugation at 5000 × g, 30 min, 
4°C (repeated four more times) in an Amicon Ultra-15 Centrifugal Filter Unit (Cat. 
No.: UFC905024, Merck KGaA, Darmstadt, Germany). The concentration of the 
isolated perlecan was then evaluated with Coomassie protein assay. From 660 mL 
of M2 macrophage-conditioned medium, approximately 28 mL of peak fraction 
with total protein of 13 mg was collected. From that peak fraction, approximately 
3 mL of perlecan-rich fraction was collected and concentrated to 380 µL with the 
total protein estimated to be 50 µg. The perlecan yield from the conditioned medium 
was 76 µg/L (Table 5.1).  
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Figure 5.12 Immunopurification of perlecan from the M2 proteoglycan-enriched 
fraction using an A74 column. Unbound proteins were washed off 
with 1 M NaCl at 0.5 mL/min. Perlecan was eluted with 6 M urea 
(at ~75 min). The spikes appeared at ~150 min may be due to the 
changes in the electrolyte charges of the flow.   
 
 
 
Table 5.1 Perlecan isolated from THP-1 M2 macrophage-conditioned medium 
by immunopurification using an anti-perlecan A74 column.  
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An ELISA was performed on the isolated fraction to confirm the presence of 
perlecan. The anti-perlecan antibody clone, A74 was used to detect the proteins. 
The absorbance in the M2 peak fraction decreased after being loaded onto the A74 
column, indicating that perlecan in the fraction had been retained by A74 in the 
column. The materials collected from the peak and the spikes showed an 
oversaturated reading compared to the positive control, and they also showed a 
noticeable absorbance even without the addition of the antibody. These data 
suggested that A74 immunoglobulins were eluted from the column during the 
process of immunopurification, thus giving the false positive results (Figure 5.13).  
 
The weakness of this experiment is the use of the same antibody clone as the one 
used for immunopurification as there may be some of this antibody in the 
immunopurified fraction.  
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Figure 5.13 ELISA performed on the immunopurified perlecan from the M2 
proteoglycan-enriched fraction. The presence of perlecan in the 
fractions was identified by the anti-perlecan antibody clone, A74. 
Data were corrected for DPBS background and presented as mean ± 
standard deviation (n = 3). Endothelial perlecan was a kind gift from 
Dr Fengying Tang, UNSW.    
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To further determine the presence of perlecan, and if the A74 immunoglobulins 
were eluted together with it during the immunopurification, Western blotting was 
performed on the peak fraction, with or without probing with the anti-perlecan 
antibody clone, A74. A ~460 kDa band only appeared when the fraction was probed 
with A74, suggesting that the perlecan present in the fraction was not attached to 
the antibodies, which were eluted from the column. The large smeary band at ~150 
kDa indicated the presence of antibody (Figure 5.14). This suggested that not all 
the A74 conjugated firmly to the sepharose beads, thus leading to the false positive 
results seen in the ELISA (Figure 5.13). 
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Figure 5.14 The presence of perlecan in the A74-immunopurified fraction from 
M2 macrophage proteoglycan-enriched fraction as detected by 
Western blotting. Samples were electrophoresed on a 3 – 8% SDS-
PAGE gel. Proteins were transferred to a PVDF membrane and 
probed for perlecan with the anti-perlecan antibody clone, A74. 
Protein ladders were run and the molecular weights were indicated 
on the left.  
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The LDL binding of the isolated perlecan was assessed with QCM-D. Heparinase 
III was used to remove the heparan sulphate decorating the core protein as the M2 
macrophage-derived perlecan was found to be decorated with heparan sulphate in 
Chapter 4.  
 
Under the same flow and temperature, the representative Df-t plots showed that 
LDL only bound to the digested perlecan preparation, as indicated by the noticeable 
decrease in the Δf and increase in the ΔD, which were not observed in the flow-
through material (i.e. the M2 fraction after immunopurification) and the undigested 
perlecan preparations. This indicated that more LDL bound to the digested perlecan 
preparation than either the flow-through material and the undigested perlecan 
(Figure 5.15A).  
 
The Voigt-based modelled data showed that the flow-through material from the 
immunopurification did not bind LDL, suggesting that perlecan was the key LDL 
binding factor in the M2 macrophage-derived proteoglycans. The isolated perlecan 
showed an increased LDL binding after digestion with heparinase III (p < 0.05), 
suggesting that LDL bound to the perlecan core protein and that this binding was 
modulated by heparan sulphate (Figure 5.15B).   
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Figure 5.15 LDL binding to the M2 macrophage-derived perlecan as determined 
by QCM-D. (A) Representative Df-t plots showing the binding of 
LDL (highlighted area) and the flow-through material or perlecan, 
either undigested or digested. The dotted line indicates the Δf 
whereas the solid line indicates the ΔD. (B) Data modelled showing 
the amount of LDL bound. Data were corrected for BSA background 
and presented as mean ± standard deviation (n = 4). *p < 0.05 vs 
digested perlecan (ANOVA with post-hoc Tukey). Abbreviation: 
H’ase III, heparanase III.  
 
 
-1
0
1
2
3
4
-50
-40
-30
-20
-10
0
10
0 10 20 30 40 50
Δ
D
(1
 ×
1
0
-6
)
Δ
f
(H
z
)
Time (min)
-1
0
1
2
3
4
-50
-40
-30
-20
-10
0
10
0 10 20 30 40 50
Δ
D
(1
 ×
1
0
-6
)
Δ
f
(H
z
)
Time (min)
-1
0
1
2
3
4
-50
-40
-30
-20
-10
0
10
0 10 20 30 40 50
Δ
D
(1
 ×
1
0
-6
)
Δ
f
(H
z
)
Time (min)
0
10
20
30
40
50
Flow-through M2 perlecan M2 perlecan
digested with
H'ase III
M
a
s
s
 o
f 
L
D
L
 b
o
u
n
d
 (
n
g
/c
m
2
)
A     Flow-through material   Undigested M2 perlecan 
H’ase III-digested M2 perlecan           B 
Proteoglycan
s 
Proteoglycan
s 
Proteoglycan
s 
DPBS  
DPBS  
DPBS  
D
P
B
S
  D
P
B
S
  
D
P
B
S
  
LDL 
LDL 
LDL 
BSA  
BSA  
BSA  
* 
LDL binding to macrophage proteoglycans 
 
159 
 
5.3.8 Cloned perlecan domain II in binding low-density lipoprotein 
 
Perlecan domain II has been reported to bind LDL, an interaction which is 
facilitated by heparan sulphate on the adjacent domain I [103]. The data in Section 
5.3.7 here is not consistent with the idea that heparan sulphate aids in LDL binding 
to perlecan. Though the contribution of heparan sulphate is not clear, Xu et al. also 
found that perlecan domain II alone can bind LDL via the glycans on the domain 
itself. This suggests that perlecan core protein can bind LDL via domain II. To test 
if perlecan domain II needs glycans to bind LDL, the protein was cloned in E. coli 
because a prokaryotic system does not involve post-translational modifications, 
including glycosylation [179]. The data obtained from each of the cloning steps are 
shown here because they are important to understand the final LDL binding result.  
 
1. Reconstitution of HSPG2 domain II DNA  
 
The DNA encoding perlecan domain II was synthesised by Invitrogen (Thermo 
Fisher Scientific, Waltham, MA USA) in a form of lyophilised plasmid.  The DNA 
sequence for human HSPG2 domain II is illustrated in Figure 5.16A. The plasmid 
was designed to include the cleavage sites for restriction enzymes Ncol and BamHI 
(Figure 5.16B). The plasmid was reconstituted in distilled water into 0.1 µg/µL. It 
was digested with restriction enzymes (one unit of each enzyme to digest 1 µg of 
plasmid for 1 h, 37°C) to release the HSPG2 domain II sequence. The released 
sequence was cleaned with DNA Clean & ConcentratorTM-5 (Cat. No.: D4003, 
Zymo Research, Irvine, CA, USA) before ligation.  
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A 
 
CAGTTCCCAAGAGCCTGCACGGAGGCCGAGTTTGCCTGCCACAGCTACAATGAGTGTGTGGCCCTG
GAGTATCGCTGTGACCGGCGGCCCGACTGCAGGGACATGTCTGATGAGCTCAATTGTGAGGAGCCA
GTCCTGGGTATCAGCCCCACATTCTCTCTCCTTGTGGAGACGACATCTTTACCGCCCCGGCCAGAG
ACAACCATCATGCGACAGCCACCAGTCACCCACGCTCCTCAGCCCCTGCTTCCCGGTTCCGTCAGG
CCCCTGCCCTGTGGGCCCCAGGAGGCCGCATGCCGCAATGGGCACTGCATCCCCAGAGACTACCTC
TGCGACGGACAGGAGGACTGCGAGGACGGCAGCGATGAGCTAGACTGTGGCCCCCCGCCACCCTGT
GAGCCCAACGAGTTCCCCTGCGGGAATGGACATTGTGCCCTCAAGCTGTGGCGCTGCGATGGTGAC
TTTGACTGTGAGGACCGAACTGATGAAGCCAACTGCCCCACCAAGCGTCCTGAGGAAGTGTGCGGG
CCCACACAGTTCCGATGCGTCTCTACCAACATGTGCATCCCAGCCAGCTTCCACTGTGACGAGGAG
AGCGACTGTCCTGACCGGAGCGACGAGTTTGGCTGCATGCCCCCCCAGGTGGTGACACCTCCCCGG
GAGTCCATCCAGGCTTCCCGGGGCCAGACAGTGACCTTCACCTGCGTGGCCATTGGCGTCCCCACC
CCCATCATCAATTGGAGGCTCAACTGGGGCCACATCCCCTCTCATCCCAGGGTGACAGTGACCAGC
GAGGGTGGCCGTGGCACACTGATCATCCGTGATGTGAAGGAGTCAGACCAGGGTGCCTACACCTGT
GAGGCCATGAACGCCCGGGGCATGGTGTTTGGCATTCCTGACGGTGTCCTTGAGCTCGTCCCACAA
CGAGGCCCC 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 (A) Nucleotide sequence that encodes for human perlecan domain II 
(amino acids 194 – 504 of the full-length perlecan). The HSPG2 
sequence was obtained from GenBank, NCBI, U.S. National Library 
of Medicine. (B) Map showing the plasmid synthesised by the 
company containing the DNA sequence encoding perlecan domain 
II. The vector used was pMA-T. Note the cleavage sites for 
restriction enzymes Ncol and BamHI at the ends of the sequence. 
Digestion of this plasmid with these enzymes releases the HSPG2 
domain II sequence for the next procedures. 
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2.  pMAL-p5X vector  
 
The pMAL-p5X vector (Cat. No.: E8200S, New England BioLabs, Ipswich, MA, 
USA) was used in this experiment. The system of this vector is briefly discussed 
below.  
 
The schematic of a pMAL-p5X vector is shown in Figure 5.17. The HSPG2 gene 
was inserted at the cloning site which was located downstream from the malE gene 
of E. coli. This malE gene encoded maltose-binding protein (MBP), thus resulting 
in the expression of perlecan domain II-MBP fusion protein. This MBP was 
engineered for binding to amylose, allowing the purification of the fusion proteins 
from other E. coli materials using an amylose column. The pMAL-p5X vector used 
the strong Ptac promoter to give a high-level expression of the cloned sequence. This 
Ptac was under the control of the lacl gene, which encoded for Lac repressor. Lac 
repressor is a DNA-binding protein which inhibits the expression of the genes 
downstream of the lacl gene. This protein is released from the lacl gene only when 
isopropyl β-D-1-thiogalactopyranoside (IPTG) binds to it. As such, this kept the 
expression of perlecan domain II low in the absence of IPTG. Lastly, the pMAL-
p5X vector also contained a sequence coding for the recognition site of protease 
Factor Xa, located just 5’ to the insertion sites. This allowed MBP to be cleaved 
from the perlecan domain II after purification from an amylose column. 
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Figure 6.2 (A) Nucleotide sequence that encodes for human perlecan domain II 
(amino acids 194 – 504 of the full-length perlecan). The HSPG2 
sequence was obtained from GenBank, NCBI, U.S. National Library 
of Medicine. (B) Map showing the plasmid synthesised by the 
company containing the DNA sequence encoding perlecan domain 
II. Note the cleavage sites for restriction enzymes Ncol and BamHI 
at the ends of the sequence. Digestion of this plasmid with these  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 Schematic of a pMAL-p5X vector. The arrows indicate the direction 
of gene transcription. Abbreviations are: isopropyl β-D-1-
thiogalactopyranoside (IPTG); MBP, maltose binding protein. 
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3.  Ligation of the released HSPG2 domain II sequence with vector 
 
The released HSPG2 domain II sequence from the p-MAT vector was ligated with 
pMAL-p5X vector at a 1:3 molar ratio of vector: insert DNA. Ligation was carried 
out in 100 ng of vector. The vector was opened to enable insertion of the DNA 
sequence by digestion with Ncol and BamHI. To know the mass of insert DNA 
sequence needed, the following calculation was done:  
 
After that, the required amount of insert DNA was ligated into pMAL-p5X vector 
with T4 DNA ligase (Cat. No.: M1801, Promega, Alexandria, NSW, Australia) at 
room temperature for 3h.  
 
4.  Transformation of E. coli 
 
The ligated pMAL-p5X vector was then inserted into E. coli to be replicated. A 
tube of NEB® Express Competent E. coli cells (Cat. No.: C2523H, New England 
BioLabs, Ipswich, MA, USA) was thawed on ice for 10 min. Then, 10 µL of vector 
was added to the bacterial mixture and mixed well by flicking the tube 4 – 5 times 
carefully. The mixture was left on ice for 30 min before being heat shocked at 42°C 
for 20 seconds, followed by placing it back on ice for another 5 min. After 5 min, 
the mixture was incubated at 37°C for 1h in 950 µL of Super Optimal broth with 
Catabolite repression (SOC) Outgrowth Medium (Cat. No.: B9020S, New England 
BioLabs, Ipswich, MA, USA). Finally, a range of different dilutions of the cell 
100 ng of vector  kb size of insert DNA insert
 molar ratio of  = ng of insert DNA
kb size of vector vector


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mixture (neat, 1:2, 1:10, 1:50 and 1:100 in SOC Outgrowth Medium) was spread 
onto antibiotic (100 µg/mL of ampicillin) selection plates and let to grow overnight 
at 37°C.  
 
5. Screening for DNA ligation with agarose gel electrophoresis  
 
To check if the vector taken up by E. coli had been ligated with DNA insert, a 
screening test was carried out. After an overnight incubation, the selection plates 
were observed. Under sterile conditions, two to three individual colonies (labelled 
as ‘Colonies 1 or 2’ here) were randomly picked from the plate and then inoculated 
in 5 mL of lysogeny broth (LB) medium (1% peptone, 0.5% yeast extract, 0.5% 
NaCl, and 100 µg/mL ampicillin) in separate 50 mL FalconTM tubes. The bacteria 
were grown overnight at 37°C with continuous agitation.  
 
On the next day, the bacterial culture was observed (it should look cloudy). Plasmid 
DNA was isolated from the bacteria by following the protocol in ZyppyTM Plasmid 
Miniprep Kit (Cat. No.: D4036, Zymo Research, Irvine, CA, USA). The plasmid 
DNA was then cleaved with Ncol and BamHI, followed by running agarose gel 
electrophoresis (Figure 5.18A).         
 
In Colony 1, there was only a ~5 kbp band that indicated the pMAL-p5X vector 
sequence. This suggested that the bacteria in Colony 1 did not take up ligated 
vectors. In contrast, for Colony 2, in addition to the ~5 kbp band, there were ~6 kbp 
and ~1 kbp bands, which indicated the ligated vector and the HSPG2 domain II 
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sequence, respectively. This indicated that the bacteria in Colony 2 took up the 
vectors that had been ligated with the HSPG2 domain II sequence. Colony 2 was 
thus used for the next experiment (Figure 5.18B). 
 
 
           
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 (A) Illustration showing the screening test performed to check if the 
pMAL-p5X vectors taken up by E. coli had been ligated with the 
HSPG2 domain II sequence. Plasmid DNA was isolated from the 
bacteria and cleaved with Ncol and BamHI, producing bands of 
different sizes which indicated different DNA sequences. (B) An 
agarose gel electrophoresis was performed to visualise these bands 
obtained from two bacterial colonies.  
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6.  Determining the optimal time for IPTG induction in E. coli 
 
A small-scale experiment was done to determine the time to obtain an optimal 
amount of perlecan domain II. Colony 2 was grown in 100 mL of LB medium for 
overnight at 37°C with constant agitation. Then, 1 mL of the culture was spun for 
2 min and resuspended in 50 µL SDS-PAGE sample buffer (uninduced cells). 
Isopropylthiogalactoside (IPTG) was added to the remaining culture to a final 
concentration of 0.3 mM to induce the expression of protein. Induction was carried 
out at 37°C with constant agitation for 1, 2 and 3 h. For each of these time points, 
1 mL culture was withdrawn and spun for 2 min to get cell pellet which was then 
resuspended in 50 µL SDS-PAGE sample buffer. The presence of perlecan domain 
II and MBP was detected with Western blotting using the anti-perlecan antibody, 
CCN-1 and the anti-MBP antibody.  
 
There were ~75 kDa bands that indicated the fusion protein (perlecan domain II, 
~33 kDa + MBP, ~42 kDa = ~75 kDa) in both the uninduced and induced samples 
probed for perlecan (Figure 5.19A). However, there was only a ~42 kDa band in 
the uninduced sample probed for MBP; whereas ~42 kDa and ~75 kDa bands were 
seen in the induced samples (Figure 5.19B). The identity of the ~75 kDa band seen 
in the uninduced sample probed for perlecan was unknown, but overall, this 
experiment suggested that only the bacteria induced with IPTG expressed fusion 
protein. Having seen that the ~75 kDa band intensity was fairly similar across the 
induced samples (1, 2 and 3 h), bacteria were hence induced with IPTG for the 
average time of 2 h in the next experiment.     
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Figure 5.19 Western blotting performed to determine the optimal time for IPTG 
induction in E. coli to obtain an optimal amount of perlecan domain 
II. PVDF blot were probed for (A) perlecan or (B) MBP with the 
polyclonal anti-perlecan antibody, CCN-1, and the monoclonal anti-
MBP antibody, respectively. Protein ladders were electrophoresed 
on each gel and marked on the left.  
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7.  Determining the optimal extraction method to harvest perlecan domain 
II-MBP fusion proteins from E. coli after IPTG induction  
 
Colony 2 was grown in 100 mL of LB medium for overnight at 37°C with constant 
agitation, followed by a 2 h IPTG induction, as determined from the data in Figure 
5.12. Then, 0.5 mL culture was withdrawn and spun for 2 min at 4000 × g to obtain 
a bacterial pellet, which was resuspended in 100 µL SDS-PAGE buffer 
(extracellular extract).  
 
The remaining culture was divided into two aliquots. Bacteria were harvested by 
centrifugation at 4000 × g for 10 min at 4°C. Then, one of the bacterial pellets was 
resuspended in 5 mL of cold column buffer (20 mM Tris-HCl, 200 mM NaCl, and 
1 mM EDTA). It was frozen overnight at -20°C. After thawing in cold water, the 
bacteria were sonicated in short pulses of 15 sec or less. The release of protein was 
monitored using Coomassie protein assay. Sonication was continued until the 
released protein reached a maximum (i.e. the colour of sample turned blue, which 
usually happened after approximately 2 min). The sample was then centrifuged at 
20,000 × g at 4°C for 20 min. The supernatant was saved on ice (intracellular: crude 
extract), while the cell pellet was resuspended in 5 mL column buffer (intracellular: 
insoluble matter).   
 
The other bacterial pellet was resuspended in 10 mL of Tris/sucrose buffer (30 mM 
Tris-HCl, 20% sucrose, and 0.5 M EDTA, pH 8.0) for 10 min at room temperature 
with shaking. After centrifugation at 8000 × g at 4°C for 10 min, the bacterial pellet 
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was resuspended in 10 mL ice-cold 5 mM magnesium sulphate solution, followed 
by shaking for 10 min in an ice-water bath. The samples were then centrifuged again 
as above, and the supernatant was saved and added 10 µL SDS-PAGE buffer 
(pericellular extract). Finally, all four samples were boiled for 5 min. After spinning 
down, 10 µL of the samples were loaded on a 4 – 12% Bis-Tris gel carefully (to 
avoid disturbing the pellets). Western blotting was performed to detect the presence 
of perlecan domain II, using the anti-perlecan antibody, CCN-1.  
 
Except in the pericellular extract, there was a ~75 kDa band that indicated the fusion 
protein, in both the extracellular and intracellular (both crude and insoluble) 
extracts. The band intensity from the intracellular extracts was stronger than that 
obtained from the extracellular extract. This suggested that a higher amount of 
fusion protein can be obtained from the E. coli intracellularly rather than 
extracellularly. Of these two intracellular extracts, although the ~75 kDa band 
intensity appeared to be stronger in the insoluble extract, the lane of the crude 
extract looked much cleaner. This suggested that other cellular components from E. 
coli had contaminated the insoluble extract. Therefore, the crude extraction method 
was used for the large-scale production of perlecan domain II (Figure 5.20). 
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Figure 5.20 Western blotting performed to determine the optimal extraction 
method to harvest perlecan domain II-MBP fusion proteins from E. 
coli after a 2 h IPTG induction. PVDF blot was probed for perlecan 
using the anti-perlecan antibody, CCN-1. Protein ladders were 
marked on the left.  
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8. Affinity chromatography to isolate the fusion protein  
 
The large-scale preparation of perlecan domain II was purified from other proteins 
in the bacterial extract by running the extract through an amylose column, in which 
perlecan domain II with its pendant MBP bound to. Before loading the sample, the 
column was first washed with five column volumes of column buffer, with a 
conductivity of ~25 mS/cm. Then, sample was loaded at a flow rate of 2 mL/min, 
indicated by the increase in the UV absorbance. After that, the column was washed 
with column buffer at a rate of 4 mL/min to wash away any unbound proteins. The 
fusion protein was then eluted with column buffer + 10 mM maltose at a flow rate 
of 2 mL/min, indicated by a sharp peak in the UV absorbance. The column then 
was washed with the following sequence: three column volumes of water, three 
column volumes of 0.1% SDS, and one column volume of water, indicated with a 
conductivity of ~0 mS/cm. Lastly, the column was washed with a column volume 
of column buffer, with a conductivity of ~25 mS/cm (Figure 5.21).   
 
The collected peak fraction was centrifuged at 5000 × g for 30 min at 4°C and the 
process was repeated until its concentration became 1 mg/mL as determined by 
Coomassie protein assay. Samples were stored at -20°C until required. 
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Figure 5.21 An affinity chromatography performed on an amylose column to 
separate the perlecan domain II-MBP fusion proteins from other 
materials in the crude extract obtained from E. coli.  
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9. Determining the optimal time for cleaving the perlecan domain II-MBP 
fusion protein with Factor Xa     
                      
The fusion protein was cleaved with Factor Xa at a w/w ratio of 0.1% the amount 
of fusion protein (e.g. 1 mg Factor Xa for a reaction containing 100 mg fusion 
protein). A pilot experiment was first carried out with a small portion of the sample: 
20 µL fusion protein (1.0 mg/mL) was incubated with 1 µL Factor Xa (200 µg/mL) 
at room temperature or 4°C for 2, 4 and 8 h. At these time points, 5 µL of the 
mixture was taken and 300 mM benzamidine was added to it at 1:50 ratio to stop 
the Factor Xa. The samples were saved at -20°C until Western blotting was 
performed to check for complete cleavage.         
 
As probed with the anti-MBP antibody, the ~75 kDa fusion protein band intensity 
decreased gradually as the duration of cleavage prolonged. The intensity changes 
of the ~42 kDa MBP bands were not obvious. After 8 h, no ~75 kDa band was 
observed, indicating that all fusion proteins had been cleaved. Although the ~75 
kDa fusion protein band was not clearly seen, the band intensity for perlecan 
domain II (~35 kDa), as probed with the anti-perlecan antibody, CCN-1, increased 
with time. These observations suggested that perlecan domain II was released from 
MBP in the fusion protein completely after an 8 h of cleavage. Therefore, for the 
next experiment, the fusion protein was cleaved with Factor Xa for 8 h before the 
separation using an amylose column (Figure 5.22).      
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Figure 5.22 Western blotting performed to determine the optimal duration for 
the cleavage of the perlecan domain II-MBP fusion proteins with 
Factor Xa. The blots were probed with the (A) anti-MBP antibody 
or (B) anti-perlecan antibody, CCN-1. Note the changing in the 
intensity of the bands for the fusion proteins (~75 kDa) and perlecan 
domain II (~35 kDa) over the time.  
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MBP     Perlecan domain II 
10. Separating the perlecan domain II from MBP after cleavage  
 
The perlecan domain II was separated from MBP by running the cleaved sample 
through an amylose column, to which MBP bound. The sample was diluted ten 
times with column buffer and loaded directly onto the column. Then, the column 
was washed with column buffer and UV absorbance was monitored. The eluate was 
collected when a peak appeared. Western blotting was performed on the eluate to 
check the outcomes. Only the band for MBP (~42 kDa), but not perlecan domain II 
(~33 kDa), was seen in the fraction after the separation. This suggested that perlecan 
domain II was missing in the separation. The reason was unknown (Figure 5.23).   
 
  
 
 
 
 
 
 
 
 
 
Figure 5.23 Western blotting performed on the eluate to determine the presence 
of MBP and perlecan domain II in the Factor Xa-cleaved fraction 
before and after the separation in an amylose column, using the anti-
MBP antibody and anti-perlecan antibody, CCN-1, respectively.  
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11. Examining LDL binding to the fusion protein using QCM-D 
 
At this stage, the most time-efficient way to study the LDL binding ability of 
perlecan domain II was to use the fusion protein directly. The LDL binding was 
assessed on a same mass of the samples using QCM-D, with or without the blocking 
of the MBP. The MBP alone, which was produced from Colony 1, was used as a 
control. 
 
In the representative Df-t plots, LDL bound to the blocked fusion protein 
preparation with no noticeable changes to the Δf and ΔD compared to the unblocked 
fusion protein and MBP preparations, suggesting no LDL was bound to the blocked 
fusion protein (Figure 5.24A).  
 
The Voigt-modelled data showed that the amount of LDL bound to the fusion 
protein was decreased significantly, nearly to zero, when they were blocked for 
MBP (p < 0.01). This indicated that perlecan domain II alone did not bind LDL. 
Furthermore, the MBP alone bound significantly more LDL than the unblocked 
fusion protein itself (p < 0.001), suggesting that the presence of perlecan domain II 
in the fusion protein led to a smaller amount of LDL bound, hence further 
supporting the lack of LDL binding to perlecan domain II (Figure 5.24B).  
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Figure 5.24 LDL binding of the cloned perlecan domain II-MBP fusion protein 
as determined by QCM-D. (A) Representative Df-t plots showing 
the binding of LDL (highlighted area) to the fusion proteins, with or 
without blocking for MBP; and to MBP. The dotted line indicates 
the Δf whereas the solid line indicates the ΔD. (B) Voigt-based data 
showing the amount of LDL bound. Data were corrected for BSA 
background and presented as mean ± standard deviation (n = 4). **p 
< 0.01; ***p < 0.001 (ANOVA with post-hoc Tukey).  
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5.4 Discussion 
 
These experiments aimed to compare the LDL binding of the M1 and M2 
proteoglycans, which was determined mainly with the QCM-D technique. This 
thesis is the first to apply the QCM-D to assess LDL-proteoglycan interactions, 
rather than using affinity chromatography on sepharose-LDL columns and gel 
mobility shift assay, which have been used in almost all previous studies. There are 
several reasons for choosing this technique. For one, QCM-D is more sensitive as 
it allows detection in the nanogram level, as compared to affinity chromatography 
and mobility shift assay that can only give semi-quantitative data based on 
densitometric measurement of LDL-proteoglycan bands. Additionally, the 
measurements are real-time, meaning that the behaviour of the binding can be 
monitored rather than end-point analyses provided by affinity chromatography and 
mobility shift assays. Also, due to its high-sensitivity, the amount of LDL needed 
is reduced, hence minimising the influence of compositional differences [161] from 
different batches of LDL on the binding. In contrast, the affinity chromatography 
usually requires pre-treatment of LDL to enable it to be coupled to the sepharose 
beads, and to protect the proteoglycan-binding arginine- and lysine-rich regions of 
apoB from being blocked by the beads [180]. Although the effects of these 
modification treatments on the binding to proteoglycans have not been studied, the 
LDL particles used in this assay are certainly no longer in their natural form. 
Proteoglycans also need to be radiolabelled for detection in both affinity 
chromatography and gel mobility shift assay. As not all proteoglycans have good 
antibodies, this step could be problematic particularly when macrophages were 
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found to produce several types of proteoglycans in Chapter 4. To enable 
extrapolation of these results to the clinical situation, it is preferable to measure 
LDL-proteoglycan binding in their natural forms as offered by the QCM-D 
technique.    
 
The key novel finding in this chapter was that the proteoglycans secreted by M1 
macrophages bound more LDL than those secreted by M2 macrophages. For the 
first time, this study suggests a novel role for M1 macrophages in the development 
of atherosclerosis: aside from being pro-inflammatory, they also promote the 
disease by secreting proteoglycans that bind LDL.   
 
The proteoglycans produced by M1 macrophages bind LDL predominantly through 
their GAGs, evident by their reduced LDL binding upon GAG removal. This result 
also indicates a different function of the GAGs that M1 and M2 macrophages 
produce: while the GAGs produced by M1 macrophages bind LDL, the GAGs 
produced by M2 macrophages inhibit the LDL binding to the core proteins. This 
difference could be due to the sulphation on their GAGs. The higher sulphation of 
the GAGs that M1 macrophages produce may lead to the greater LDL binding 
because the LDL-GAG interaction is electrostatic [17].   
 
Surprisingly, although the chondroitin and heparan sulphates produced by M1 
macrophages were both highly sulphated, the chondroitin sulphate was not involved 
in the LDL binding, but heparan sulphate was. This suggests that the LDL binding 
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ability of chondroitin sulphate may not solely depend on the degree of sulphation; 
its pattern of sulphation may be equally important [177]. For example, although 
chondroitin 4-sulphate has an equal amount of sulphate as chondroitin 6-sulphate, 
it is not retained on an LDL-affinity column [123]. Chondroitin 6-sulphate has also 
been shown to be more potent in aggregating LDL than chondroitin 4-sulphate 
[181]. A similar finding has also been observed in vivo: the chondroitin sulphate 
isolated from the atherosclerosis-susceptible White Carneau pigeons have a higher 
ratio of 6- to 4-sulphates than those from the atherosclerosis-resistant Show Racer 
pigeons [14], and they exhibit a higher binding affinity for plasma LDL [182]. 
Taken together, the key determinant in the LDL binding ability of chondroitin 
sulphate is the position of sulphation (particularly 6-sulphate), not the degree of 
sulphation. As shown in the FACE analysis in Chapter 4, while the M1 chondroitin 
sulphate was more sulphated than that of M2 macrophages due to the higher content 
of chondroitin 4-sulphate, the proportion of chondroitin 6-sulphate in the chains 
was however similar between the phenotypes. As such, the chondroitin sulphate of 
both M1 and M2 macrophages theoretically have a similar affinity for LDL.  
 
Little is known about the impact of sulphation pattern on the LDL binding to 
chondroitin sulphate. It could be due to the accessibility of the sulphate [113,178]. 
Since 6-sulphate is present on an exocyclic carbon of chondroitin sulphate, it would 
protrude beyond the backbone of the GAG chain more than the 4-sulphate, which 
is present on an endocyclic carbon. As such, 6-sulphate is more sterically accessible 
to LDL (Figure 5.25).  
LDL binding to macrophage proteoglycans 
 
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25 Proposed impact of sulphation pattern on the LDL binding ability of 
chondroitin sulphate. The 6-sulphate is present on an exocyclic 
carbon of chondroitin sulphate. Thus, it would protrude beyond the 
backbone of the GAG chain more than the 4-sulphate, which is 
present on an endocyclic carbon, making it more accessible to LDL. 
(Adapted from [113,177,178]) 
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However, whether chondroitin 4- and 6-sulphates can really alter the flexibility of 
the chondroitin sulphate chain in binding LDL as illustrated in the figure above was 
not shown in this study, as no significant changes to the LDL binding were observed 
after removal of any of these sulphates. It could be due to the fairly low presence 
of 6-sulphate (~9%) in the chondroitin sulphate. Thus, the impact of sulphation 
pattern on chondroitin sulphate’s LDL binding remains theoretical.  
 
The M1 proteoglycans were found to interact with LDL through heparan sulphate 
in this study. While this agrees with a previous study showing a decrease in the 
amount of LDL bound by the macrophage-derived matrix after digestion with 
heparinase III [110], the findings about heparan sulphate in binding LDL have been 
contradicting so far. For example, heparan sulphate was reported to inhibit LDL 
binding to the endothelial matrix [104]. Furthermore, the heparan sulphate 
produced by THP-1 cells only bound very low-density lipoproteins (VLDL), not 
LDL [183]. The use of heparan sulphate as isolated chains rather than the 
proteoglycan form as in this study, may have led to the different results. 
Proteoglycans can usually bind more LDL than the isolated GAG chains because 
several GAG chains in a single structure can act cooperatively in the binding [182].  
 
While the different cells and forms of heparan sulphate may account for the 
disagreement, the present study hypothesises that the sulphation of heparan sulphate 
is the key reason behind these differences in the findings. This is because the 
binding of LDL to heparan sulphate was found to involve the negative charges on 
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the chain. As such, the pattern and/or degree of sulphation may influence its binding 
affinity for LDL. In Chapter 4, the FACE analysis revealed sulphation at C-2 and 
C-6 in the heparan sulphate produced by M1 and M2 macrophages. Since these 
sulphates are both on exocyclic carbons, theoretically, they are both sterically 
accessible to LDL. As such, it is quite logical that if there are more sulphates in the 
chain, at either C-2 or C-6, the heparan sulphate will then be able to bind more LDL.  
 
It is still not known if a single sulphate is enough to bind LDL. Thus, it is also 
tempting to speculate that LDL may be bound more easily to the regions of dense 
charges that span across multiple disaccharides in the heparan sulphate. The 
adjacent sulphates are likely to work cooperatively to have a stronger charged field 
to bind more LDL. As such, multi-sulphated disaccharides may technically have a 
higher affinity for LDL than mono-sulphated disaccharides. This is plausible, as the 
binding of fibroblast growth factor-1 to heparan sulphate requires the tri-sulphated 
disaccharides; a reduction of the sulphation prevents the binding [184]. As shown 
in the FACE analysis in Chapter 4, the overall higher sulphation of the heparan 
sulphate produced by M1 macrophages was due in part to the higher proportion of 
di-sulphated disaccharides than the M2. This may thus lead to the higher LDL 
binding ability by the M1 heparan sulphate. Therefore, this study proposes that, 
unlike chondroitin sulphate, the LDL binding ability of heparan sulphate depends 
on its degree of sulphation (Figure 5.26).     
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Figure 5.26 Proposed theory on the LDL binding ability of heparan sulphate. 
Heparan sulphate can be sulphated at the positions of C-2 and C-6. 
Both positions are exocyclic, and hence, all sulphates on heparan 
sulphate can be accessible to LDL. Therefore, the LDL binding 
ability may depend on the degree of sulphation: more sulphates on 
the GAG, more LDL will be bound. The adjacent sulphates may also 
help in stronger LDL binding.  
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In contrast, the LDL binding to the proteoglycans produced by M2 macrophages 
was increased upon cleavage of GAGs. This result indicates that there are LDL 
binding sites on the core proteins of the M2 proteoglycans, such as perlecan. This 
is fairly controversial considering that the interaction between the apoB of LDL and 
proteoglycans has been well established to involve the negatively charged GAG 
chains on proteoglycans [12, 15]. However, a binding to proteoglycan core proteins 
is not impossible as matrix digestion with pronase or trypsin markedly reduced the 
binding of LDL [185], indirectly suggesting the possible participation of core 
proteins in binding LDL. Here, the core proteins of perlecan, but not of biglycan 
and versican, were found to participate in the LDL binding after the removal of 
GAG chains with chondroitinase ABC and heparinase III. Having seen from 
Chapter 4 that M2 macrophages produced an abundance of perlecan, and from this 
chapter that the flow-through material from the perlecan immunopurification did 
not bind LDL, perlecan thus is the key contributor to the LDL binding in their 
proteoglycans.   
 
Here, the interaction between LDL and the immunopurified perlecan from M2 
macrophages was modulated by its heparan sulphate. This contradicts with the 
previous studies showing that heparan sulphate facilitates the LDL binding to both 
the human [103] and mouse perlecan [90]. However, the mechanism of heparan 
sulphate in helping this binding of LDL to perlecan in their studies is not known. 
Given that the binding of LDL to GAG depends on the electrostatic interaction [17], 
the heparan sulphate on the perlecan may be structurally different between the 
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studies, thus leading to the different findings. This is possible because, as discussed 
above, sulphation can determine the LDL binding of heparan sulphate. As the 
glycosylation of perlecan has been found to be affected by macrophage polarisation 
in Chapter 4, the use of perlecan from different cell types and activation may also 
cause the difference.  
 
Binding of LDL to the core protein of perlecan has been shown before [90]. The 
three-dimensional structure of perlecan domain II is highly homologous to the 
ligand-binding portion of the LDL-binding receptor [102], and its LDL binding 
function has recently been demonstrated [103]. Although the domain II on the M2 
macrophage-derived perlecan was not tested for its LDL binding in the present 
study, due to the lack of commercial availability of an antibody against that 
particular domain, this is the first report that the human perlecan (full length) can 
bind LDL via its core protein. The binding mechanism is not clear, but it may be 
mediated by its glycans on domain II [103]. This thesis cloned perlecan domain II 
in E. coli to understand the binding mechanism. Despite the technical issue of 
separating perlecan domain II from MBP, the result obtained from the cloning 
experiment supports the hypothesis that perlecan domain II alone does not bind 
LDL, but needs glycans to do so, as the E. coli system does not glycosylate the 
proteins expressed [179]. However, the exact binding mechanism is still vaguely 
understood, as the role of the glycans present on perlecan domain II in the binding 
has not been elucidated. The LDL receptor, which is expressed on most cells, has a 
ligand-binding domain that is characterised by a group of negatively charged amino 
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acids that interact with the positively charged residues on apoB [186]. Perlecan 
domain II conceivably may also interact with LDL ionically, but whether it really 
acts like an LDL receptor is outside of the scope of this thesis. 
 
Lastly, this study does not infer that biglycan and versican in the M2 proteoglycans 
do not bind LDL, because the experiment only examined the function of core 
proteins, not the intact proteoglycans. Biglycan and versican have been proposed to 
bind LDL via the GAG chains, not the core protein [139,177]. Due to technical 
limitation, the intact biglycan and versican were not isolated and tested for their 
LDL binding in this study.  
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5.5 Summary  
 
The proteoglycans produced by M1 macrophages exhibited a superior LDL binding 
ability than those produced by M2 macrophages. This binding was mediated by 
heparan sulphate, not chondroitin sulphate. However, the proteoglycans produced 
by M2 macrophages had an increased LDL binding ability upon cleavage of GAGs, 
suggesting the presence of LDL binding sites on their core proteins, such as 
perlecan. M2 macrophage-derived perlecan bound LDL via its core protein. This 
binding ability was modulated by its heparan sulphate.  
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6.1 Introduction 
 
Having seen from the results presented in the previous chapter that M1 and M2 
macrophages used different proteoglycan components to interact with LDL, it is 
thus important to determine if the cells produce these components in atherosclerotic 
plaques, so that the in vitro data can be better translated into a clinical perspective. 
Thus, in this chapter, a double immunostaining was performed to examine the 
localisation of macrophage phenotypes and proteoglycans in human atherosclerotic 
lesions. Here, the term ‘cholesterol clefts’ is used to define the crystal-like structure, 
which are usually found in the necrotic core; whereas the term ‘lipid deposits’ is 
used to define the void, non-nuclear, droplet-like structure, which are usually found 
in the thickened cap [187]. Negative controls were displayed to validate the staining. 
The structures on the lesion were annotated on the negative controls, so that the 
positive staining could be presented more clearly without obstruction from the 
letters.  
 
6.2 Materials and methods 
 
Double immunostaining was performed as per Section 2.6. Human carotid 
specimens were obtained from Westmead Hospital. All specimens were fibrous (or 
thin fibrous) cap atheroma based on the descriptions in the updated version of the 
American Heart Association classification [188], characterised by a well-formed 
core and overlying cap. Proteoglycans such as heparan sulphate and perlecan were 
stained as brown colour with DAB. CD86 and CD163, which are the markers for 
Macrophages and proteoglycans in atherosclerotic plaques 
191 
 
M1 and M2 phenotypes, respectively, were visualised as green colour with Vina 
Green.  
 
 
6.3 Results 
 
6.3.1 Heparan sulphate is present in lipid-rich regions of the 
lesions 
 
In Chapter 5, it was found that M1 macrophages produced heparan sulphate that 
bound LDL. Here, an experiment was performed on human atherosclerotic lesions 
to examine the co-localisation of M1 macrophages and heparan sulphate. Heparan 
sulphate was stained using the anti-heparan sulphate antibody clone, 10E4; whereas 
anti-CD86 was used to stain for M1 macrophages. In the representative lesion, 
heparan sulphate was observed along the border of the necrotic core as well as 
throughout the core (upper image; Figure 6.1). The staining was particularly intense 
around the cholesterol clefts. In contrast, the intensity of the staining was weak to 
absent in the otherwise cell-abundant cap (lower image; Figure 6.1). Taken together, 
heparan sulphate was present in the lipid-rich regions of the plaques, which is an 
indication of a possible association with lipid accumulation. While staining for 
heparan sulphate was evident, staining for CD86 was not demonstrated in the 
plaques, as no staining occurred either with Vina Green or DAB (data not shown). 
The lab had trialled several M1 antibodies with limited success. Technical issues 
such as low antibody affinity, or difficulties in antigen retrieval could be the causes.  
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Figure 6.1 Representative microphotographs showing the localisation of 
heparan sulphate (brown) in human late atherosclerotic lesions. 
Heparan sulphate was stained with the antibody clone, 10E4. The 
dotted lines delimitated the necrotic core. The small boxes marked 
in the images were magnified and shown below. (n = 5; 3 out of 5 
showed heparan sulphate in lipid-rich regions of the plaques).  
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6.3.2 M2 macrophages are co-localised with perlecan in 
atherosclerotic lesions  
 
M2 macrophages were found to produce an abundance of perlecan in Chapter 4, 
and their perlecan bound LDL as shown in Chapter 5. Therefore, this experiment 
aimed to examine the co-localisation of M2 macrophages and perlecan in human 
atherosclerotic lesions. Perlecan was stained using the anti-perlecan antibody, 
CCN-1; whereas CD163 was stained as the marker for M2 macrophages. 
 
In the representative lesion (Figure 6.2), perlecan was found in the necrotic core 
(the area marked by blue dotted line). The staining was particularly concentrated 
around the cholesterol clefts in the lipid-rich region of the core (the area marked by 
yellow dotted line). In contrast, the staining was absent in the matrix-rich region of 
the core. Perlecan was also observed around the lipid deposits in the intimal cap 
regions (the area marked by red dotted line). Otherwise, its staining in the other 
areas of the cap where were cells were abundant, was weak to absent. These 
observations suggested a role of perlecan in lipid retention.  
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Figure 6.2 Representative microphotographs showing a human late atherosclerotic lesion stained for perlecan (brown). Perlecan 
was stained with the anti-perlecan antibody, CCN-1. Note the localisation of perlecan that was mostly concentrated 
around the cholesterol clefts in the necrotic core (n = 5; 3 out of 5 showed M2 macrophages co-localising with perlecan). 
The areas marked ‘A’ and ‘B’ were enlarged sequentially and shown in Figures 6.3 and 6.4, respectively. 
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The cap area marked ‘A’ in Figure 6.2 was enlarged. Here, it showed that the 
CD163-positive M2 macrophages were localised around the lipid deposits. Here, 
perlecan staining was co-localised with M2 macrophages (arrowed), indicating that 
M2 macrophages produced perlecan in the lesion (Figure 6.3).  
 
At the border of the necrotic core marked ‘B’ in Figure 6.2, the staining for perlecan 
was intense particularly around the cholesterol clefts in the core, but no staining for 
CD163-positive M2 macrophages was observed. Instead, a few of M2 macrophages 
(arrowed) were found away from the core, in the cap area next to the lumen. These 
macrophages were localised around the lipid deposits, but no clear co-localisation 
with perlecan was observed (Figure 6.4). 
 
Taken together, while perlecan is secreted, co-localisation within the cell is an 
indication that the cell is capable of producing the proteoglycan within the plaque. 
However, as most of the perlecan staining was not co-localised with the M2 
macrophages, this suggests that the cells are not the prime source for perlecan in 
the lesions.  
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Figure 6.3 The enlarged ‘A’ area from Figure 6.2 showing the co-localisation of CD163 (M2 macrophages, green) with perlecan 
(brown) as indicated by the arrow.   
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Figure 6.4 The enlarged ‘B’ area from Figure 6.2 showing the border of the necrotic core. Indicated by the arrows, the CD163 
positive M2 macrophages (green, arrowed) did not show a clear co-localisation with perlecan (brown). 
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6.4 Discussion 
 
This study reported localisation of heparan sulphate in the lipid-rich areas of 
atherosclerotic lesions, which suggests that heparan sulphate has a role in retaining 
lipids. The content of heparan sulphate in human atherosclerotic lesions has 
previously been explored and found to be decreased compared to the healthy aortae 
[189,190], but its localisation within the lesions has never been reported. This study 
supports the findings in Chapter 5 that heparan sulphate can bind LDL. However, 
this study was not able to determine if the heparan sulphate observed in the lesions 
was secreted by M1 macrophages. The M1 marker did not stain; the lab had trialled 
several M1 antibodies with limited success. Several technical issues may be the 
cause, such as low antibody affinity, or difficulties in antigen retrieval. Nevertheless, 
of important note was the use of anti-heparan sulphate antibody clone, 10E4 in this 
experiment. Although M1 macrophages were not demonstrated, they were not 
expected to co-localise with this staining from that antibody, given the absence of 
reactivity towards this antibody shown by the M1 heparan sulphate in Chapter 4.       
 
On the other hand, M2 macrophages were localised in the cap region with perlecan, 
which expression is in line with a previous study [89]. Although that study found 
that the accumulation of perlecan in human atherosclerotic lesions was reduced 
when compared to normal arteries, a co-localisation study was not previously 
performed. This thesis revealed a co-localisation of M2 macrophages and perlecan. 
This observation implies that M2 macrophages produce perlecan in vivo. As such, 
extrapolation of the in vitro data from Chapter 5 to the clinical situation of a lesion 
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suggests that M2 macrophages might retain LDL through their perlecan. It thus 
challenges the current thinking that M2 macrophages are entirely atheroprotective 
[191]. To confirm that the M2 macrophages were indeed producing perlecan in vivo, 
additional investigations, such as a proximity ligation assay (PLA) will be required. 
Furthermore, apoB was not stained in this thesis due to challenges of performing a 
triple immunostaining (apoB + macrophage marker + perlecan). The presence of 
lipid deposits was identified only based on histological appearance. Thus, the 
participation of M2 macrophages in LDL retention via perlecan was not directly 
demonstrated. Additionally, it should be noted that almost all perlecan in the lesions 
was not co-localised with M2 macrophages. This is expected as perlecan is a 
secreted proteoglycan, and few M2 macrophages were present which may be due 
to the plaques being advanced. So, whether M2 macrophages have a considerable 
contribution to perlecan accumulation in the lesions and the subsequent lipid 
retention remains to be determined. This observation also suggests that other cell 
types in the lesions contribute to the perlecan population, such as arterial smooth 
muscle cells [192] and endothelial cells [192,193], which perlecan production has 
been shown in vitro. Whether their perlecan contributes to lipid retention is beyond 
the scope of this study.  
 
Despite the limited analysis of the clinical samples, the data in this chapter provide 
preliminary evidence that (1) heparan sulphate might be involved with lipid 
accumulation in the lesions; and (2) M2 macrophages might produce perlecan in 
the atherosclerotic lesions. 
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6.5 Summary 
 
This chapter aimed to provide some preliminary evidence for the clinical relevance 
of the in vitro data presented in the previous chapter, and as a pilot for future 
direction. Although the co-localisation of M1 macrophages and heparan sulphate 
was not demonstrated, heparan sulphate was present in lipid-rich regions of the 
lesions, suggesting an association between this GAG and lipid accumulation. On 
the other hand, the co-localisation of M2 macrophages and perlecan suggests that 
M2 macrophages produce perlecan in the lesions.  
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7.1 Introduction 
 
The experiments in this chapter aimed to examine the production of proteoglycans 
by M1 and M2 foam cells and the LDL binding of their proteoglycans. This is a key 
area to explore because as atherosclerosis progresses, macrophages in the arterial 
wall internalise the retained lipoproteins and transform into foam cells [6]. 
Proteoglycans produced by these foam cells and their ability to bind LDL may then 
be different to those produced by macrophages. For this chapter, only the 
macrophages derived from THP-1 cells were transformed into foam cells, as each 
of the batch of the primary macrophages were used for phenotyping at the end of 
polarisation to make sure the cells had polarised into the specific phenotype as 
intended. Besides, due to the need for large amount of oxLDL for the foam cell 
transformation, the proteoglycan samples collected were limited. Therefore, based 
on the observations from the previous chapters, experiments were performed to 
examine the foam cell proteoglycans that are important in LDL binding, such as the 
GAGs.   
 
7.2 Materials and methods 
 
THP-1 derived M1 and M2 macrophages were differentiated into foam cells as per 
Section 2.1.8. The formation of the foam cells was visualised with Oil Red O as per 
Section 2.1.9. Proteoglycans were enriched from their conditioned medium and 
characterised with various techniques as per Section 2.3.   
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7.3 Results  
 
7.3.1 Macrophages produce fewer proteoglycans when in a foam 
cell form  
 
First, the foam cell morphology was examined with Oil Red O staining. The M1 
and M2 macrophages treated with oxLDL showed noticeable lipid droplets 
(appeared as red dots within the cytoplasm) compared to the macrophages that were 
untreated. Associated with this, the M1 foam cells also adopted a round shape after 
the transformation, which morphology was initially spindle-shaped. The M2 foam 
cells showed an increase in size compared to their macrophage counterpart and 
were relatively larger than the M1 foam cells. Although a quantification analysis 
was not performed in this study, the M2 foam cells were observed to contain more 
lipid droplets in their cytoplasm than the M1 foam cells overall (Figure 7.1).  
 
The secreted proteoglycans from foam cells were enriched from their conditioned 
media by performing anion exchange chromatography. Total protein harvested was 
estimated by Coomassie protein assay. From 20 mL of conditioned medium (for 
both M1 and M2 phenotypes), 5 mL of peak material was collected and 
concentrated to approximately 1 mL. The total protein was estimated to be 0.3 mg 
and 0.1 mg for M1 and M2, respectively. The protein yield was 15 mg/L and 5 
mg/L for M1 and M2, respectively (Table 7.1).    
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Figure 7.1 Microphotographs showing Oil Red O staining on M1 and M2 
macrophages treated with or without oxLDL to form foam cells. 
Note the lipid inclusions in the cytoplasm (appear as red dots) and 
changes in the morphology as the cells transformed into foam cells.  
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Table 7.1 The proteoglycan-enriched fractions obtained from M1 or M2 foam 
cells-conditioned media by DEAE chromatography.  
 
 Volume of 
conditioned 
medium 
(mL) 
Volume of 
peak 
fraction 
(mL) 
Volume of 
peak fraction 
after 
concentration 
(mL) 
 
Total 
protein 
(mg) 
Yield 
(mg/L) 
M1 
foam 
cells 
 
20 5 1.0 0.3 15 
M2 
foam 
cells 
20 5 0.8 0.1 5 
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Mass spectrometry was used to identify peptides derived from proteoglycan protein 
cores in the foam cell fractions. Syndecan-2 was the only heparan sulphate 
proteoglycan identified in the M1 foam cell fraction. In contrast, there were three 
types of heparan sulphate proteoglycans identified in the M2 foam cell fraction, 
namely agrin, perlecan and syndecan-2. Based on their MOWSE scores, perlecan 
was the most abundant among them, followed by agrin. However, chondroitin 
sulphate proteoglycans were detected neither in the M1 nor the M2 foam cell 
fraction (Table 7.2).    
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Table 7.2 Proteoglycan core proteins identified in the chromatography-enriched fractions derived from foam cells as detected by 
peptide LC-MS2 from an in-solution tryptic digestion. Peptides were categorised into either heparan sulphate or 
chondroitin sulphate proteoglycans in alphabetical order and the values shown were the molecular mass search score 
(MOWSE).  
 
Peptide 
identified 
Accession 
number* 
Molecular 
mass (Da) 
M1 foam cells M2 foam cells 
MOWSE 
score# 
Peptides 
matched† 
Sequence 
coverage 
(%)‡ 
MOWSE 
score# 
Peptides 
matched† 
Sequence 
coverage 
(%)‡ 
HSPGs         
Agrin  O00468 212,745    212 7 7 
Perlecan P98160 468,525    431 14 12 
Syndecan-2 P34741 22,160 56 1 1 190 4 2 
 
* Obtained from Swiss-Prot.  
# MOWSE as determined by Mascot query. This is the value (p) that is a measure of the probability that the match is a random event 
expressed as -10log(p). The higher the score means that the more confidence that the match is not due to a random event.  
† The number of peptide sequences that matched to theoretical sequence in the NCBI database.  
‡ The number of amino acids detected as a proportion of the total number of amino acids in the protein listed in Mascot.  
Abbreviations are: HSPGs, heparan sulphate proteoglycans. 
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Having seen that peptides for perlecan, which is found to be important in LDL 
retention atherosclerosis [90], were detected by mass spectrometry in the M2 
fraction, ELISA was performed to further confirm its presence. A monoclonal anti-
perlecan antibody clone, E-6, was used to detect perlecan. However, both fractions 
were not reactive towards the antibody (data not shown).  
 
The presence of perlecan in the fractions was further examined by performing 
Western blotting using the polyclonal anti-perlecan antibody, CCN-1. However, no 
immunoreactive bands were observed in either fraction (data not shown), further 
supporting the ELISA result about the low amount of perlecan in the fractions. 
 
To further confirm the production of perlecan by foam cells, PCR was performed 
to examine the gene expression for perlecan, HSPG2, in the cells. A pair of primers 
specific to domain V of perlecan were used and the products were visualised by an 
agarose gel electrophoresis. Only the M2 foam cells showed a product band at the 
expected size. This indicated that there was gene expression of perlecan in M2 foam 
cells, but not in the M1 foam cells (Figure 7.2). However, due to the limited number 
in the cells harvested, qPCR was not performed to quantitate their relative 
expression of perlecan.      
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Figure 7.2 The expression of HSPG2 mRNA in M1 and M2 foam cells as 
determined by PCR. mRNA obtained from the cells was isolated and 
used to generate cDNA, which was amplified for perlecan gene with 
PCR and electrophoresed on 1.5 % (w/v) agarose gels. Products for 
GAPDH used to as a control to indicate the same amount of cDNA 
was loaded on each gel for each subset. (Note: HSPG2 is the gene 
name for perlecan)  
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7.3.2 Proteoglycans produced by M2 foam cells are more 
glycosylated than those of M1 foam cells, with the presence 
of both chondroitin sulphate and heparan sulphate 
 
This experiment was performed to examine the GAG content of the proteoglycans 
secreted by the foam cells. A DMMB assay was used to determine the level of 
GAGs whereas a Coomassie protein assay was performed to measure the protein 
concentration. The data showed that the M1 foam cell fraction contained a high 
protein concentration compared to the M2 foam cell fraction. In contrast, the M2 
foam cell fraction showed a higher content of GAG. By normalising the GAG 
content to the protein, the data showed a higher reading in the M2 foam cell fraction. 
This suggests that the proteoglycans secreted by M2 foam cells are more 
glycosylated than those produced by M1 foam cells (Figure 7.3).   
 
Having seen that GAGs were present in the fractions, an experiment was performed 
to detect the presence of chondroitin sulphate and heparan sulphate in the fractions. 
Chondroitin sulphate and heparan sulphate were identified using the monoclonal 
antibody clones, CS-56 and 10E4, respectively. Both M1 and M2 foam cell 
fractions showed reactivity towards CS-56. This indicated the presence of 
chondroitin sulphate in the fractions. Whereas for heparan sulphate, only the M2 
foam cell fraction showed reactivity with 10E4, but not the M1 foam cell fraction. 
This indicated the presence of heparan sulphate in the M2 foam cell fraction (Figure 
7.4).  
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Figure 7.3 The content of protein, GAG and the ratio of GAG to protein of the 
proteoglycan-enriched fractions derived from M1 and M2 foam cells. 
The concentration of protein and GAG was determined by 
Coomassie protein assay and DMMB test, respectively. (n = 1) 
 
 
 
0
5
10
15
20
25
30
M1 foam cells M2 foam cells
G
A
G
 c
o
n
c
e
n
tr
a
ti
o
n
 
(µ
g
/m
L
)
0
50
100
150
200
250
300
350
M1 foam cells M2 foam cells
P
ro
te
in
 c
o
n
c
e
n
tr
a
ti
o
n
 
(µ
g
/m
L
)
0
0.04
0.08
0.12
0.16
0.2
M1 foam cells M2 foam cells
R
a
ti
o
 G
A
G
/p
ro
te
in
Foam cells and proteoglycans 
 
212 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 The types of GAG present in the proteoglycan-enriched fractions 
derived from M1 and M2 foam cells as determined by ELISA. 
Chondroitin sulphate and heparan sulphate were detected using the 
antibody clones, CS-56 and 10E4, respectively. Data were corrected 
for DPBS background and presented as mean ± standard deviation 
(n = 3).  
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The sulphation of chondroitin sulphate stubs secreted by the foam cells was next 
examined. The fractions were first digested with chondroitinase ABC to reveal the 
stub neo-epitopes. An ELISA was then performed on the fractions to detect the 
presence of unsulphated, 4- and 6-sulphated stubs with antibody clones 1B5, 2B6 
and 3B3, respectively. Both M1 and M2 foam cell fractions showed no reactivity 
towards 1B5, indicating the stubs were sulphated. However, the fractions showed 
reactivity only with 2B6, not with 3B3. This indicated that the chondroitin sulphate 
stubs in the M1 and M2 foam cell fractions were sulphated at the position C-4 of 
galactosamine (Figure 7.5).  
 
It should be noted that these results only show the sulphation of the linkage region 
of the chondroitin sulphate. The results therefore are not discriminant in defining 
the total sulphation degree of the GAG chains. An analysis by FACE would be 
required to achieve that, but it was not done here due to limited sample size.   
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Figure 7.5 The presence of chondroitinase ABC-generated stub neo-epitopes in 
the proteoglycan-enriched fractions derived from M1 and M2 foam 
cells as determined by ELISA. The presence of unsulphated, 4- and 
6-sulphated stub neo-epitopes was detected with 1B5, 2B6 and 3B3, 
respectively. Data were corrected for DPBS background and 
presented as mean ± standard deviation (n = 3).   
 
 
 
 
 
 
 
 
0
0.04
0.08
0.12
0.16
0.2
Non-sulphated
stub
4-sulphated
stub
6-sulphated
stub
A
b
s
o
rb
a
n
c
e
 (
4
0
5
 n
m
)
M1 foam cells M2 foam cells
Foam cells and proteoglycans 
 
215 
 
7.3.3 Proteoglycans produced by M1 and M2 foam cells do not 
differ in their LDL binding ability 
 
This QCM-D experiment was performed to evaluate the LDL binding ability of the 
proteoglycans produced by M1 and M2 foam cells. The representative Df-t plot 
showed that LDL bound to both M1 and M2 proteoglycan preparations with a 
similar amplitude in the Δf decrease and the ΔD increase, marked in the highlighted 
sections. This indicated that a similar amount LDL bound to both M1 and M2 foam 
cell proteoglycans (Figure 7.6A).  
 
The QCM-D data were modelled based on Voigt model to determine the amount of 
LDL bound. The modelled data showed that there was no significant difference in 
the amount of LDL bound by the M1 and M2 foam cell proteoglycans (Figure 7.6B).  
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Figure 7.6 The LDL binding ability of the proteoglycans produced by M1 and 
M2 foam cells. Proteoglycans were without digestion. (A) 
Representative Df-t plots showing the binding of LDL the foam cell 
proteoglycan preparations. The dotted line indicates the Δf whereas 
the solid line indicates the ΔD. (B) The Voigt-modelled data 
showing the amount of LDL bound. Data were corrected for BSA 
background and presented as mean ± standard deviation (n = 4). Not 
significant (NS) vs. M1 foam cells (t-test).   
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7.4 Discussion 
 
Like their macrophage counterpart, foam cells also produced proteoglycans, thus 
implying that they may also contribute to LDL retention in atherosclerosis. 
However, foam cells were found to secrete noticeably less proteoglycans compared 
to their macrophage counterpart, as shown by the mass spectrometry data. The 
amount of protein was also decreased in the foam cells, as evidenced by the lack of 
reactivity with the anti-perlecan antibodies in ELISA and Western blotting. These 
findings are consistent with the previous study showing that the uptake of oxLDL 
by macrophages leads to a decrease in the production of matrix proteins [194]. This 
is probably because the accumulation of oxLDL is cytotoxic to macrophages 
[195,196], which may then lead cell death.  
 
Despite the reduction in the amount, the proteoglycans that foam cells produce still 
showed a similar trend as their macrophage counterparts in the GAG chains. For 
example, like macrophages, the proteoglycans produced by M2 foam cells were 
more glycosylated than those secreted by M1 foam cells. Although the present data 
are not enough to conclude that the structure of the GAG chains that foam cells and 
macrophages produce are similar, only native LDL, but not oxLDL, was found 
stimulate alterations to the structure of the proteoglycans produced by macrophages, 
including the GAG length and sulphation degree [197]. Hence, it is likely that foam 
cell transformation does not affect the structure of the GAG chains as much as the 
M1/M2 polarisation does. 
 
Foam cells and proteoglycans 
 
218 
 
However, unlike macrophages, both the M1 and M2 foam cell proteoglycans did 
not differ from each other in the amount of LDL bound. As observed in Chapter 5, 
the LDL binding ability of proteoglycans relies on the GAG structure. As such, this 
similar LDL binding suggests that the structure of the GAG chains produced by M1 
and M2 foam cells are not different. Still, it is not conclusive to predict the GAG 
structure from the LDL binding, because core proteins may also participate in the 
binding, which was not tested in this study. In the future, the involvement of the 
proteoglycan core proteins produced by foam cells in LDL binding needs to be 
examined.  
 
The limitation of this study was the size of samples due to the limited amount of 
oxLDL available. This prevented further examination of the proteoglycans that 
foam cells produced. If this study is to be taken further in the future, it is suggested 
that LDL is to be oxidised in-house to reduce the cost, since a large amount of media 
would be needed to complete additional analyses. 
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7.5 Summary  
 
M1 and M2 foam cells produced less proteoglycans than their macrophage forms, 
but showed a similar trend in the glycosylation. The proteoglycans produced by M1 
and M2 foam cells bound LDL and did not show a difference in the amount bound.   
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8.1 Clinical significance of the findings  
 
A key contributor to atherosclerosis is the macrophage, with the pro-inflammatory 
M1 macrophages associated with plaque instability, whereas the ‘wound-healing’ 
M2 macrophages are thought to be stabilising [56,69]. Our group has demonstrated 
that M2 macrophages produce collagen in the plaques [64]. Indeed, skewing 
macrophages to the M2 phenotype has recently been shown to enhance plaque 
stability in murine model [120]. While this is undeniably an exciting breakthrough 
in the search for an alternative way of treating atherosclerosis, a range of other 
macrophage functions are still yet to be explored, including their production of 
proteoglycans, as these matrix molecules can retain LDL in the arterial wall, which 
would initiate atherosclerosis and promote its progression [12]. Therefore, this 
thesis examined what proteoglycans are produced by M1 and M2 macrophages and 
their ability to bind LDL.  
 
Briefly, M1 and M2 macrophages were found to produce a range of heparan 
sulphate and chondroitin sulphate proteoglycans, such as perlecan, biglycan and 
versican, which varied in the level of expression. Furthermore, these proteoglycans 
produced by M1 macrophages contained GAG chains that were more highly 
sulphated than those of M2 macrophages, leading to more LDL binding, which 
occurred predominantly through heparan sulphate. However, core proteins of the 
proteoglycans produced by M2 macrophages, such as perlecan, which they were 
co-localised with in the plaques, bound more LDL upon cleavage of GAG chains. 
When M1 and M2 macrophages transformed into foam cells, they produced less 
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proteoglycans. These proteoglycans bound LDL, but did not differ in the amount 
between the phenotypes. While these results have been discussed in detail in the 
previous chapters, which was primarily from the angle of matrix biology, this 
chapter here moves on to discuss the possible pathophysiological roles of the 
proteoglycans produced by M1 and M2 macrophages in atherogenesis, 
extrapolating from these in vitro findings.      
 
The healthy human arterial wall is devoid of macrophages and LDL [198]. Upon 
provocation by atherogenic stimuli such as elevated LDL, the permeability of the 
arterial endothelial layer increases [13]. This promotes the entry and subsequent 
retention of LDL in the subendothelial space, as it is thought to be bound by the 
proteoglycans produced by the endothelial and arterial smooth muscle cells 
[180,199]. The trapped LDL undergoes oxidative modifications into oxLDL, 
inducing the recruitment of circulating monocytes/macrophages [200]. These 
infiltrating macrophages exhibit a heterogeneous phenotype of M1 and M2 at a 
relatively similar proportion [198]. Here, their production of proteoglycans may 
cause changes to the content of proteoglycans that are already present in the arterial 
wall (see Table 1.1, Chapter 1), although arterial smooth muscle cells and 
endothelial cells are the major sources of proteoglycans [201]. This is plausible 
because, for example, the content level of biglycan in the arterial wall increases as 
atherosclerosis progresses [202]. With both M1 and M2 macrophages producing 
biglycan (Chapter 4), they may then contribute to this increase of biglycan. 
Conversely, with the lower production of perlecan by M1 macrophages than M2 
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macrophages (Chapter 4), this may be associated with the reduce of perlecan in the 
arterial wall when atherosclerosis begins [89]. However, the changes of versican 
during atherosclerosis progression has not been reported.        
 
Whilst the proportion of M1 and M2 macrophages in the early lesion is similar 
[198], the M1 macrophages may promote the lesion development more than M2 
macrophages, as their proteoglycans bound more LDL than those produced by M2 
macrophages (Chapter 5), with this binding related to the higher degree of 
sulphation of their heparan sulphate (Chapter 4). Indeed, reports of elevated 
sulphation of the GAG chains of the arterial proteoglycans has been found in 
atherosclerosis, which in turn increased lipid retention within the wall [159,160]. 
M1 macrophages may thus contribute to this increase of sulphation and help the 
endothelial and arterial smooth muscle cells in the subendothelial space in trapping 
more LDL. In addition, M1 macrophages have been shown to produce a large 
amount of reactive oxygen species [204], which may aid in the oxidative 
modifications of the trapped LDL to generate oxLDL [205]. Therefore, this study 
supports the current understanding that M1 macrophages are atherogenic.     
 
Although the proteoglycans produced by M2 macrophages did not bind as much 
LDL as those of M1 macrophages, they may also contribute to the LDL retention 
(Chapter 5). The arterial expression of GAG-degrading endoglycosidases, such as 
heparanase, have been found to be increased in atherosclerosis [206]. Although not 
reported, this elevation of heparanase may result in the removal of heparan sulphate 
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from the proteoglycans present in the arterial wall. As such, the heparan sulphate 
produced by M2 macrophages, which can inhibit the LDL binding to the core 
proteins (Chapter 5), may be cleaved. Consequently, the LDL binding sites, such as 
perlecan, will be revealed, leading to greater LDL retention. This is supported by 
the staining data (Chapter 6) showing the co-localisation of M2 macrophages with 
perlecan in human atherosclerotic plaques.   
 
Interestingly, the LDL binding ability of the proteoglycans produced by M1 
macrophages was decreased upon removal of heparan sulphate (Chapter 5). Hence, 
this elevation of heparanase [206] may also degrade the heparan sulphate produced 
by M1 macrophages, subsequently leading to reduced LDL binding to their 
proteoglycans. Although heparan sulphate was co-localised with lipids in human 
plaques (Chapter 6), the intimal level of heparan sulphate decreases during lesion 
development [190], which further suggests that the LDL binding ability of the M1 
proteoglycans may be affected. However, the core proteins in the M1 proteoglycans 
still could bind LDL, though the amount bound was lower than when heparan 
sulphate was present (Chapter 5). This suggests that M1 macrophages may still 
contribute to LDL retention regardless of the enzymatic changes in atherosclerosis.  
 
Since M2 macrophages are well recognised for their clearance of lipids [207,208] 
and better ability than M1 macrophages in taking up lipids [67], it is tempting to 
hypothesise that this LDL-proteoglycan interaction could be beneficial to M2 
macrophages in the early stage of atherosclerosis. This is because LDL-
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proteoglycan complexes are more easily internalised by macrophages than LDL 
alone [111,209]. Thus, the binding of LDL by proteoglycans may in turn help the 
M2 macrophages clean up the trapped LDL, which would then slow down the lesion 
development. Other cell types have also been found to exhibit such function, such 
as hepatocytes, which secrete proteoglycans to mediate the uptake of triglyceride-
rich lipoproteins in the liver [210]. Conceivably, M2 macrophages may act in a 
comparable way.  
 
While this clearance of LDL by M2 macrophages is seen as beneficial for 
atheroprotection, if the internalised LDL cannot be metabolised efficiently and exit 
the cells, then the macrophages become foam cells. Indeed, although M2 
macrophages have a high phagocytic ability, they are poor in handling LDL 
metabolism and its efflux [211] and this has been shown here that after the uptake 
of LDL (or oxLDL), M2 macrophages can transform into foam cells (Chapter 7). 
M2 foam cells produced less proteoglycans than their macrophage counterparts 
(Chapter 7). This may then hinder the hypothesised function of M2 macrophages in 
taking up the LDL-proteoglycan complexes. Unexpectedly, the proteoglycans 
produced by M2 foam cells still could bind LDL, and the LDL bound was as much 
as that bound by those produced by M1 foam cells. The foam cell-derived 
proteoglycan components that bound LDL were not tested in this study due to 
sample size. However, this finding indicates that M1 and M2 macrophages may 
have a similar contribution to LDL retention when they transform into foam cells.   
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As the plaque progresses, its microenvironment can become quite complex due to 
multiple pathological events, such as intra-plaque haemorrhage [212]. In this 
respect, macrophages can be driven to a new phenotype by the haeme and 
haemoglobin [213]. As such, macrophages are present as a spectrum of phenotypes, 
rather than just a few distinct M1 and M2 populations during the advanced stage. 
Therefore, the proteoglycans produced by the different macrophages at this stage 
as well as their function in binding LDL may be different to what this study has 
found. However, the proteoglycans produced by possible macrophage phenotypes 
was not examined in this study.         
 
Lastly, despite the landmark publication of the 4S trial on improved survival of 
coronary heart disease with the use of statins [214], which are now the go-to drugs 
for the prevention and treatment of cardiovascular events due to their ability to 
lower plasma LDL cholesterol levels, their effects on atherosclerotic lesions are not 
yet fully elucidated. For example, while some studies suggest statins reduce lesional 
volume [215,216], the reduction is small to none in a population of obese patients 
with hyperlipidaemia, despite optimised statin therapy [217]. Statin therapy alone 
is not sufficient to control atherosclerosis particularly in obese or other high-risk 
patients, and so, other alternative treatments are needed. Currently, high density 
lipoprotein (HDL) has been found to prevent M1 polarisation, but has no effect on 
M2 [69]. Feig et al. [218] also discovered that increasing HDL levels altered the 
expression of lesional macrophages from an M1 to M2 phenotype in mouse models. 
While HDL could be a novel therapeutic way for dampening inflammation in 
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atherosclerosis, its clinical application is still not promising [219] and having seen 
in this study that the assumingly atheroprotective M2 macrophages could be 
atherogenic through binding LDL via their proteoglycans, hence more angles of 
macrophages, rather than just inflammation should be considered in developing an 
alternative treatment.  
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8.2 Conclusions  
 
Polarisation of macrophages into M1 and M2 phenotypes results in different 
proteoglycan production. However, these proteoglycans, both produced when they 
are in a macrophage form or a foam cell form, bind LDL, just in different ways. 
Therefore, M1 and M2 macrophages are likely to contribute to LDL retention 
during the development of atherosclerosis.  
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8.3 Future directions  
 
This study can be strengthened by additional experiments, particularly from the in 
vivo angle. For example, whether M1 and M2 macrophages in the plaques also 
produce the same proteoglycans and GAG chains as shown in the in vitro data here 
needs to be assessed in the future. This may be achieved by extracting proteoglycans 
from the region of the plaque that is abundant with each of the macrophage 
phenotypes. Then, the LDL binding ability of these proteoglycans can be examined 
as per the same way performed in this study.  
 
In addition, the structure of proteoglycans is hypothesised to be altered as the 
disease progresses, due to the presence of heparanase [206]. Having seen that 
structural modification can change the LDL binding ability of the proteoglycans, it 
is also important to examine the structure of the proteoglycans extracted from the 
plaques.  
 
Then, whether the LDL binding ability of these proteoglycans is beneficial or 
detrimental in the plaque also needs further elucidation. While the results in this 
study are interpreted as lipid retention in the arterial wall, the proteoglycans are 
hypothesised to facilitate M2 macrophages in lipid clearance. Therefore, it is 
important to examine the clinical functions of their proteoglycans in vivo. Methods 
such as proximity ligation assay can be useful in examining the LDL-proteoglycan 
interaction in the plaque.  
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Although the major immune cell in atherosclerotic lesions is the macrophage, they 
are not considered to be the principal source of proteoglycans that can retain LDL 
to initiate atherosclerosis. That role belongs to the arterial smooth muscle cells and 
endothelial cells [12]. As such, a considerable number of studies in the past 
[114,180,220-223] have looked at the binding of LDL to the proteoglycans 
produced by arterial smooth muscle cells, but not those of macrophages. A direct 
comparison of the amount and degree of LDL binding to the proteoglycans derived 
from macrophages and arterial smooth muscle cells could not be established here 
due to the different techniques used to assess the interaction. While all previous 
studies used a gel mobility shift assay, this thesis used the QCM-D method. This 
thesis also did not explore the LDL-proteoglycan binding by arterial smooth muscle 
cells to enable a direct comparison. Having seen that macrophage-derived 
proteoglycans can bind LDL, and that the relative contribution of those 
proteoglycans to the overall arterial LDL retention is completely unknown, then a 
comparative study of LDL binding by macrophage and arterial smooth muscle cell-
derived proteoglycans should be performed, using the same measurement method. 
The relative contribution of macrophage proteoglycans to the overall LDL retention 
hence needs further investigations. Moreover, with the arterial smooth muscle cells 
shown to be able to trans-differentiate into a macrophage-like phenotype in vivo 
during atherogenesis [218], then the profile of proteoglycans these muscle-
macrophage cells can produce should also be assessed.  
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Lastly, the proteoglycans produced by foam cells should be investigated further, as 
the proteoglycan components that bound LDL was not studied here due to limited 
sample size. This is important to know given that the presence of endoglycosidases 
in the plaques has been shown [206], which may affect the binding of LDL to the 
proteoglycans. Also, there are a spectrum of macrophage phenotypes in the plaque 
as the disease progresses. The proteoglycans produced by these different 
phenotypes then should be studied too.   
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Appendix 1 
 
Collagens identified in the M1 and M2 fractions as detected by peptide LC-MS2 
from an in-solution tryptic digestion.  
 
Peptide for 
collagen 
identified 
Accession 
number* 
Molecular 
mass (Da) 
M1 M2 
MOWSE 
score# 
Peptides 
matched† 
Sequence 
coverage 
(%)‡ 
MOWSE 
score# 
Peptides 
matched† 
Sequence 
coverage 
(%)‡ 
V, alpha 1 P20908 183499 190 4 4 46 1 1 
VI, alpha 1 P12109 28565 79 1 1    
XI, alpha 1 P12107 181029 49 3 2 45 1 1 
XII, alpha 
1 
Q99715 332987 127 5 5    
 
* Obtained from Swiss-Prot.  
# MOWSE as determined by Mascot query. This is the value (p) that is a measure 
of the probability that the match is a random event expressed as -10log(p). The 
higher the score means that the more confidence that the match is not due to a 
random event.  
† The number of peptide sequences that matched to theoretical sequence in the 
NCBI database.  
‡ The number of amino acids detected as a proportion of the total number of amino 
acids in the protein listed in Mascot.  
 
 
 
 
 
 
 
 
 
 
